Patent Grant
11708554
The potential use of stem cells in a variety of treatments and therapies has achieved particular attention. Cell expansion systems can be used to expand, e.g., grow, stem cells, as well as other types of cells, such as bone marrow cells. Stem cells which are expanded from donor cells can be used to repair or replace damaged or defective tissues and have broad clinical applications for a wide range of diseases. Recent advances in the regenerative medicine field demonstrates that stem cells have properties such as proliferation and self-renewal capacity, maintenance of the unspecialized state, and the ability to differentiate into specialized cells under particular conditions.
Cell expansion systems include one or more compartments for expanding the cells, such as a cell growth chamber, also referred to herein as a “bioreactor.” In order to expand cells, an initial volume of cells is typically loaded into, and distributed within, the bioreactor. Accordingly, there is a need for a method of loading and distributing cells in a bioreactor associated with a cell expansion system. The present disclosure addresses this and other needs.
Embodiments of the present invention have been made in light of these and other considerations. However, the relatively specific problems discussed above do not limit the applicability of the embodiments of the present invention to solving other problems.
The summary is provided to introduce aspects of some embodiments of the present invention in a simplified form, and is not intended to identify key or essential elements of the claimed invention, nor is it intended to limit the scope of the claims.
It is to be understood that the present invention may include a variety of different versions or embodiments, and this Summary is not meant to be limiting or all-inclusive. This Summary provides some general descriptions of features that may be included in embodiments, and also include some more specific descriptions of other features that may be included in other embodiments.
One or more embodiments are generally directed to a method and system for loading and distributing cells in a bioreactor of a cell expansion system. Accordingly, embodiments include methods that may provide for adding a plurality of cells to a fluid circulating at a first rate within a bioreactor of the cell expansion system. In embodiments, the bioreactor may include a hollow fiber membrane with a plurality of individual hollow fibers through which the cells and other fluids are circulated. Initially, fluid is circulated through the hollow fiber membrane of the bioreactor and cells are added to the circulating fluid. The fluid is circulated at a first predetermined circulation rate. During circulation, the bioreactor may be in a horizontal position. After the cells are loaded by being added to the circulation fluid, the cells may be allowed to circulate and distribute evenly throughout the system, with cells flowing into and out of the hollow fibers of the hollow fiber membrane. The circulation may then be stopped. The cells are then allowed to settle, under the influence of gravity, and attached to a first portion of the hollow fibers in the bioreactor. In embodiments, the cells may be allowed to settle for a first predetermined period of time. In some embodiments, the predetermined period of time may be selected to allow the cells also to attach to the first portion of the hollow fibers.
After the first predetermined period of time, the bioreactor is rotated 180 degrees. After rotation of the bioreactor, cells within the bioreactor are allowed to settle again. Cells may then settle on an opposing portion of the hollow fibers for a second predetermined period of time that may be selected to also allow the cells to attach to the opposing portion. After the second predetermined period of time, the bioreactor is rotated back to its original horizontal position and the cells undergo an expansion process.
In some embodiments, the loading process includes additional steps. In some embodiments, after the bioreactor is returned to its original horizontal position, circulation is restarted. The circulation rate may be set at a lower rate than the first predetermined circulation rate. The circulation would be performed to once again distribute cells that have not attached to a surface. The circulation would continue for a third predetermined period of time to allow unattached cell to become evenly distributed throughout the system including the bioreactor. The circulation would then be stopped allowing cells in the bioreactor to settle, and in embodiments attach to portions of the hollow fibers, once again.
After a fourth predetermined period of time to allow the cells to settle again, the bioreactor is rotated 180 degrees. After rotation of the bioreactor, cells within the bioreactor are allowed to settle again. Cells may then settle on an opposing portion of the hollow fibers for a fifth predetermined period of time that may be selected to also allow the cells to attach to the opposing portion of the hollow fibers. After the fifth predetermined period of time, the bioreactor is rotated back to its original horizontal position.
The process is again repeated by circulating cells in the system to evenly distribute any unattached cells, again. However, each time circulation is restarted, it is restarted at a lower rate than the previous circulation. When the circulation is stopped, the cells are allowed to settle and attach. The bioreactor is rotated 180 degrees and the cells are allowed to settle and attach. Then the bioreactor is rotated back to its original position. These steps of circulation, settling, rotation, settling, and rotation may be repeated a predetermined number of times, after which the attached cells, which have been attached in layers, are expanded in the bioreactor.
Other embodiments are also directed to a method and system for loading and distributing cells in a bioreactor of a cell expansion system. Embodiments include methods that may provide for adding a plurality of cells to a fluid circulating at a first rate within a bioreactor of the cell expansion system. In embodiments, the bioreactor may include a hollow fiber membrane with a plurality of individual hollow fibers through which the cells and other fluids are circulated. Initially, fluid is circulated through the hollow fiber membrane of the bioreactor and cells are added to the circulating fluid. The fluid is circulated at a first predetermined circulation rate. During circulation, the bioreactor may be in a horizontal position. After the cells are loaded by being added to the circulation fluid, the cells may be allowed to circulate and distribute evenly throughout the system, with cells flowing into and out of the hollow fibers of the hollow fiber membrane. The circulation may then be stopped. The cells are then allowed to settle, under the influence of gravity, and attached to a first portion of the hollow fibers in the bioreactor. In embodiments, the cells may be allowed to settle for a first predetermined period of time. In some embodiments, the predetermined period of time may be selected to allow the cells also to attach to the first portion of the hollow fibers.
After the first predetermined period of time, the bioreactor is rotated 180 degrees. After rotation of the bioreactor, the cells undergo an expansion process. As may be appreciated, the previously attached cells may be on a top portion of the hollow fibers. As the cells are expanded, they may be subjected to gravity, which may influence cell growth toward a bottom portion of the hollow fibers.
Additional advantages of the embodiments presented herein will become readily apparent from the following discussion, particularly when taken together with the accompanying drawings.
To further clarify the above and other advantages and features of the present invention, a more particular description of the invention will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings. It is appreciated that these drawings depict only typical embodiments of the invention and are therefore not to be considered limiting of its scope. The invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:
The principles of the present invention may be further understood by reference to the following detailed description and the embodiments depicted in the accompanying drawings. It should be understood that although specific features are shown and described below with respect to detailed embodiments, the present invention is not limited to the embodiments described below. The present disclosure is generally directed to a method for distributing a plurality of cells in a bioreactor of a cell expansion system. As described below, a method of distributing cells within a bioreactor may include loading cells into the bioreactor, rotating the bioreactor, and holding the bioreactor still at certain orientations.
A schematic of an example cell expansion system (CES) is depicted in
Second fluid circulation path 14 includes second fluid flow path 34, cell growth chamber 24, and a second fluid flow controller 32. The second fluid flow path 34 has at least opposing ends 36 and 38. Opposing ends 36 and 38 of second fluid flow path 34 are fluidly associated with inlet port 40 and outlet port 42 respectively of cell growth chamber 24. Fluid flowing through cell growth chamber 24 is in contact with the outside of hollow fiber membrane in the cell growth chamber 24. Second fluid circulation path 14 is operably connected to second fluid flow controller 32.
First and second fluid circulation paths 12 and 14 are thus separated in cell growth chamber 24 by a hollow fiber membrane. Fluid in first fluid circulation path 12 flows through the intracapillary (“IC”) space of the hollow fibers in the cell growth chamber. First circulation path 12 is thus referred to as the “IC loop.” Fluid in second circulation path 14 flows through the extracapillary (“EC”) space in the cell growth chamber. Second fluid circulation path 14 is thus referred to as the “EC loop.” Fluid in first fluid circulation path 12 can flow in either a co-current or counter-current direction with respect to flow of fluid in second fluid circulation path 14.
Fluid inlet path 44 is fluidly associated with first fluid circulation path 12. Fluid inlet path 44 allows fluid into first fluid circulation path 12, while fluid outlet path 46 allows fluid to leave CES 10. Third fluid flow controller 48 is operably associated with fluid inlet path 44. Alternatively, third fluid flow controller 48 can alternatively be associated with fluid outlet path 46.
Fluid flow controllers as used herein can be a pump, valve, clamp, or combination thereof. Multiple pumps, valves, and clamps can be arranged in any combination. In various embodiments, the fluid flow controller is or includes a peristaltic pump. In further embodiments, fluid circulation paths, inlet ports, and outlet ports can be constructed of tubing of any material.
Various components are referred to herein as “operably associated.” As used herein, “operably associated” refers to components that are linked together in operable fashion, and encompasses embodiments in which components are linked directly, as well as embodiments in which additional components are placed between the two linked components. “Operably associated” components can be “fluidly associated.” “Fluidly associated” refers to components that are linked together such that fluid can be transported between them. “Fluidly associated” encompasses embodiments in which additional components are disposed between the two fluidly associated components, as well as components that are directly connected. Fluidly associated components can include components that do not contact fluid, but contact other components to manipulate the system (e.g. a peristaltic pump that pumps fluids through flexible tubing by compressing the exterior of the tube).
Generally, any kind of fluid, including buffers, protein containing fluid, and cell-containing fluid can flow through the various circulations paths, inlet paths, and outlet paths. As used herein, “fluid,” “media,” and “fluid media” are used interchangeably.
With regard to the IC loop 802, samples of media can be obtained from sample coil 818 during operation. Media then returns to IC inlet port 801A to complete fluid circulation path 802. Cells grown/expanded in cell growth chamber 801 can be flushed out of cell growth chamber 801 into harvest bag 899 through valve 898 and line 897. Alternatively, when valve 898 is closed, the cells may be redistributed, e.g., circulated back, within chamber 801 for further growth or loading.
Fluid in second fluid circulation path 804 enters cell growth chamber 801 via EC inlet port 801C, and leaves cell growth chamber 801 via EC outlet port 801D. Media in the EC loop 804 is in contact with the outside of the hollow fibers in the cell growth chamber 801, thereby allowing diffusion of small molecules into and out of the hollow fibers that may be within chamber 801.
Pressure/temperature sensor 824 disposed in the second fluid circulation path 804 allows the pressure and temperature of media to be measured before the media enters the EC space of the cell growth chamber 801. Sensor 826 allows the pressure and temperature of media in the second fluid circulation path 804 to be measured after it leaves the cell growth chamber 801. With regard to the EC loop 804, samples of media can be obtained from sample port 830 or a sample coil during operation.
After leaving EC outlet port 801D of cell growth chamber 801, fluid in second fluid circulation path 804 passes through EC circulation pump 828 to gas transfer module 832. EC circulation pump 828 may also pump the fluid in opposing directions. Second fluid flow path 822 is fluidly associated with gas transfer module 832 via an inlet port 832A and an outlet port 832B of gas transfer module 832. In operation, fluid media flows into gas transfer module 832 via inlet port 832A, and exits gas transfer module 832 via outlet port 832B. Gas transfer module 832 adds oxygen to and removes bubbles from media in the CES 800. In various embodiments, media in second fluid circulation path 804 is in equilibrium with gas entering gas transfer module 832. The gas transfer module 832 can be any appropriately sized device known in the art and useful for oxygenation or gas transfer. Air or gas flows into gas transfer module 832 via filter 838 and out of oxygenator or gas transfer device 832 through filter 840. Filters 838 and 840 reduce or prevent contamination of oxygenator 832 and associated media. Air or gas purged from the CES 800 during portions of a priming sequence can vent to the atmosphere via the gas transfer module 832.
In the configuration depicted for CES 800, fluid media in first fluid circulation path 802 and second fluid circulation path 804 flows through cell growth chamber 801 in the same direction (a co-current configuration). The CES 800 can also be configured to flow in a counter-current conformation.
In accordance with at least one embodiment, media, including cells (from a source such as a cell container, e.g. a bag) can be attached at attachment point 862, and fluid media from a media source can be attached at attachment point 846. The cells and media can be introduced into first fluid circulation path 802 via first fluid flow path 806. Attachment point 862 is fluidly associated with the first fluid flow path 806 via valve 864, and attachment point 846 is fluidly associated with the first fluid flow path 806 via valve 850. A reagent source may be fluidly connected to point 844 and be associated with fluid inlet path 842 via valve 848, or second fluid inlet path 874 via valves 848 and 872.
Air removal chamber (ARC) 856 is fluidly associated with first circulation path 802. The air removal chamber 856 may include one or more sensors including an upper sensor and lower sensor to detect air, a lack of fluid, and/or a gas/fluid interface, e.g., an air/fluid interface, at certain measuring positions within the air removal chamber 856. For example, ultrasonic sensors may be used near the bottom and/or near the top of the air removal chamber 856 to detect air, fluid, and/or an air/fluid interface at these locations. Embodiments provide for the use of numerous other types of sensors without departing from the spirit and scope of the present disclosure. For example, optical sensors may be used in accordance with embodiments of the present disclosure. Air or gas purged from the CES 800 during portions of the priming sequence or other protocols can vent to the atmosphere out air valve 860 via line 858 that is fluidly associated with air removal chamber 856.
An EC media source may be attached to EC media attachment point 868 and a wash solution source may be attached to wash solution attachment point 866, to add EC media and/or wash solution to either the first or second fluid flow path. Attachment point 866 may be fluidly associated with valve 870 that is fluidly associated with first fluid circulation path 802 via valve 872 and first fluid inlet path 842. Alternatively, attachment point 866 can be fluidly associated with second fluid circulation path 804 via second fluid inlet path 874 and EC inlet path 884 by opening valve 870 and closing valve 872. Likewise, attachment point 868 is fluidly associated with valve 876 that may be fluidly associated with first fluid circulation path 802 via first fluid inlet path 842 and valve 872. Alternatively, fluid container 868 may be fluidly associated with second fluid inlet path 874 by opening valve 876 and closing valve distribution 872.
In the IC loop 802, fluid may be initially advanced by the IC inlet pump 854. In the EC loop 804, fluid is initially advanced by the EC inlet pump 878. An air detector 880, such as an ultrasonic sensor, may also be associated with the EC inlet path 884.
In at least one embodiment, first and second fluid circulation paths 802 and 804 are connected to waste line 888. When valve 890 is opened, IC media can flow through waste line 888 and to waste bag 886. Likewise, when valve 892 is opened, EC media can flow to waste bag 886.
After cells have been grown in cell growth chamber 801, they may be harvested via cell harvest path 897. Here, cells from cell growth chamber 801 can be harvested by pumping the IC media containing the cells through cell harvest path 897, with valve 898 open, into cell harvest bag 899.
Various components of the CES 800 can be contained or housed within a machine or housing 899, such as cell expansion machine, wherein the machine maintains cells and media at a predetermined temperature. It is further noted that in embodiments, components of CES 800 may be combined with other CES's such as CES 10 (
First fluid flow path 906 is fluidly associated with cell growth chamber 908 through first fluid circulation path 902. Fluid flows into cell growth chamber 908 through inlet port 910, through hollow fibers in cell growth chamber 908, and exits via outlet port 907. Pressure gauge 917 measures the pressure of media leaving cell growth chamber 908. Media flows through valve 913 and pump 911, which can be used to control the rate of media flow. Samples of media can be obtained from sample port 905 or sample coil 909 during operation. Pressure/temperature gauge 915 disposed in first fluid circulation path 902 allows detection of media pressure and temperature during operation. Media then returns to inlet port 910 to complete fluid circulation path 902. Cells expanded in cell growth chamber 908 can be flushed out of cell growth chamber 908 or redistributed within hollow fibers for further growth.
Second fluid circulation path 904 includes second fluid flow path 912 that is fluidly associated with cell growth chamber 908 in a loop. Fluid in second fluid circulation path 904 enters cell growth chamber 908 via inlet port 914, and leaves cell growth chamber 908 via outlet port 916. Media is in contact with the outside of the hollow fibers in the cell growth chamber 908, allowing diffusion of small molecules into and out of the hollow fibers.
Pressure/temperature gauge 919 disposed in the second circulation path 904 allows the pressure and temperature of media to be measured before the media enters the EC space of the cell growth chamber 908. Pressure gauge 921 allows the pressure of media in the second circulation path 904 to be measured after it leases leaves the cell growth chamber 908.
After leaving outlet port 916 of cell growth chamber 908, fluid in second fluid circulation path 904 passes through pump 920 and valve 922 to oxygenator 918. Second fluid flow path 912 is fluidly associated with oxygenator 918 via oxygenator inlet port 924 and oxygenator outlet port 926. In operation, fluid media flows into oxygenator 918 via oxygenator inlet port 924, and exits oxygenator 918 via oxygenator outlet port 926.
Oxygenator 918 adds oxygen to media in the CES 900. In various embodiments, media in second fluid circulation path 904 is in equilibrium with gas entering oxygenator 918. The oxygenator can be any oxygenator known in the art. Gas flows into oxygenator 918 via filter 928 and out of oxygenator 918 through filter 930. Filters 928 and 930 reduce or prevent contamination of oxygenator 918 and associated media.
In the configuration depicted for CES 900, fluid media in first circulation path 902 and second circulation path 904 flow through cell growth chamber 908 in the same direction (a co-current configuration). Those of skill in the art will recognize that CES 900 can also be configured in a counter-current conformation. Those of skill in the art will recognize that the respective inlet and outlet ports can be disposed in the cell growth chamber 908 at any location.
Cells and fluid media can be introduced to fluid circulation path 902 via first fluid inlet path 932. Fluid container 934 and fluid container 936 are fluidly associated with first fluid inlet path 932 via valves 938 and 940 respectively. Likewise, cell container 942 is fluidly associated with first fluid circulation path 902 via valve 943. Cells and fluid may in some embodiments proceed through heat exchanger 944, pump 946, and into drip chamber 948. In embodiments where cells from container 942 are passed through heat exchanger 944, an additional line (not shown) would be used to connect container 942 to heat exchanger 944. Drip chamber 948 is fluidly associated with first circulation path 902. Overflow from drip chamber 948 can flow out of drip chamber 948 from overflow line 950 via valve 952.
Additional fluid can be added to first or second fluid circulation paths 902 and 904 from fluid container 954 and fluid container 956. Fluid container 954 is fluidly associated with valve 958 which is fluidly associated with first fluid circulation path 902 via valve 964, patt 960, and path 932. Alternatively, fluid container 954 is fluidly associated with second fluid inlet path 962. Likewise, fluid container 956 is fluidly associated with valve 966, which is fluidly associated with first fluid circulation path 902 via first fluid inlet path 960. Alternatively, fluid container 956 is fluidly associated with second fluid inlet path 962.
Second fluid inlet path 962 is configured to allow fluid to flow through heat exchanger 944, pump 968, before entering drip chamber 970. Second fluid inlet path 962 continues to second fluid circulation path 904. Overflow fluid can flow out via overflow line 972 through valve 974 to waste container 976.
Cells can be harvested via cell harvest path 978. Cells from cell growth chamber 908 can be harvested by pumping media containing the cells through cell harvest path 978 to cell harvest bag 980, when valve 982 is opened.
First and second fluid circulation paths 902 and 904 are connected by connector path 984. When valve 986 is opened, media can flow through connector path 984 between first and second circulation paths 902 and 904. Likewise, pump 990 can pump media through another connector path 988 between first and second fluid circulation paths 902 and 904.
Various components of the CES 900 can be contained within incubator 999. Incubator 999 maintains cells and media at a constant temperature.
As will be recognized by those of skill in the art, any number of fluid containers (e.g. media bags) can be fluidly associated with the CES 900 in any combination. It will further be noted that the location of the drip chamber 948, or sensors independent of the drip chamber 948, can be at any location in the CES 900 before inlet port 910.
CES's 800 and 900 can include additional components. For example, one or more pump loops (not shown) can be added at the location of peristaltic pumps on a CES. The pump loops may be made of polyurethane (PU) (available as Tygothane C-210A)). Alternatively, a cassette for organizing the tubing lines and which may also contain tubing loops for the peristaltic pumps may also be included as part of the disposable.
A detachable flow circuit (also referred to herein as a “detachable circulation module”) may also be provided in some embodiments. The detachable flow circuit may be a portion of a cell expansion module configured to attach to a more permanent fixed portion of the CES. Generally, the fixed portions of the CES include peristaltic pumps. In various embodiments, the fixed portions of the CES can include valves and/or clamps.
The detachable flow circuit can include a first fluid flow path having at least two ends. The first end is configured to be fluidly associated with a first end of a cell growth chamber, and a second end of the first fluid flow path configured to fluidly associated with a second end of the cell growth chamber.
Likewise, the detachable flow circuit can include a second fluid flow path having at least two ends. Portions of the detachable flow circuit can be configured to be fluidly associated with an oxygenator and/or bioreactor. The detachable flow circuit can include a second fluid flow path that may be configured to fluidly associate with the oxygenator and cell growth chamber.
In various embodiments, the detachable flow circuit may be detachably and disposably mounted to a fluid flow controller. The detachable flow circuit can include detachable fluid conduits (e.g. flexible tubing) that connects portions of the CES.
In further embodiments, the detachable flow circuit can include a cell growth chamber, oxygenator, as well as bags for containing media and cells. In various embodiments, the components can be connected together, or separate. Alternatively, detachable flow circuit can include one or more portions configured to attach to fluid flow controllers, such as valves, pumps, and combinations thereof. In variations where peristaltic pumps are used, the detachable circuit module can include a peristaltic loop configured to fit around a peristaltic portion of the tubing. In various embodiments, the peristaltic loop can be configured to be fluidly associated with the circulations paths, inlet paths, and outlet paths. The detachable flow circuit can be combined in a kit with instructions for its assembly or attachments to fluid flow controllers, such as pumps and valves.
Embodiments provide for using a number of different methods to introduce cells into bioreactors of CES. As described in greater detail below, embodiments include methods and systems that distribute cells in the bioreactor to promote consistent expansion of cells.
According to embodiments, cells can be grown (“expanded”) in either the IC loop or the EC loop. Adherent and non-adherent suspension cells can be expanded. In one embodiment, the lumen of the cell growth chamber fibers can be coated with fibronectin. Divalent cation-free (e.g. calcium and magnesium-free) PBS is added to a CES system. After adherent cells are introduced into a cell growth chamber, e.g., chamber 24, 801, or 908 they are incubated for a sufficient time to adhere to the hollow fibers. IC and EC media are circulated to ensure sufficient nutrients are supplied to the cells.
The flow rate of the IC loop and EC loop can be adjusted to a specific value. In various embodiments, the flow rate of the IC loop and EC loops can be, independently set to, about 2, about 4, about 6, about 8, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 60, about 70, about 80, about 90, about 100, about 200, about 300, about 400 or even about 500 mL/minute. In various embodiments, the flow rates for the IC circuit loop may be set from about 10 to about 20 mL/minute, and the flow rate of the EC circuit loop may be set from 20 to about 30 mL per minute (allowing media to flow through an oxygenator and re-establish oxygen levels). Additional media may be pumped into the CES at a lower flow rate (e.g. 0.1 mL per minute in some embodiments) to replace media that evaporates through a gas exchange module(s) such as gas exchange/oxygenators 832 and 918. In various embodiments, the EC loop removes cellular waste, and the IC loop includes growth factors in the media.
CES's may provide a great deal of flexibility in varying growth conditions and criteria. Cells can be kept in suspension in the IC loop by circulating media continuously. Alternatively, media circulation can be stopped, causing cells to settle. Fresh media can be added to the IC loop by ultrafiltration to accommodate excess volume without removing cells. EC media circulation allows for exchange of gas, nutrients, waste products, and addition of new media without removing cells.
Expanded cells can include adherent cells, non-adherent cells, or a co-culture of any combination of cells in the art. Some non-limiting examples of cells that maybe grown in a embodiments of a CES, include, without limitation, stem cells (e.g., mesenchymal, hematopoietic, etc.), fibroblasts, keratinocytes, progenitor cells, other fully differentiated cells and combinations thereof.
In embodiments, to harvest adherent cells, the IC and EC media may be replaced with media that is free of divalent cations (e.g. divalent cation-free PBS). In one embodiment, trypsin may be loaded into a first circulation path, and allowed to incubate with adherent cells for a period of time (in some embodiments about 5 to about 10 minutes). The trypsin may then be flushed from the system. A shearing force may be applied to the cells by increasing the flow rate through cell growth chamber, and adherent cells that are released from the cell growth chamber may be pumped to a cell harvest bag.
When non-adherent cells are expanded, the cells can be flushed from the circulating IC circuit. Adherent cells remain in the cell growth chamber, while non-adherent cells are removed.
The CES can be used to perform a variety of cell expansion methods. In one embodiment, a seeded population of cells can be expanded. Cells are introduced, or seeded, into the CES. In certain circumstances, the lumen of the hollow fibers can be conditioned to allow cell adhesion. Cells are then added to the cell growth chamber, and adherent cells adhere to the hollow fibers, while non-adherent cells (e.g. hematopoietic stem cells, or HSCs) do not adhere. The non-adherent cells can be flushed from the system. After incubation for a period of time, the adherent cells can be released and harvested.
The cell growth chamber of the cell expansion system in embodiments includes a hollow fiber membrane comprised of a plurality of semi-permeable hollow fibers separating first and second fluid circulation paths.
The CES can include a device configured to move or “rock” the cell growth chamber relative to other components of the cell expansion system by attaching it to a rotational and/or lateral rocking device.
A first rotational rocking device component 402 rotates the bioreactor 400 around central axis 410 of the bioreactor. Bioreactor 400 is also connected to lateral rocking device 404. Rotational rocking device component 402 is rotationally associated to bioreactor 400. The rotational rocking device 402 then rotates bioreactor 400 around central axis 410 of the bioreactor. Rotation can occur in a clockwise or counter-clockwise direction. Bioreactor 400 can be rotated continuously in a single direction around central axis 410 in a clockwise or counterclockwise direction. Alternatively, bioreactor 400 can rotate in alternating fashion, first clockwise, then counterclockwise around central axis 410.
The CES can also include a second rotational rocking component that rotates bioreactor 400 around rotational axis 412. Rotational axis 412 passes through the center of point of bioreactor 400 and is normal to central axis 410. Bioreactor 400 can be rotated continuously in a single direction around rotational axis 412 in a clockwise or counterclockwise direction. Alternatively, bioreactor 400 can be rotated around rotational axis 412 in an alternating fashion, first clockwise, then counterclockwise. In various embodiments, bioreactor 400 can also be rotated around rotational axis 412 and positioned in a horizontal or vertical orientation relative to gravity.
Lateral rocking component 404 is laterally associated with bioreactor 400. The plane of lateral rocking component 404 moves laterally in the −x and −y directions. The settling of cells in the bioreactor 400 is thereby reduced with the movement of cell-containing media within the hollow fibers.
The rotational and/or lateral movement of the rocking device can reduce the settling of cells within the device and reduce the likelihood of cells becoming trapped within a portion of the bioreactor 400. The rate of cells settling in the cell growth chamber (e.g., bioreactor 400) is proportional to the density difference between the cells and the suspension media according to Stoke's Law. In certain embodiments, a 180 degree rotation (fast) with a pause (having a total combined time of 30 seconds) repeated as described above keeps non-adherent red blood cells suspended. A minimum rotation of about 180 degrees is performed in some embodiments; however, one could use rotation of up to 360 degrees or greater in other embodiments. Different rocking components can be used separately, or can be combined in any combination. For example, a rocking component that rotates bioreactor 400 around central axis 410 can be combined with the rocking component that rotates bioreactor 400 around axis 412. Likewise, clockwise and counterclockwise rotation around different axes can be performed independently in any combination.
It is noted that the rocking devices, and their components, described above, may be implemented in embodiments using any appropriate structure. For example, in embodiments, one or more motors may be used as rocking devices, or components (e.g. 402 and 404) of rocking devices. In one embodiment, the rocking devices may be implemented using embodiments shown and described in U.S. Pat. No. 8,339,245 entitled ROTATION SYSTEM FOR CELL GROWTH CHAMBER OF A CELL EXPANSION SYSTEM AND METHOD OF USE THEREFOR, issued Mar. 19, 2013, which is hereby incorporated by reference in its entirety as if set forth herein in full.
An embodiment of a cell growth chamber is depicted in
Fluid in the first circulation path enters cell growth chamber 200 through inlet port 204, passes into and through the intracapillary side of a plurality of hollow fibers 212 (referred to in various embodiments as the intracapillary (“IC”) side or “IC space” of a hollow fiber membrane), and out of cell growth chamber 200 through outlet port 206. The terms “hollow fiber,” “hollow fiber capillary,” and “capillary” are used interchangeably. A plurality of hollow fibers 212 are collectively referred to as a “membrane.” Fluid in the second circulation path flows in the cell growth chamber through inlet port 208, comes in contact with the outside of the hollow fibers 212 (referred to as the “EC side” or “EC space” of the membrane), and exits cell growth chamber 200 via outlet port 210. Cells can be contained within the first circulation path or second circulation path, and can be on either the IC side or EC side of the membrane.
Although cell growth chamber housing 202 is depicted as cylindrical in shape, it can have any other shape known in the art. Cell growth chamber housing 202 can be made of any type of biocompatible polymeric material. Various other cell growth chamber housings may differ in shape and size.
Those of skill in the art will recognize that the term cell growth chamber does not imply that all cells being grown or expanded in a CES are grown in the cell growth chamber. In many embodiments, adherent cells can adhere to membranes disposed in the growth chamber, or may grow within the associated tubing. Non-adherent cells (also referred to as “suspension cells”) can also be grown. Cells can be grown in other areas within the first or second fluid circulation path.
For example, the ends of hollow fibers 212 can be potted to the sides of the cell growth chamber 200 by a connective material (also referred to herein as “potting” or “potting material”). The potting can be any suitable material for binding the hollow fibers 212, provided that the flow of media and cells into the hollow fibers is not obstructed and that liquid flowing into the cell growth chamber 200 through the IC inlet port flows only into the hollow fibers 212. Exemplary potting materials include, but are not limited to, polyurethane or other suitable binding or adhesive components. In various embodiments, the hollow fibers 212 and potting may be cut through perpendicular to the central axis of the hollow fibers 212 at each end to permit fluid flow into and out of the IC side. End caps 214 and 216 are disposed at the end of the cell growth chamber.
Fluid entering cell growth chamber 200 via inlet port 208 is in contact with the outside of hollow fibers 212. This portion of the hollow fiber cell growth chamber is referred to as the “extracapillary (EC) space.” Small molecules (e.g. water, oxygen, lactate, etc.) can diffuse through the hollow fibers 212 from the interior of the hollow fiber to the EC space, or from the EC space to the IC space. Large molecular weight molecules such as growth factors are typically too large to pass through the hollow fibers 212, and remain in the IC space of the hollow fibers. In embodiments in which cells are grown in the IC space, the EC space is used as a medium reservoir to supply nutrients to the cells and remove the byproducts of cellular metabolism. The media may be replaced as needed. Media may also be circulated through an oxygenator to exchange gasses as needed.
In various embodiments, cells can be loaded into the hollow fibers 212 by any of a variety of methods, including by syringe. The cells may also be introduced into the cell growth chamber 200 from a fluid container, such as a bag, which may be fluidly associated with the cell growth chamber.
Hollow fibers 212 are configured to allow cells to grow in the intracapillary space (i.e. inside the hollow fiber lumen) of the fibers. Hollow fibers 212 are large enough to allow cell adhesion in the lumen without substantially impeding the flow of media through the hollow fiber lumen. In various embodiments, the inner diameter of the hollow fiber can be greater than or equal to about 10000, about 9000, about 8000, about 7000, about 6000, about 5000, about 4000, about 3000, about 2000, about 1000, about 900, about 800, about 700, about 650, about 600, about 550, about 500, about 450, about 400, about 350, about 300, about 250, about 200, about 150, or even about 100 microns. Likewise, the outer diameter of the hollow fiber can be less than or equal to about 10000, about 9000, about 8000, about 7000, about 6000, about 5000, about 4000, about 3000, about 2000, about 1000, about 900, about 800, about 700, about 650, about 700, about 650, about 600, about 550, about 500, about 450, about 400, about 350, about 300, about 250, about 200, about 150, or even about 100 microns. The hollow fiber wall thickness should be sufficient to allow diffusion of small molecules, in some embodiments.
Any number of hollow fibers can be used in a cell growth chamber, provided the hollow fibers can be fluidly associated with the inlet and outlet ports of the cell growth chamber. In various embodiments, the cell growth chamber can include a number of hollow fibers greater than or equal to about 1000, about 2000, about 3000, about 4000, about 5000, about 6000, about 7000, about 8000, about 9000, about 10000, about 11000 or about 12000. In other embodiments, the cell growth chamber can include a number of hollow fibers less than or equal to about 12000, about 11000, about 10000, about 9000, about 8000, about 7000, about 6000, about 5000, about 4000, about 3000, or even about 2000. In other various embodiments, the length of the hollow fibers can be greater than or equal to about 100, about 200, about 300, about 400, about 500, about 600, about 700, about 800, or about 900 millimeters. In embodiments, the cell growth chamber contains about 9000 hollow fibers that have an average length of about 295 mm, an average inner diameter of 215 microns, and an average outer diameter of about 315 microns.
Hollow fibers can be constructed of any material capable of forming a size sufficient to form fibers capable of transporting liquid from the cell growth chamber inlet port to the cell growth chamber outlet port. In various embodiments, the hollow fibers can be constructed from plastic adherent materials capable of binding to certain types of cells, such as adherent stem cells (e.g. MSCs). In various other embodiments, hollow fibers can be treated with compounds such as fibronectin to form adherent surfaces.
In certain embodiments, the hollow fibers may be made of a semi-permeable, biocompatible polymeric material. One such polymeric material which can be used is a blend of polyamide, polyarylethersulfone and polyvinylpyrrolidone (referred to herein as “PA/PAES/PVP”). The semi-permeable membrane allows transfer of nutrients, waste and dissolved gases through the membrane between the EC space and IC space. In various embodiments, the molecular transfer characteristics of the hollow fiber membranes are chosen to minimize loss of expensive reagents necessary for cell growth such as growth factors, cytokines etc. from the hollow fiber, while allowing metabolic waste products to diffuse through the membrane into the hollow fiber lumen side to be removed.
In certain variations, one outer layer of each PA/PAES/PVP hollow fiber may be characterized by a homogenous and open pore structure with a defined surface roughness. The openings of the pores may be in the size range of about 0.5 to about 3 microns, and the number of pores on the outer surface of the fibers may be in the range of about 10,000 to about 150,000 pores per mm2. This outer layer has a thickness of about 1 to about 10 microns. The next layer in each hollow fiber may be a second layer having the form of a sponge structure and, in embodiments have a thickness of about 1 to about 15 microns. This second layer may serve as a support for the outer layer. A third layer next to the second layer may have the form of finger-like structures. This third layer provides mechanical stability and a high void volume which gives the membrane a low resistance to transporting molecules through the membrane. During use, the finger-like voids are filled with fluid and the fluid gives a lower resistance for diffusion and convection than a matrix with a sponge-filled structure having a lower void volume. This third layer may have a thickness of about 20 to about 60 microns.
In further embodiments, the hollow fiber membrane can include between about 65 to about 95% by weight of at least one hydrophobic polymer and between about 5 to about 35% by weight of at least one hydrophilic polymer. The hydrophobic polymer may be chosen from the group consisting of polyamide (PA), polyaramide (PAA), polyarylethersulphone (PAES), polyethersulphone (PES), polysulphone (PSU), polyarylsulphone (PASU), polycarbonate (PC), polyether, polyurethane (PUR), polyetherimide and copolymer mixtures of any of the above polymers, such as polyethersulphone or a mix of polyarylethersulphone and polyamide. In additional embodiments, the hydrophilic polymer may be chosen from the group consisting of polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), polyglycolmonoester, water soluble cellulosic derivates, polysorbate and polyethylene-polypropylene oxide copolymers.
Depending upon the type of cells to be expanded in the cell growth chamber, the polymeric fibers may be treated with a substance, such as fibronectin, to enhance cell growth and/or adherence of the cells to the membrane.
With reference now to
Fluid in a first circulation path enters bioreactor 300 through IC inlet port 308 at a first longitudinal end 312 of the bioreactor 300, passes into and through the intracapillary side (referred to in various embodiments as the intracapillary (“IC”) side or “IC space” of a hollow fiber membrane) of a plurality of hollow fibers 316, and out of bioreactor 300 through IC outlet port 320 located at a second longitudinal end 324 of the bioreactor 300. Fluid in a second circulation path flows in the bioreactor 300 through EC inlet port 328, comes in contact with the extracapillary side or outside (referred to as the “EC side” or “EC space” of the membrane) of the hollow fibers 316, and exits bioreactor 300 via EC outlet port 332. Fluid entering bioreactor via an EC inlet port 328 is in contact with the outside of the hollow fibers. Small molecules (e.g. water, oxygen, lactate, etc.) can diffuse through the hollow fibers from the interior of the hollow fiber to the EC space, or from the EC space to the IC space. Large molecular weight molecules such as growth factors are typically too large to pass through the hollow fibers, and remain in the IC space of the hollow fibers. The media may be replaced as needed. Media may also be circulated through an oxygenator to exchange gasses as needed. Cells can be contained within the first circulation path and/or second circulation path, and can be on either the IC side and/or EC side of the membrane. By way of example and not limitation, in one embodiment, the bioreactor 300 may include about 11520 fibers that have about 215×10−6 m inner diameters (ID).
Although bioreactor housing 304 is depicted as cylindrical in shape, it could have a variety of shapes, such as a rectangular cube. Bioreactor housing 304 can be made of any type of biocompatible polymeric material, including a substantially transparent material that permits an observer to see one or more of the plurality of hollow fibers 316, as well as fluid residing within the bioreactor housing 304. Various other bioreactor housings may differ in shape and size.
Referring now to
Referring now to
Flow chart 500 starts at 502 and passes to 504 where a bioreactor 300 and any associated tubing and related structures are connected to the body 408 to provide an operable CES 430. Once connected to the body 408, the bioreactor 300 and its associated tubing and related structures are primed at 508 using an appropriate priming fluid, such as saline. At 512, cells are loaded and distributed in the bioreactor 300.
The loading and distributing of cells in embodiments involves a number of substeps, for example, in some embodiments step 512 additionally includes optional steps of orienting the bioreactor 300 in a first orientation at optional substep 516, and then loading and distributing the cells in the bioreactor 300 at optional substep 520. At optional substep 524, cells may be allowed to attach to the bioreactor.
Following loading and distributing cells in the bioreactor 300, the cells undergo expansion at 528. That is, the cells within the bioreactor 300 are allowed to expand, i.e., grow and/or multiply. At 532, an assessment is made as to whether additional cells need to be added to the bioreactor 300 and/or whether the bioreactor 300 needs to be rotated to distribute cells within the bioreactor 300. If additional cells need to be loaded into the bioreactor 300 and/or if cells need to be distributed in the bioreactor 300, then the flow chart 500 returns to step 512. If cells do not need to be added and/or the bioreactor 300 does not need to be rotated, then at 536 an assessment is made as to whether the cell expansion process 528 is complete. As used herein, the cell expansion process is determined to be complete if a sufficient number of cells and/or change in cell characteristics have been achieved. If the cell expansion process 528 is complete, the cells are harvested at 540. If cell expansion process 528 is not complete, then the cell expansion process at 528 is allowed to continue. Flow chart 500 ends at 544.
Additional detail is now provided regarding processes that may be used to load, distribute and expand cells in a bioreactor and CES's, e.g., steps 512 and 528 (
Flow chart 600 starts at 604, and passes to step 608 where fluid that includes cells may be circulated through a bioreactor such as bioreactor 300 (see
Step 608 may in some embodiments involve also rotating the bioreactor 300 in a particular sequence to facilitate distribution of the cells through the bioreactor 300 and circulation paths of the CES to which the bioreactor 300 may be fluidly associated. Examples of embodiments for rotating bioreactor 300 in a particular sequence to facilitate distribution of the cells during circulation or loading is described in U.S. patent application Ser. No. 12/968,483, filed on Dec. 15, 2010, entitled “METHOD OF LOADING AND DISTRIBUTING CELLS IN A BIOREACTOR OF A CELL EXPANSION SYSTEM,” which is hereby incorporated by reference in its entirety as if set forth herein in full. In other embodiments, the circulating step 608 may involve rotating the bioreactor 300 for some periods of time, but maintaining the bioreactor 300 stationary for other periods of time.
After step 608, the fluid circulation rate is reduced at step 612. The circulation rate may be reduced to about zero (0) ml/min, or in other embodiments may be reduced to a rate that is above zero (0) ml/min but still allows cells to settle and attach to the bioreactor 300, e.g., an inside surface of hollow fibers 316 of bioreactor 300. In embodiments, step 612 may involve stopping or turning off one or more pumps used in step 608 to circulate the fluid.
Flow passes from step 612 to optional step 616, which may be performed to orient a bioreactor, e.g. bioreactor 300 to an initial orientation. In embodiments, a bioreactor may already be oriented in an initial orientation, which would make step 616 unnecessary. When performed, step 616 may be performed by one or more motors in embodiments.
Referring now to
Flow passes from 616, to step 620 where the bioreactor is maintained at a first orientation to allow cells to settle and in some embodiments attach to a first portion of bioreactor 300. Step 620 is performed for a first predetermined period of time.
Referring now to
In embodiments, with the bioreactor 300 in the first horizontal orientation (
In some embodiments, the first predetermined period of time may be long enough in duration merely to allow the cells to settle and attach to portion 1308. In these embodiments, the cells may only need to travel the distance of the inner diameter of hollow fiber 1308. For example, in embodiments where the hollow fiber has an inner diameter of between about 150 microns and about 300 microns, the first predetermined period of time may be less than about 20 minutes, less than about 15 minutes, or even less than about 10 minutes. In other embodiments, the first predetermined period of time may be greater than about 1 minute, greater than about 2 minutes, greater than about 3 minutes, or even greater than about 4 minutes. In one embodiment, the first period of time may be between about 3 minutes and about 8 minutes, such as about 5 minutes.
In other embodiments, the first predetermined period of time may be long enough in duration to not only allow cells to settle and attach to a hollow fiber, it may be long enough in duration to allow attached cells to grow. In these embodiments, the cells may grow laterally since either lateral direction may provide the least resistance. In other words, because the cells on portion 1308 would be growing against the force of gravity 1304 if they grew upward on the fiber wall, it is believe that in embodiments, they may grow laterally, at least initially. In these embodiments, when the cells are allowed to grow after attachment, the first predetermined period of time may be greater than about 5 hours, greater than about 10 hours, greater than about 15 hours, greater than about 20 hours, or even greater than about 24 hours. In other embodiments, the first predetermined period of time may be less than about 60 hours, less than about 55 hours, less than about 50 hours, or even less than about 45 hours. In one embodiment, the predetermined period of time may be between about 10 hours and about 48 hours.
Referring back to
In embodiments, after rotation to the second horizontal orientation, flow 600 may pass to step 644, where the cell expansion is then performed with the bioreactor 300 in the second horizontal orientation.
Without being bound by theory, it is believed that in embodiments, the cell expansion is improved if the cells are grown as illustrated in
In other embodiments, flow 600 may include additional steps. For example, in some embodiments, after step 620, flow 600 may pass to step 624 where bioreactor 628 may be rotated to a vertical orientation. For example, bioreactor 300 may be rotated to a first vertical orientation as shown in
Referring now to
As noted above, without being bound by theory, it is believed that the cells that are attached to fiber 1300 will be influenced by gravity 1304 and begin to grow, i.e., expand, longitudinally toward end 1316. Therefore, in embodiments, step 628 (maintain first vertical orientation) is performed for a second predetermined period of time that may be long enough in duration to allow the cells to grow longitudinally. The second predetermined period of time may be in some embodiments, greater than about 5 hours, greater than about 10 hours, greater than about 15 hours, greater than about 20 hours, or even greater than about 24 hours. In other embodiments, the second predetermined period of time may be less than about 60 hours, less than about 55 hours, less than about 50 hours, or even less than about 45 hours. In one embodiment, the predetermined period of time may be between about 10 hours and about 48 hours.
After step 628, flow may pass to step 632, where the bioreactor may be rotated to a second vertical orientation. One example of bioreactor 300 in a second vertical orientation is shown in
Referring to
Similar to step 628 (maintain first vertical orientation), step 636 (maintain second vertical orientation) is performed because it is believed that in embodiments, the cells that are attached to fiber 1300 will be influenced by gravity 1304 and begin to grow, i.e., expand, longitudinally toward end 1312. Step 636 may be performed in embodiments for a third predetermined of period of time that may be long enough in duration to allow the cells to grow longitudinally toward end 1312 as shown in
Referring back to flow chart 600, after step 636, flow may pass to step 640 where as described above, the bioreactor may be rotated to a second horizontal position as shown in
Turning now to
In embodiments, the first circulation flow rate may be a relatively high flow rate. In embodiments, the first circulation flow rate may be less than about 500 ml/min, less than about 400 ml/min, or even less than about 300 ml/min. In other embodiments, the first circulation rate may be greater than about 50 ml/min, greater than about 100 ml/min, or even greater than about 150 ml/min. In one embodiment, the first circulation flow rate is between about 100 ml/min and about 300 ml/min, such as about 200 ml/min.
Step 708 may in some embodiments involve also rotating the bioreactor 300 in a particular sequence to facilitate distribution of the cells through the bioreactor 300 and circulation paths of the CES to which the bioreactor 300 may be fluidly associated. In other embodiments, the circulating step 708 may involve rotating the bioreactor 300 for some periods of time, but maintaining the bioreactor 300 stationary for other periods of time.
After step 708, the fluid circulation rate is reduced at step 712. The circulation rate may be reduced to about zero (0) ml/min, or in other embodiments may be reduced to a rate that is above zero (0) ml/min but still allows cells to settle and attach to the bioreactor 300, e.g., an inside surface of hollow fibers 316 of bioreactor 300. In embodiments, step 712 may involve stopping or turning off one or more pumps used in step 708 to circulate the fluid.
Flow passes from step 712 to optional step 716, which may be performed to orient a bioreactor, e.g. bioreactor 300 to an initial orientation. In embodiments, a bioreactor may already be oriented in an initial orientation, which would make step 716 unnecessary. When performed, step 716 may in some embodiments be performed by one or more motors.
Referring now to
Flow passes from 716, to step 720 where the bioreactor is maintained at a first orientation to allow cells to settle and in some embodiments attach to a first portion of bioreactor 300. Step 820 is performed for a first predetermined period of time.
Referring now to
In embodiments, with the bioreactor 300 in the first horizontal orientation (
In some embodiments, the first predetermined period of time may be long enough in duration to allow the cells to settle and attach to portion 1408 and 1508. In these embodiments, the cells may only need to travel the distance of the inner diameter of hollow fiber 1400 or 1500. For example, in embodiments where the hollow fiber has an inner diameter of between about 150 microns and about 300 microns, the first predetermined period of time may be less than about 20 minutes, less than about 15 minutes, or even less than about 10 minutes. In other embodiments, the first predetermined period of time may be greater than about 1 minute, greater than about 2 minutes, greater than about 3 minutes, or even greater than about 4 minutes. In one embodiment, the first period of time may be between about 3 minutes and about 8 minutes, such as about 5 minutes.
After step 720, flow passes to step 724, where the bioreactor 300 is rotated to a second horizontal orientation that is about 180 degrees from the first horizontal orientation. As shown in
In some embodiments, flow 700 will pass from step 724 to step 736 where the bioreactor 300 is maintained in the second horizontal orientation (
In some embodiments, flow 700 may include optional steps 728 and 732 prior to proceeding to step 736. Similar to step 708, step 728 provides for circulating fluid through the bioreactor 300. In embodiments, step 728 may involve activating one or more pumps to circulate fluid through the bioreactor 300. As noted above, an IC circulation pump (e.g., 812 or 911) may be activated to circulate fluid through the IC side of bioreactor 300 at a second circulation flow rate. In at least one embodiment, fluid carrying the cells may pass through hollow fibers of the bioreactor 300 from the IC side to the EC side. In other embodiments, cells may be loaded into the EC side of the bioreactor 300 and have the fluid carrying the cells pass from the EC side to the IC side. In these embodiments, an EC circulation pump (e.g., 828 or 974) may be activated to circulate fluid through the EC side of bioreactor 300 at a second circulation flow rate.
In embodiments, the second circulation flow rate may be less than the first circulation rate. In embodiments, the second circulation flow rate may be less than about 400 ml/min, less than about 300 ml/min, or even less than about 200 ml/min. In other embodiments, the second circulation rate may be greater than about 25 ml/min, greater than about 500 ml/min, or even greater than about 75 ml/min. In one embodiment, the second circulation flow rate is between about 50 ml/min and about 150 ml/min, such as about 100 ml/min.
In some embodiments, step 728 may also involve circulation in a different direction than the circulation performed in step 708. In other words, in some embodiments, step 708 may involve circulating fluid in a counter clockwise direction (see IC loop in
Optional step 728 may in some embodiments involve also rotating the bioreactor 300 in a particular sequence to facilitate distribution of the cells through the bioreactor 300 and circulation paths of the CES to which the bioreactor 300 may be fluidly associated. In other embodiments, the circulating step 728 may involve rotating the bioreactor 300 for some periods of time, but maintaining the bioreactor 300 stationary for other periods of time.
After optional step 728, the fluid circulation rate is once again reduced at step 732. The circulation rate may be reduced to about zero (0) ml/min, or in other embodiments may be reduced to a rate that is above zero (0) ml/min but still allows cells to settle and attach to the bioreactor 300, e.g., an inside surface of hollow fibers 316 of bioreactor 300. In embodiments, step 732 may involve stopping or turning off one or more pumps used in step 728 to circulate the fluid.
Referring once again to step 736, maintaining the bioreactor in the second horizontal orientation allows cells to settle on portion 1412 (or 1512 in
In some embodiments, the second predetermined period of time may be long enough in duration allow the cells to settle and attach to portion 1412 (or 1512 in
In some embodiments, after step 736, flow 700 may pass to step 772 where cells are expanded. Step 772 may involve a number of substeps, such as circulating fluid into the bioreactor to feed and provide nutrients to the cells attached in the bioreactor. As can be appreciated, step 772 may also involve providing oxygen to the cells so that they may multiply. Several other parameters in the bioreactor may be controlled in order to optimize the expansion, i.e. growth of the cells. In some embodiments, step 772 may include circulating fluid to feed the cells for about 24 hours, about 36 hours, about 48 hours, about 60 hours, or even about 72 hours. In some embodiments, the feeding of the cells as part of step 772 may be performed for less than about 120 hours, less than about 108 hours, less than about 96 hours, less than about 84 hours, or even less than about 72 hours.
In other embodiments, flow 700 may pass to step 740, where the bioreactor 300 is rotated back to its original first horizontal orientation.
In other embodiments, flow 700 passes from step 740 to step 744, or in other embodiments, flow may pass directly from step 736, to step 744 (when no additional rotation is performed), where fluid is again circulated but at a third circulation flow rate. Similar to steps 708 and 728, fluid is circulated through the bioreactor 300. In embodiments, step 744 may involve activating one or more pumps to circulate fluid through the bioreactor 300. As noted above, an IC circulation pump (e.g., 812 or 911) may be activated to circulate fluid through the IC side of bioreactor 300 at a third circulation flow rate. In at least one embodiment, fluid carrying the cells may pass through hollow fibers of the bioreactor 300 from the IC side to the EC side. In other embodiments, cells may be loaded into the EC side of the bioreactor 300 and have the fluid carrying the cells pass from the EC side to the IC side. In these embodiments, an EC circulation pump (e.g., 828 or 974) may be activated to circulate fluid through the EC side of bioreactor 300 at the third circulation flow rate.
In embodiments, the third circulation flow rate may be less than the second circulation rate. In embodiments, the third circulation flow rate may be less than about 200 ml/min, less than about 150 ml/min, or even less than about 100 ml/min. In other embodiments, the third circulation rate may be greater than about 10 ml/min, greater than about 20 ml/min, or even greater than about 30 ml/min. In one embodiment, the third circulation flow rate is between about 20 ml/min and about 100 ml/min, such as about 50 ml/min.
In some embodiments, step 744 may also involve circulation in a different direction than the circulation performed in step 728. In other words, in some embodiments, step 728 may involve circulating fluid in a clockwise direction. In some embodiments, the circulation at step 744 may be similar to step 708 and be in a counter clockwise direction (see IC loop in
Optional step 744 may in some embodiments involve also rotating the bioreactor 300 in a particular sequence to facilitate distribution of the cells through the bioreactor 300 and circulation paths of the CES to which the bioreactor 300 may be fluidly associated. In other embodiments, the circulating step 744 may involve rotating the bioreactor 300 for some periods of time, but maintaining the bioreactor 300 stationary for other periods of time.
Flow passes from 744 to step 748, where, the fluid circulation rate is once again reduced. The circulation rate may be reduced to about zero (0) ml/min, or in other embodiments may be reduced to a rate that is above zero (0) ml/min but still allows cells to settle and attach to the bioreactor 300, e.g., an inside surface of hollow fibers 316 of bioreactor 300. In embodiments, step 748 may involve stopping or turning off one or more pumps used in step 744 to circulate the fluid.
From step 748, flow passes to step 752 where the bioreactor is maintained in a horizontal orientation. In those embodiments that include step 744 (rotate to first orientation), step 752 will involve maintaining the first horizontal orientation. In those embodiments that do not include the rotation of step 740, step 752 will involve maintaining the second horizontal orientation. In any case, step 752 is performed to allow cells to settle again, such as on portion 1508 (See
In some embodiments, the third predetermined period of time may be long enough in duration to allow the cells to settle and attach to portion 1508. In these embodiments, the cells may only need to travel the distance of the inner diameter of hollow fiber 1500. For example, in embodiments where the hollow fiber 1500 has an inner diameter of between about 150 microns and about 300 microns, the third predetermined period of time may be less than about 20 minutes, less than about 15 minutes, or even less than about 10 minutes. In other embodiments, the third predetermined period of time may be greater than about 1 minute, greater than about 2 minutes, greater than about 3 minutes, or even greater than about 4 minutes. In one embodiment, the third period of time may be between about 3 minutes and about 8 minutes, such as about 5 minutes.
In some embodiments, flow 700 may pass from step 752 to step 772 where the cells are expanded.
In other embodiments, as described below, flow 700 may include additional rotation (756), circulation (760), reduce circulation (764), and maintain orientation (768) steps before moving to step 772 where cells are expanded. In these embodiments, flow 700 may pass from step 752 to step 756, where the bioreactor 300 is rotated back to the second horizontal orientation, if it was rotated at step 740 to the first horizontal orientation.
Flow 700 passes to step 760 where fluid is again circulated but at a fourth circulation flow rate. Similar to steps 708, 728, and 744, fluid is circulated through the bioreactor 300. In embodiments, step 744 may involve activating one or more pumps to circulate fluid through the bioreactor 300, as noted above, an IC circulation pump (e.g., 812 or 911) may be activated to circulate fluid through the IC side of bioreactor 300 at a fourth circulation flow rate. In at least one embodiment, fluid carrying the cells may pass through hollow fibers of the bioreactor 300 from the IC side to the EC side. In other embodiments, cells may be loaded into the EC side of the bioreactor 300 and have the fluid carrying the cells pass from the EC side to the IC side. In these embodiments, an EC circulation pump (e.g., 828 or 974) may be activated to circulate fluid through the EC side of bioreactor 300 at the fourth circulation flow rate.
In embodiments, the fourth circulation flow rate may be less than the third circulation rate. In embodiments, the fourth circulation flow rate may be less than about 100 ml/min, less than about 75 ml/min, or even less than about 50 ml/min. In other embodiments, the fourth circulation rate may be greater than about 5 ml/min, greater than about 10 ml/min, or even greater than about 15 ml/min. In one embodiment, the fourth circulation flow rate is between about 15 ml/min and about 35 ml/min, such as about 25 ml/min.
In some embodiments, step 760 may also involve circulation in a different direction than the circulation performed in step 744. In other words, in some embodiments, step 744 may involve circulating fluid in a counter clockwise direction. In some embodiments, the circulation at step 760 may be similar to step 728 and be in a clockwise direction. In other words, the circulation at step 760 may flow opposite to the circulation at step 744, and the same as the direction of circulation of step 728. In other embodiments, the circulation in steps 708, 728, 744 and 760 may flow in the same direction, clockwise or counter clockwise.
Step 760 may in some embodiments involve also rotating the bioreactor 300 in a particular sequence to facilitate distribution of the cells through the bioreactor 300 and circulation paths of the CES to which the bioreactor 300 may be fluidly associated. In other embodiments, the circulating step 760 may involve rotating the bioreactor 300 for some periods of time, but maintaining the bioreactor 300 stationary for other periods of time.
Flow passes from 760 to step 764, where, the fluid circulation rate is once again reduced. The circulation rate may be reduced to about zero (0) ml/min, or in other embodiments may be reduced to a rate that is above zero (0) ml/min but still allows cells to settle and attach to the bioreactor 300, e.g., an inside surface of hollow fibers 316 of bioreactor 300. In embodiments, step 764 may involve stopping or turning off one or more pumps used in step 760 to circulate the fluid.
From step 764, flow passes to step 768 where the bioreactor is maintained in the second horizontal orientation to allow cells to settle on for example portion 1512 again (see
In some embodiments, the fourth predetermined period of time may be long enough in duration allow the cells to settle and attach. In these embodiments, the cells may only need to travel the distance of the inner diameter of the hollow fiber, e.g., fiber 1500. For example, in embodiments where the hollow fiber 1500 has an inner diameter of between about 150 microns and about 300 microns, the fourth predetermined period of time may be less than about 20 minutes, less than about 15 minutes, or even less than about 10 minutes. In other embodiments, the fourth predetermined period of time may be greater than about 1 minute, greater than about 2 minutes, greater than about 3 minutes, or even greater than about 4 minutes. In one embodiment, the fourth period of time may be between about 3 minutes and about 8 minutes, such as about 5 minutes.
After step 768, flow 700 passes to step 772 where the cells settled and attached to the bioreactor 300, e.g., to hollow fibers of the bioreactor, are expanded, i.e., multiplied. Flow 700 then ends at 776.
Without being bound by theory, it is believe that in embodiments, the cell expansion is improved if the steps of flow 700 are performed. It is believed that these embodiments help to ensure that more portions of the bioreactor, e.g., surface of hollow fibers in the bioreactor, are seeded with cells prior to cell expansion. This may provide for more cells to initially be seeded, and ultimately may improve cell yield and reduce cell doubling time, as compared to conventional processes.
Although flow 700 includes specific number of steps that provide for rotating, circulating, reducing circulation, and maintaining the orientation of the bioreactor, other embodiments are not limited to these specific number of steps. In other embodiments, even after step 768, the bioreactor may be rotated again, circulation can be restarted again, followed by another period of reducing circulation to allow cells to settle and maintain the orientation for a period of time to allow cells to attach to portion of a bioreactor. These steps may be performed any number of times. In embodiments, each time the circulation is restarted, it is at a lower rate than the previous circulation. In other embodiments, the circulation rates may be the same each time circulation is started. In yet other embodiments, the direction of circulation may be changed, with circulation in a first direction, followed by stopping the circulation to allow the cells to settle and attach, circulation in a direction opposite the first direction (clockwise vs. counter clockwise) and again stopping the circulation to allow the cells to settle.
Referring now to
Also shown in
Accordingly, without being bound by theory, it is believed that having steps 708, 728, 744 and 752 circulate at different flow rates, allows the fluid to flow through more of the hollow fibers 1608 than if just a single flow rate would be used. In one embodiment of a process that follows flow chart 700, at step 708 (at the flow rates described above), fluid may flow through the hollow fibers in zone 1612. At step 728 (at the flow rates described above), fluid may flow through the hollow fibers in both zones 1612 and 1616 because the rate is slower and the fluid may disperse more. At step 744 (at the flow rates described above), fluid may flow through the hollow fibers in zones 1612, 1616, and 1620 because the flow rate is yet slower and fluid may disperse even more. At step 752 (at the flow rates described above), fluid may flow through the hollow fibers in all the zones 1612, 1616, 1620 and 1624 because the flow rates are even slower and the fluid may disperse through all of the fibers in the various zones. Thus, it is believe that fluid with the cells may flow into more of the hollow fibers using a sequence of different flow rates, than if a single high flow rate circulation is used.
Furthermore, it is also believed that the different flow rates may also affect the longitudinal distribution of cells along the bioreactor, e.g., along a hollow fiber. That is, a higher flow rate may allow cells to flow further along inside a hollow fiber. For example, at a higher flow rate, a cell being carried by fluid may reach beyond half the length of the hollow fiber. At a lower flow rate, a cell being carried by fluid may reach half the length of the hollow fiber. At even a lower flow rate, a cell being carried by fluid may reach less than half the length of the hollow fiber. Accordingly, in some embodiments, it is believed that the use of different flow rates may provide some improvement in longitudinal distribution of cells along the length of the bioreactor, e.g., a hollow fiber.
It is noted that the embodiments described with respect to flow charts 500, 600 and 700 may be used in the expansion of any type of cell some non-limiting examples including, stem cells (mesenchymal, hematopoietic, etc.), fibroblasts, keratinocytes, progenitor cells, endothelial cells, other fully differentiated cells and combinations thereof. Different cells may be expanded using processes that have different features, and combinations of features, some of which may include steps described above with respect to flow charts 500, 600 and/or 700.
Although flow charts 500 (
Finally,
Computer system 1700 includes output device(s) 1704, and/or input device(s) 1708. Output device(s) 1704 may include one or more displays, including CRT, LCD, and/or plasma displays. Output device(s) 1704 may also include a printer, speaker, etc. Input device(s) 1708 may include a keyboard, touch input devices, a mouse, voice input device, etc.
Basic computer system 1700 may also include a processing unit 1712 and/or a memory 1716, according to embodiments of the present invention. The processing unit 1712 may be a general purpose processor operable to execute instructions stored in memory 1716. Processing unit 1712 may include a single processor or multiple processors, according to embodiments. Further, in embodiments, each processor may be a multi-core processor having one or more cores to read and execute separate instructions. The processors may include general purpose processors, application specific integrated circuits (ASICs), field programmable gate arrays (FPGAs), other integrated circuits.
The memory 1716 may include any tangible medium for short-term or long-term storage for data and/or processor executable instructions, according to embodiments. The memory 1716 may include, for example, Random Access Memory (RAM), Read-Only Memory (ROM), or Electrically Erasable Programmable Read-Only Memory (EEPROM). Other storage media may include, for example, CD-ROM, tape, digital versatile disks (DVD) or other optical storage, tape, magnetic disk storage, magnetic tape, other magnetic storage devices, etc. In embodiments, system 1700 may be used to control the rotation of bioreactor 300 and/or various flow control devices, pumps, valves, etc. of CES systems. Memory 1716 can store protocols 1720 and procedures 1724, such as protocols and procedures for loading and distributing cells in a bioreactor, which would control operation of circulation pumps, valves, rotation of bioreactor(s), etc.
Storage 1728 may be any long-term data storage device or component. Storage 1220 may include one or more of the systems described in conjunction with memory 1716, according to embodiments. Storage 1728 may be permanent or removable. In embodiments, system 1700 is part of a CES system and storage 1728 may store various procedures for utilizing a CES system to load, distribute, attach, expand, and harvest cells of various types.
Below, some examples of specific embodiments of the present invention are described. However, it is noted that although specific parameters, features, and/or values are described below, e.g., for programming a CES (namely a QUANTUM® cell expansion system), according to some embodiments, these are provided merely for illustrative purposes, and the present invention is not limited to the specific details provided below.
The objective of this study is to characterize the expansion of human bone marrow derived mesenchymal stem cells (hMSCs) using two unique cell seeding methodologies in the QUANTUM® cell expansion system.
The current cell loading procedure used on the QUANTUM cell expansion system for pre-selected hMSCs distributes the cells in the bioreactor via uniform cell suspension. The cells are loaded into the IC Circulation loop of the QUANTUM cell expansion system and then circulated at relatively high flow rates (200 mL/min) for two minutes. This circulation method, coinciding with deliberate bioreactor motion, results in a uniform suspension of cells. Once the cells are uniformly suspended, circulation and bioreactor motion stops and the cells settle onto the bioreactor surface.
One limitation of this cell loading procedure is that only the trough of the bioreactor fiber is seeded with cells. hMSCs are frequently seeded at a specified cell density (e.g., 500 cells/cm2). In order to achieve a specified seed density, only approximately 50% of the bioreactor surface area can be considered when determining the appropriate number of cells to load. At 500 cells/cm2, the QUANTUM cell expansion system bioreactor can be seeded with 10.5 E+06 cells (500 cells/cm2×21000 cm2). However, only 50% of the bioreactor surface area can be considered “seed able” due to the aforementioned mechanics of the current cell load protocol. In addition, expanding cells attempting to migrate to the “unseedable” surface of the bioreactor must overcome gravity in order to utilize that surface. It is theorized here that migrating cells may take the path of least resistance; resulting in rapid confluence within the cell population compared to those expanded in its flask counter-part.
A total of seven sterilized Quantum CES Disposable sets with a bioreactor may be fibronectin coated (5 mg) overnight. All Quantum systems may be seeded with pre-cultured hMSCs. One Quantum cell expansion system may use the current Load with Circulation Task and serve as the experiment control. Three Quantum cell expansion systems may use “Load with Circulation Task: Modification 1” (Modification 1) and three Quantum cell expansion systems may use “Load with Circulation Task: Modification 2” (Modification 2).
Disposable Sets: All bioreactors may be integrated into a QUANTUM cell expansion system (CES) disposable set and sterilized with ethylene oxide.
Cell Source and Density: The bioreactor that may be used may have a 2.1 m2 inner (IC) surface area. As a result, an adjustment to seeding densities for control flasks may need to be made based on the bioreactor volume fraction of the IC loop. All bioreactors may be uniformly loaded with a maximum of 20 E+06 pre-selected MSCs (existing passages 1-3) from a direct re-load of the same cell source. Cells from a single donor are preferred. Seed three (3) T25 control flasks with hMSCs at the same density per cm2 as the bioreactor for comparative purposes.
CES Media IC Input Q Management & Harvest: The media feed rate (IC Input Q) may be doubled when the glucose levels fall below 70 mg/dL; the IC Input Q may be doubled a second time in the course of one day if the glucose values continue to fall below 70 mg/dL. All disposable sets may be harvested at the same time and no later than Day 8 to limit potential aggregation. Cell harvest time may be determined as a result of the metabolic characteristics displayed by the cell cultures. The target harvest time may be post-log phase growth of the cells.
Post-Harvest Evaluation: Evaluations may be performed on each of the harvest products. These evaluations may include cell count and viability.
Quantum CES Cell Load Modification 1
The current cell load procedure may be performed with the following modifications shown in bold. After allowing the cells to attach for 5 minutes, all bioreactors may be rotated 180 degrees to allow unattached cells to settle to the top of the hollow fiber membrane for an additional 5 minutes. Then bioreactor may be rotated back to the home horizontal position and proceed with the expansion protocol. The rationale for the modification is to distribute the cells over the entire surface area of the bioreactor hollow fiber.
Day: 0 Attach Cells with One (1) Rotation
Purpose: enables adherent cells to attach to the bioreactor membrane while allowing flow on the EC circulation loop. The pump flow rate to the IC loop may be set to zero.
Table 1 describes the bags of solution that may be attached to each line when performing Attach Cells. These solutions and corresponding volumes are based on the default settings for this task.
Cells pathway: Task>Load and Attach>Attach Cells
Enter the values for each setting for Attach Cells shown in Protocol Table 2 a-c.
Quantum CES Cell Load Modification 2
The current cell load procedure, pre-selected MSC Expansion Protocol, may be performed with the following modifications shown in bold. Cells may be attached to the top of the hollow fiber by rotating the bioreactor to the 180 degree position during the cell attachment phase (18-24 hours). Then rotate the bioreactor back to the home position and proceed with the expansion protocol. The rationale for the modification is to allow gravity to influence the direction of cell migration toward the empty growth surface during cell expansion.
The force of gravity may be used to “influence” the cell migration during expansion. This may be accomplished by seeding the cells as described in the current cell load procedure, then during expansion the bioreactor may be rotated 180°. In this configuration the unoccupied growth surface of the bioreactor is below the seeded cells. The cells may then expand in the direction of least resistance (e.g., downward, aided by gravity).
Day: 0 Attach Cells with One (1) Rotation
Purpose: enables adherent cells to attach to the bioreactor membrane while allowing flow on the EC circulation loop. The pump flow rate to the IC loop may be set to zero.
Table 5 describes the bags of solution that may be attached to each line when performing Attach Cells. These solutions and corresponding volumes are based on the default settings for this task.
Cells pathway: Task>Load and Attach>Attach Cells
The results may be as follows:
The Bull's Eye cell loading procedure is a series of steps designed to increase cell yield by allowing for a more even distribution of cells within the bioreactor of the QUANTUM® cell expansion system and by reducing the number of cells lost during a seeding process.
The Bull's Eye cell loading technique for the QUANTUM cell expansion system provides a series of steps that include and add to the ‘Load Cells with Uniform Suspension’ protocol (Quantum Cell Expansion System Operator's Manual for Software Version 2.0) that is commonly used to seed the bioreactor. In Load Cells with Uniform Suspension (LCWUS), suspended cells have a single opportunity to enter and attach to the internal surface of one fiber of the bioreactor after the cell suspension is circulated through the IC loop at 200 mL/min. Bull's Eye may allow cells that do not attach after the initial suspension and those that may be left in the IC loop rather than in the bioreactor to be re-suspended and transported to a different fiber within the bioreactor for subsequent attachment.
The Bull's Eye load may operate on the principle that a cell suspension introduced to the bioreactor via circulation of the IC loop may pass through a different set of bioreactor fibers depending on the rate of circulation of that cell suspension in the IC loop.
Following an initial 200 mL/min suspension cycle in loading cells with uniform suspension (LCWUS), the cell suspension in the IC loop may be circulated alternately in the positive and negative directions at sequentially lower circulation rates: −100 mL/min, 50 mL/min, −25 mL/min. Each progressively slower cycle of the IC loop may allow those cells still left in suspension an additional opportunity to enter and attach to the inner surface of a bioreactor fiber.
Each cycling of the fluid in the IC loop may be followed by a 7-minute cell-attachment period during which the IC circulation rate may be zero. MSC cells have been demonstrated to attach within 5 minutes to the inner surface of a fiber in a bioreactor used in the QUANTUM cell expansion system. As such, the 7-minute attachment may allow for 5 minutes for cell attachment, and 2 extra minutes to allow for slower-attaching cells. The four total cycles of cell suspension and cell attachment in the IC loop may be followed by a 24 hr attachment period after which an appropriate cell feeding schedule may be input as desired.
Day: −1 Coat Bioreactor
Purpose: coats the bioreactor membrane with a reagent.
Step 1: loads a reagent into the IC loop until the bag is empty.
Step 2: chases the reagent from the ARC into the IC loop.
Step 3: circulates the reagent in the IC loop.
Before starting this task, the following preconditions may be satisfied:
Include at least 40 mL of air in the cell inlet bag.
Table 10 describes the bags of solution that may be used to attach to each line when performing Coat Bioreactor. These solutions and corresponding volumes may be based on the default settings for this task.
Coat Bioreactor pathway: Task>System Management>Coat Bioreactor
Enter the values for each setting for step 1 shown in Table 11.
Enter the values for each setting for step 2 shown in Table 12.
Enter the values for each setting for step 3 shown in Table 13.
Day: 0 IC EC Washout
Purpose: used to replace the fluid on both the IC circulation loop and the EC circulation loop. The replacement volume is specified by the number of IC Volumes and EC Volumes exchanged. Table 14 describes the bags of solution that may be attached to each line when performing IC EC Washout. These solutions and corresponding volumes may be based on the default settings for this task.
IC EC Washout pathway: Task>Washout>IC EC Washout
Confirm the values for each setting for IC EC Washout shown in Table 15.
Day: 0 Condition Media
Follow the instructions in this task to allow the media to reach equilibrium with the provided gas supply before loading the cells. This task may include two separate steps:
Step 1: provides rapid contact between the media and the gas supply by using a high EC circulation rate.
Step 2: maintains the system in a proper state until the operator is ready to load the cells.
Table 16 describes the bags of solution that may be attached to each line when performing Condition Media. These solutions and corresponding volumes may be based on the default settings for this task.
Condition Media pathway: Task>System Management>Condition Media
Enter the values for each setting for step 1 shown in Table 17.
Enter the values for each setting for step 2 shown in Table 18.
Day: 0 Load Cells with Uniform Suspension
Purpose: loads the cells into the bioreactor from the cell inlet bag until the bag is empty. This task only uses IC circulation to distribute the cells and does not attempt to chase the cells from the line into the bioreactor. This task may include three separate steps.
Step 1: loads the cells from the cell inlet bag into the bioreactor.
Step 2: chases the cells from the ARC to the bioreactor. Larger chase volumes spread the cells and move them towards the IC outlet.
Step 3: promotes distribution of cells across membrane via IC circulation and no IC inlet thus no ultrafiltration.
Before starting this task, the following preconditions may be satisfied:
Include at least 40 mL of air in the cell inlet bag.
Table 19 describes the bags of solution that may be attached to each line when performing Load Cells With Uniform Suspension. These solutions and corresponding volumes may be based on the default settings for this task.
Load Cells with Uniform suspension pathway: Task>Load and Attach>Load Cells with Uniform Suspension
Confirm the values for each setting for step 1 shown in Table 20.
Confirm the values for each setting for step 2 shown in Table 21.
Confirm the values for each setting for step 3 shown in Table 22.
Day: 0 Bull's Eye Attachment
Purpose: allows adherent cells to attach to the bioreactor membrane while allowing flow on the EC circulation loop. The pump flow rate to the IC loop may be set to zero.
Step 1: Allows cells 7 minutes to attach to the inner surface of the bioreactor at 180°.
Step 2: Circulates the IC fluid and the remaining suspended cells at a high rate in a direction opposite to the initial load.
Step 3: This step is a second 7.0 minute allowance for further cell attachment. Those cells that were relocated from the IC loop or from a different region of the bioreactor will be given a chance to settle and adhere to the bioreactor.
Step 4: Again re-circulates those cells remaining in the IC loop and those cells that have yet to attach to a surface. Circulation may be in the positive direction and the circulation rate may be lower this time to avoid removing those cells that have already attached and to seed preferentially regions of the bioreactor that may not have been seeded in previous steps.
Step 5: This step is a third 7.0 minute allowance for further cell attachment. Those cells that were relocated from the IC loop or from a different region of the bioreactor will be given a chance to settle and adhere to the bioreactor.
Step 6: re-circulates those cells remaining in the IC loop and those cells that have yet to attach to a surface. Circulation may be in the negative direction and the circulation rate is lower this time to avoid removing those cells that have already attached.
Step 7: 24 hour attach cells phase. Cells may have 24 hours to anchor solidly to the bioreactor before feeding begins.
Table 23 describes the bags of solution that may be attached to each line when performing Bull's Eye Attachment. These solutions and corresponding volumes may be based on the default settings for this task.
Bull's Eye attachment Cells pathway: Task>Custom>Custom
Enter the values for each setting shown in table 24.
Enter the values for each setting shown in table 25.
Enter the values for each setting shown in table 26
Enter the values for each setting shown in table 27
Enter the values for each setting shown in table 28.
Enter the values for each setting shown in table 29.
Enter the values for each setting shown in table 30.
Day: 1 Feed Cells
Purpose: continuously adds a low flow rate to the IC circulation loop and/or the EC circulation loop. There are several outlet settings that can be used to remove the fluid added to the system during this task.
Table 31 describes the bags of solution that may be attached to each line when performing Feed Cells. These solutions and corresponding volumes may be based on the default settings for this task.
Feed Cells pathway: Task>Feed and Add>Feed Cells
Confirm the values for each setting for step 1 for shown in Table 32.
Increase IC Inlet rate as needed.
Release Adherent Cells And Harvest
Purpose: releases cells from the membrane, leaving the cells in the IC loop and transfers cells in suspension from the IC circulation loop, including cells in the bioreactor, into the harvest bag.
Step 1: performs the IC EC Washout task in preparation for adding a reagent. For example, the system replaces IC EC media with PBS to remove protein, Ca++, and Mg++ in preparation for adding trypsin.
Step 2: loads a reagent into the system until the bag is empty.
Step 3: chases the reagent into the IC loop.
Step 4: mixes the reagent within the IC loop.
Step 5: transfers cells in suspension from the IC circulation loop, including cells in the bioreactor, to the harvest bag.
Before starting this task, the following preconditions may be satisfied:
Include at least 40 mL of air on the cell inlet bag.
Table 33 describes the bags of solution that may be attached to each line when performing Release Adherent Cells And Harvest. These solutions and corresponding volumes may be based on the default settings for this task.
Release Adherent Cells pathway: Task>Release and Harvest>Release Adherent Cells And Harvest
Confirm the values for each setting for step 1 shown in Table 34.
Confirm the values for each setting for step 2 shown in Table 35.
Confirm the values for each setting for step 3 shown in Table 36.
Confirm the values for each setting for step 4 shown in Table 37.
Confirm the values for each setting for step 5 shown in Table 38.
The results of the study may be as follows:
The Bull's Eye load may be evaluated using MSC from four different donors. Yields from Bull's Eye loaded harvests may be consistently higher than the yields loaded using LCWUS and cultured under identical conditions. The mean cell yield increase using Bull's Eye (n=6) vs. LCWUS (n=4) may be 25%.
Viability of MSC samples from the IC loop taken immediately after performing the Bull's Eye load may be 100%. Viability of MSC from Bull's Eye harvests may be over 98% for all samples. MSC from Bull's Eye harvests may display typical morphology in culture, and all MSC biomarkers measured by flow cytometry may conform to ISCT standards.
The same protocol as described above with respect to Example 2 may be used to study modifications to the Bulls Eye attachment protocol. The modifications to the Bulls Eye attachment (Bulls Eye II), and to the protocol described above, include eliminating the attachments phases after the circulation rates: 100 ml/min; −50 ml/min; and 25 ml/min. That is, instead of having 7 minute stop conditions as described above, there is no stop condition so that the next circulation rate follows the previous circulation rate. A control, as well as an original Bulls Eye run (Bulls Eye I) may also be performed as a comparison.
The results of this study may be as follows:
Various components may be referred to herein as “operably associated.” As used herein, “operably associated” refers to components that are linked together in operable fashion, and encompasses embodiments in which components are linked directly, as well as embodiments in which additional components are placed between the two linked components.
The foregoing discussion of the one or more embodiments of the present invention has been presented for purposes of illustration and description. The foregoing is not intended to be limiting. In the foregoing Detailed Description for example, various features of the one or more embodiments may have been grouped together for the purpose of streamlining the disclosure. This method of disclosure is not to be interpreted as reflecting an intention that the embodiments require more features than may be expressly recited in a claim. Rather, as the following claims reflect, inventive aspects may lie in less than all features of a single foregoing disclosed embodiment. Thus, the following claims are hereby incorporated into this Detailed Description, with each claim standing on its own as a separate embodiment of the present invention.
Moreover, though the description includes description of one or more embodiments and certain variations and modifications, other variations and modifications are within the scope of the invention (e.g., as may be within the skill and knowledge of those in the art, after understanding the present disclosure). It is intended to obtain rights which include alternative embodiments to the extent permitted, including alternate, interchangeable and/or equivalent structures, functions, ranges or steps to those claimed, whether or not such alternate, interchangeable and/or equivalent structures, functions, ranges or steps are disclosed herein, and without intending to publicly dedicate any patentable subject matter.
This application is a divisional application of, and claims priority to, U.S. patent application Ser. No. 14/542,304, entitled, “Expanding Cells in a Bioreactor,” filed on Nov. 14, 2014, which claims priority to, and the benefit of, U.S. Provisional Patent Application Ser. No. 61/905,182 filed Nov. 16, 2013, entitled METHOD OF LOADING AND DISTRIBUTING CELLS IN A BIOREACTOR OF A CELL EXPANSION SYSTEM. The disclosures of the above-identified applications are hereby incorporated by reference in their entireties as if set forth herein in full for all that they teach and for all purposes.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2997077 | Rodrigues | Aug 1961 | A |
| 3013435 | Rodrigues | Dec 1961 | A |
| 3067915 | Shapiro et al. | Dec 1962 | A |
| 3191807 | Rodrigues | Jun 1965 | A |
| 3283727 | Rodrigues | Nov 1966 | A |
| 3701717 | Ingvorsen | Oct 1972 | A |
| 3821087 | Knazek et al. | Jun 1974 | A |
| 3883393 | Knazek et al. | May 1975 | A |
| 3896061 | Tanzawa et al. | Jul 1975 | A |
| 3997396 | Delente | Dec 1976 | A |
| 4173415 | Wyatt | Nov 1979 | A |
| 4184922 | Knazek et al. | Jan 1980 | A |
| 4200689 | Knazek et al. | Apr 1980 | A |
| 4220725 | Knazek et al. | Sep 1980 | A |
| 4301010 | Eddleman et al. | Nov 1981 | A |
| 4301118 | Eddleman et al. | Nov 1981 | A |
| 4391912 | Yoshida et al. | Jul 1983 | A |
| 4412990 | Lundblad et al. | Nov 1983 | A |
| 4418691 | Yannas et al. | Dec 1983 | A |
| 4439322 | Sonoda et al. | Mar 1984 | A |
| 4439901 | Eddleman | Apr 1984 | A |
| 4478829 | Landaburu et al. | Oct 1984 | A |
| 4486188 | Altshuler et al. | Dec 1984 | A |
| 4509695 | Bessman | Apr 1985 | A |
| 4585654 | Landaburu et al. | Apr 1986 | A |
| 4618586 | Walker | Oct 1986 | A |
| 4629686 | Gruenberg | Dec 1986 | A |
| 4647539 | Bach | Mar 1987 | A |
| 4650766 | Harm et al. | Mar 1987 | A |
| 4657866 | Kumar | Apr 1987 | A |
| 4670544 | Schwinn et al. | Jun 1987 | A |
| 4722902 | Harm et al. | Feb 1988 | A |
| 4727059 | Binder et al. | Feb 1988 | A |
| 4804628 | Cracauer et al. | Feb 1989 | A |
| 4828706 | Eddleman | May 1989 | A |
| 4885087 | Kopf | Dec 1989 | A |
| 4889812 | Guinn et al. | Dec 1989 | A |
| 4894342 | Guinn et al. | Jan 1990 | A |
| 4897358 | Carrasco | Jan 1990 | A |
| 4918019 | Guinn | Apr 1990 | A |
| 4960521 | Keller | Oct 1990 | A |
| 4973558 | Wilson et al. | Nov 1990 | A |
| 4988623 | Schwarz et al. | Jan 1991 | A |
| 4999298 | Wolfe et al. | Mar 1991 | A |
| 5002890 | Morrison | Mar 1991 | A |
| 5015585 | Robinson | May 1991 | A |
| 5019054 | Clement et al. | May 1991 | A |
| 5079168 | Amiot | Jan 1992 | A |
| 5126238 | Gebhard et al. | Jun 1992 | A |
| 5130141 | Law et al. | Jul 1992 | A |
| 5149544 | Gentile et al. | Sep 1992 | A |
| 5162225 | Sager et al. | Nov 1992 | A |
| 5169930 | Ruoslahti et al. | Dec 1992 | A |
| 5192553 | Boyse et al. | Mar 1993 | A |
| 5197985 | Caplan et al. | Mar 1993 | A |
| 5202254 | Amiot | Apr 1993 | A |
| 5225346 | Matsumiya et al. | Jul 1993 | A |
| 5226914 | Caplan et al. | Jul 1993 | A |
| 5240614 | Ofsthun et al. | Aug 1993 | A |
| 5240861 | Bieri | Aug 1993 | A |
| 5262320 | Stephanopoulos | Nov 1993 | A |
| 5283058 | Faustman | Feb 1994 | A |
| 5310676 | Johansson et al. | May 1994 | A |
| 5324428 | Flaherty | Jun 1994 | A |
| 5330915 | Wilson et al. | Jul 1994 | A |
| 5342752 | Platz et al. | Aug 1994 | A |
| 5397706 | Correa et al. | Mar 1995 | A |
| 5399493 | Emerson et al. | Mar 1995 | A |
| 5416022 | Amiot | May 1995 | A |
| 5422197 | Zito | Jun 1995 | A |
| 5433909 | Martakos et al. | Jul 1995 | A |
| 5436151 | McGlave et al. | Jul 1995 | A |
| 5437994 | Emerson et al. | Aug 1995 | A |
| 5439757 | Zito | Aug 1995 | A |
| 5453357 | Hogan | Sep 1995 | A |
| 5459069 | Palsson et al. | Oct 1995 | A |
| 5460964 | McGlave et al. | Oct 1995 | A |
| H1509 | Eran et al. | Dec 1995 | H |
| 5478739 | Slivka et al. | Dec 1995 | A |
| 5486359 | Caplan et al. | Jan 1996 | A |
| 5486389 | Gerber | Jan 1996 | A |
| 5496659 | Zito | Mar 1996 | A |
| 5507949 | Ho | Apr 1996 | A |
| 5510257 | Sirkar et al. | Apr 1996 | A |
| 5512180 | Ho | Apr 1996 | A |
| 5527467 | Ofsthun et al. | Jun 1996 | A |
| 5541105 | Melink et al. | Jul 1996 | A |
| 5543316 | Zawadzka et al. | Aug 1996 | A |
| 5545492 | Zito | Aug 1996 | A |
| 5549674 | Humes et al. | Aug 1996 | A |
| 5564183 | Satou et al. | Oct 1996 | A |
| 5571720 | Grandies et al. | Nov 1996 | A |
| 5591625 | Gerson et al. | Jan 1997 | A |
| 5593580 | Kopf | Jan 1997 | A |
| 5595909 | Hu et al. | Jan 1997 | A |
| 5599703 | Davis et al. | Feb 1997 | A |
| 5605822 | Emerson et al. | Feb 1997 | A |
| 5605829 | McGlave et al. | Feb 1997 | A |
| 5605835 | Hu et al. | Feb 1997 | A |
| 5622857 | Goffe | Apr 1997 | A |
| 5626731 | Cooley et al. | May 1997 | A |
| 5627070 | Gruenberg | May 1997 | A |
| 5631006 | Melink et al. | May 1997 | A |
| 5635386 | Palsson et al. | Jun 1997 | A |
| 5635387 | Fei et al. | Jun 1997 | A |
| 5643736 | Bruder et al. | Jul 1997 | A |
| 5646043 | Emerson et al. | Jul 1997 | A |
| 5654186 | Cerami et al. | Aug 1997 | A |
| 5656421 | Gebhard et al. | Aug 1997 | A |
| 5656479 | Petitte et al. | Aug 1997 | A |
| 5658995 | Kohn et al. | Aug 1997 | A |
| 5667985 | O'Leary et al. | Sep 1997 | A |
| 5670147 | Emerson et al. | Sep 1997 | A |
| 5670351 | Emerson et al. | Sep 1997 | A |
| 5670372 | Hogan | Sep 1997 | A |
| 5674750 | Kraus et al. | Oct 1997 | A |
| 5677136 | Simmons et al. | Oct 1997 | A |
| 5677355 | Shalaby et al. | Oct 1997 | A |
| 5684712 | Goffe et al. | Nov 1997 | A |
| 5686289 | Humes et al. | Nov 1997 | A |
| 5688687 | Palsson et al. | Nov 1997 | A |
| 5695989 | Kalamasz | Dec 1997 | A |
| 5700289 | Breitbart et al. | Dec 1997 | A |
| 5705534 | D'Agostino et al. | Jan 1998 | A |
| 5707859 | Miller et al. | Jan 1998 | A |
| 5712154 | Mullon et al. | Jan 1998 | A |
| 5712163 | Parenteau et al. | Jan 1998 | A |
| 5716827 | Tsukamoto et al. | Feb 1998 | A |
| 5728581 | Schwartz et al. | Mar 1998 | A |
| 5733541 | Taichman et al. | Mar 1998 | A |
| 5733542 | Haynesworth et al. | Mar 1998 | A |
| 5736396 | Bruder et al. | Apr 1998 | A |
| 5744347 | Wagner et al. | Apr 1998 | A |
| 5750397 | Tsukamoto et al. | May 1998 | A |
| 5750651 | Oppermann et al. | May 1998 | A |
| 5753506 | Johe | May 1998 | A |
| 5759793 | Schwartz et al. | Jun 1998 | A |
| 5763194 | Slowiaczek et al. | Jun 1998 | A |
| 5763197 | Tsukamoto et al. | Jun 1998 | A |
| 5763261 | Gruenberg | Jun 1998 | A |
| 5763266 | Palsson et al. | Jun 1998 | A |
| 5766944 | Ruiz | Jun 1998 | A |
| 5766948 | Gage et al. | Jun 1998 | A |
| 5766951 | Brown | Jun 1998 | A |
| 5772994 | Ildstad et al. | Jun 1998 | A |
| 5783075 | Eddleman et al. | Jul 1998 | A |
| 5783216 | Faustman | Jul 1998 | A |
| 5785912 | Cooley et al. | Jul 1998 | A |
| 5804446 | Cerami et al. | Sep 1998 | A |
| 5806529 | Reisner et al. | Sep 1998 | A |
| 5807686 | Wagner et al. | Sep 1998 | A |
| 5811094 | Caplan et al. | Sep 1998 | A |
| 5811397 | Francavilla et al. | Sep 1998 | A |
| 5817773 | Wilson et al. | Oct 1998 | A |
| 5821218 | Toback et al. | Oct 1998 | A |
| 5827735 | Young et al. | Oct 1998 | A |
| 5827740 | Pittenger | Oct 1998 | A |
| 5830921 | Cooley et al. | Nov 1998 | A |
| 5833979 | Schinstine et al. | Nov 1998 | A |
| 5837258 | Grotendorst | Nov 1998 | A |
| 5837539 | Caplan et al. | Nov 1998 | A |
| 5837670 | Hartshorn | Nov 1998 | A |
| 5840502 | Van Vlasselaer | Nov 1998 | A |
| 5840576 | Schinstine et al. | Nov 1998 | A |
| 5840580 | Terstappen et al. | Nov 1998 | A |
| 5842477 | Naughton et al. | Dec 1998 | A |
| 5843633 | Yin et al. | Dec 1998 | A |
| 5843780 | Thomson | Dec 1998 | A |
| 5846796 | Cerami et al. | Dec 1998 | A |
| 5849553 | Anderson et al. | Dec 1998 | A |
| 5851832 | Weiss et al. | Dec 1998 | A |
| 5853247 | Shroyer | Dec 1998 | A |
| 5853717 | Schinstine et al. | Dec 1998 | A |
| 5855608 | Brekke et al. | Jan 1999 | A |
| 5855613 | Antanavich et al. | Jan 1999 | A |
| 5855619 | Caplan et al. | Jan 1999 | A |
| 5858747 | Schinstine et al. | Jan 1999 | A |
| 5858782 | Long et al. | Jan 1999 | A |
| 5861315 | Nakahata | Jan 1999 | A |
| 5866115 | Kanz et al. | Feb 1999 | A |
| 5866420 | Talbot et al. | Feb 1999 | A |
| 5868930 | Kopf | Feb 1999 | A |
| 5874301 | Keller et al. | Feb 1999 | A |
| 5882295 | Kope | Mar 1999 | A |
| 5882918 | Goffe | Mar 1999 | A |
| 5882929 | Fofonoff et al. | Mar 1999 | A |
| 5888807 | Palsson et al. | Mar 1999 | A |
| 5898040 | Shalaby et al. | Apr 1999 | A |
| 5902741 | Purchio et al. | May 1999 | A |
| 5906827 | Khouri et al. | May 1999 | A |
| 5906934 | Grande et al. | May 1999 | A |
| 5908782 | Marshak et al. | Jun 1999 | A |
| 5908784 | Johnstone et al. | Jun 1999 | A |
| 5912177 | Turner et al. | Jun 1999 | A |
| 5914108 | Tsukamoto et al. | Jun 1999 | A |
| 5914268 | Keller et al. | Jun 1999 | A |
| 5922597 | Verfaillie et al. | Jul 1999 | A |
| 5922847 | Broudy et al. | Jul 1999 | A |
| 5925567 | Kraus et al. | Jul 1999 | A |
| 5928945 | Seliktar et al. | Jul 1999 | A |
| 5935849 | Schinstine et al. | Aug 1999 | A |
| 5938929 | Shimagaki et al. | Aug 1999 | A |
| 5939323 | Valentini et al. | Aug 1999 | A |
| 5942225 | Bruder et al. | Aug 1999 | A |
| 5955353 | Amiot | Sep 1999 | A |
| 5958763 | Goffe | Sep 1999 | A |
| 5965436 | Thiede et al. | Oct 1999 | A |
| 5968829 | Carpenter | Oct 1999 | A |
| 5972703 | Long et al. | Oct 1999 | A |
| 5980795 | Klotzer et al. | Nov 1999 | A |
| 5981211 | Hu et al. | Nov 1999 | A |
| 5981708 | Lawman et al. | Nov 1999 | A |
| 5985653 | Armstrong et al. | Nov 1999 | A |
| 5994129 | Armstrong et al. | Nov 1999 | A |
| 5998184 | Shi | Dec 1999 | A |
| 6001585 | Gramer | Dec 1999 | A |
| 6001643 | Spaulding | Dec 1999 | A |
| 6001647 | Peck et al. | Dec 1999 | A |
| 6004743 | Kenyon et al. | Dec 1999 | A |
| 6010696 | Caplan et al. | Jan 2000 | A |
| 6015554 | Galy | Jan 2000 | A |
| 6022540 | Bruder et al. | Feb 2000 | A |
| 6022742 | Kopf | Feb 2000 | A |
| 6022743 | Naughton et al. | Feb 2000 | A |
| 6027743 | Khouri et al. | Feb 2000 | A |
| 6030836 | Thiede et al. | Feb 2000 | A |
| 6037174 | Smith et al. | Mar 2000 | A |
| 6040180 | Johe | Mar 2000 | A |
| 6045818 | Cima et al. | Apr 2000 | A |
| 6048721 | Armstrong et al. | Apr 2000 | A |
| 6048727 | Kopf | Apr 2000 | A |
| 6049026 | Muschler | Apr 2000 | A |
| 6054121 | Cerami et al. | Apr 2000 | A |
| 6060270 | Humes | May 2000 | A |
| 6066317 | Yang et al. | May 2000 | A |
| 6071691 | Hoekstra et al. | Jun 2000 | A |
| 6074366 | Rogers et al. | Jun 2000 | A |
| 6080581 | Anderson et al. | Jun 2000 | A |
| 6082364 | Balian et al. | Jul 2000 | A |
| 6083747 | Wong et al. | Jul 2000 | A |
| 6086643 | Clark et al. | Jul 2000 | A |
| 6087113 | Caplan et al. | Jul 2000 | A |
| 6096532 | Armstrong et al. | Aug 2000 | A |
| 6096537 | Chappel | Aug 2000 | A |
| 6103117 | Shimagaki et al. | Aug 2000 | A |
| 6103522 | Torok-Storb et al. | Aug 2000 | A |
| 6110176 | Shapira | Aug 2000 | A |
| 6110482 | Khouri et al. | Aug 2000 | A |
| 6110739 | Keller et al. | Aug 2000 | A |
| 6114307 | Jaspers et al. | Sep 2000 | A |
| 6117985 | Thomas et al. | Sep 2000 | A |
| 6120491 | Kohn et al. | Sep 2000 | A |
| 6127141 | Kopf | Oct 2000 | A |
| 6129911 | Faris | Oct 2000 | A |
| 6143293 | Weiss et al. | Nov 2000 | A |
| 6146360 | Rogers et al. | Nov 2000 | A |
| 6146888 | Smith et al. | Nov 2000 | A |
| 6149902 | Artavanis-Tsakonas et al. | Nov 2000 | A |
| 6149906 | Mosca | Nov 2000 | A |
| 6150164 | Humes | Nov 2000 | A |
| 6152964 | Van Blitterswijk et al. | Nov 2000 | A |
| 6162643 | Wille, Jr. | Dec 2000 | A |
| 6165225 | Antanavich et al. | Dec 2000 | A |
| 6165785 | Ogle et al. | Dec 2000 | A |
| 6174333 | Kadiyala et al. | Jan 2001 | B1 |
| 6174526 | Cerami et al. | Jan 2001 | B1 |
| 6174666 | Pavlakis et al. | Jan 2001 | B1 |
| 6179871 | Halpern | Jan 2001 | B1 |
| 6190910 | Kusakabe et al. | Feb 2001 | B1 |
| 6197325 | MacPhee et al. | Mar 2001 | B1 |
| 6197575 | Griffith et al. | Mar 2001 | B1 |
| 6200606 | Peterson et al. | Mar 2001 | B1 |
| 6200806 | Thomson | Mar 2001 | B1 |
| 6214369 | Grande et al. | Apr 2001 | B1 |
| 6214574 | Kopf | Apr 2001 | B1 |
| 6224860 | Brown | May 2001 | B1 |
| 6225119 | Qasba et al. | May 2001 | B1 |
| 6225368 | D'Agostino et al. | May 2001 | B1 |
| 6228117 | De Bruijn et al. | May 2001 | B1 |
| 6228607 | Kersten et al. | May 2001 | B1 |
| 6228635 | Armstrong et al. | May 2001 | B1 |
| 6238908 | Armstrong et al. | May 2001 | B1 |
| 6239157 | Mbalaviele | May 2001 | B1 |
| 6242252 | Reid et al. | Jun 2001 | B1 |
| 6248319 | Zsebo et al. | Jun 2001 | B1 |
| 6248587 | Rodgers et al. | Jun 2001 | B1 |
| 6255112 | Thiede et al. | Jul 2001 | B1 |
| 6258597 | Bachovchin et al. | Jul 2001 | B1 |
| 6258778 | Rodgers et al. | Jul 2001 | B1 |
| 6261549 | Fernandez et al. | Jul 2001 | B1 |
| 6280718 | Kaufman et al. | Aug 2001 | B1 |
| 6280724 | Moore | Aug 2001 | B1 |
| 6281012 | McIntosh et al. | Aug 2001 | B1 |
| 6281195 | Rueger et al. | Aug 2001 | B1 |
| 6287864 | Bagnis et al. | Sep 2001 | B1 |
| 6291249 | Mahant et al. | Sep 2001 | B1 |
| 6297213 | Oppermann et al. | Oct 2001 | B1 |
| 6299650 | Van Blitterswijk et al. | Oct 2001 | B1 |
| 6306169 | Lee et al. | Oct 2001 | B1 |
| 6306424 | Vyakarnam et al. | Oct 2001 | B1 |
| 6306575 | Thomas et al. | Oct 2001 | B1 |
| 6322784 | Pittenger et al. | Nov 2001 | B1 |
| 6322786 | Anderson | Nov 2001 | B1 |
| 6326198 | Emerson et al. | Dec 2001 | B1 |
| 6326201 | Fung et al. | Dec 2001 | B1 |
| 6328765 | Hardwick et al. | Dec 2001 | B1 |
| 6328960 | McIntosh et al. | Dec 2001 | B1 |
| 6333029 | Vyakarnam et al. | Dec 2001 | B1 |
| 6335195 | Rodgers et al. | Jan 2002 | B1 |
| 6338942 | Kraus et al. | Jan 2002 | B2 |
| 6340592 | Stringer | Jan 2002 | B1 |
| 6342370 | Connolly et al. | Jan 2002 | B1 |
| 6355239 | Bruder et al. | Mar 2002 | B1 |
| 6358252 | Shapira | Mar 2002 | B1 |
| 6361997 | Huss | Mar 2002 | B1 |
| 6365149 | Vyakarnam et al. | Apr 2002 | B2 |
| 6368636 | McIntosh et al. | Apr 2002 | B1 |
| 6372210 | Brown | Apr 2002 | B2 |
| 6372244 | Antanavich et al. | Apr 2002 | B1 |
| 6372494 | Naughton et al. | Apr 2002 | B1 |
| 6372892 | Ballinger et al. | Apr 2002 | B1 |
| 6376742 | Zdrahala et al. | Apr 2002 | B1 |
| 6379953 | Bruder et al. | Apr 2002 | B1 |
| 6387367 | Davis-Sproul et al. | May 2002 | B1 |
| 6387369 | Pittenger et al. | May 2002 | B1 |
| 6387693 | Rieser et al. | May 2002 | B2 |
| 6387964 | D'Agostino et al. | May 2002 | B1 |
| 6392118 | Hammang et al. | May 2002 | B1 |
| 6394812 | Sullivan et al. | May 2002 | B1 |
| 6399580 | Elias et al. | Jun 2002 | B1 |
| 6410320 | Humes | Jun 2002 | B1 |
| 6414219 | Denhardt et al. | Jul 2002 | B1 |
| 6416496 | Rogers et al. | Jul 2002 | B1 |
| 6417205 | Cooke et al. | Jul 2002 | B1 |
| 6419829 | Ho et al. | Jul 2002 | B2 |
| 6420138 | Gentz et al. | Jul 2002 | B1 |
| 6423681 | Sarasch et al. | Jul 2002 | B1 |
| 6426332 | Rueger et al. | Jul 2002 | B1 |
| 6428802 | Atala | Aug 2002 | B1 |
| 6429012 | Kraus et al. | Aug 2002 | B1 |
| 6429013 | Halvorsen et al. | Aug 2002 | B1 |
| 6432653 | Okarma | Aug 2002 | B1 |
| 6432711 | Dinsmore et al. | Aug 2002 | B1 |
| 6436701 | Evans et al. | Aug 2002 | B1 |
| 6440407 | Bauer et al. | Aug 2002 | B1 |
| 6440734 | Pykett et al. | Aug 2002 | B1 |
| 6451562 | Ruben et al. | Sep 2002 | B1 |
| 6454811 | Sherwood et al. | Sep 2002 | B1 |
| 6455678 | Yin et al. | Sep 2002 | B1 |
| 6458585 | Vachula et al. | Oct 2002 | B1 |
| 6458589 | Rambhatla et al. | Oct 2002 | B1 |
| 6461495 | Morrissey et al. | Oct 2002 | B1 |
| 6461853 | Zhu | Oct 2002 | B1 |
| 6464983 | Grotendorst | Oct 2002 | B1 |
| 6465205 | Hicks, Jr. | Oct 2002 | B2 |
| 6465247 | Weissman et al. | Oct 2002 | B1 |
| 6465249 | Reya et al. | Oct 2002 | B2 |
| 6468794 | Uchida et al. | Oct 2002 | B1 |
| 6472200 | Mitrani | Oct 2002 | B1 |
| 6475481 | Talmadge | Nov 2002 | B2 |
| 6479064 | Atala | Nov 2002 | B1 |
| 6482231 | Abatangelo et al. | Nov 2002 | B1 |
| 6482411 | Ahuja et al. | Nov 2002 | B1 |
| 6482645 | Atala | Nov 2002 | B2 |
| 6482926 | Thomas et al. | Nov 2002 | B1 |
| 6488925 | Ruben et al. | Dec 2002 | B2 |
| 6491918 | Thomas et al. | Dec 2002 | B1 |
| 6495129 | Li et al. | Dec 2002 | B1 |
| 6495364 | Hammang et al. | Dec 2002 | B2 |
| 6497875 | Sorrell et al. | Dec 2002 | B1 |
| 6498034 | Strobl | Dec 2002 | B1 |
| 6500668 | Samarut et al. | Dec 2002 | B2 |
| 6506574 | Rambhatla et al. | Jan 2003 | B1 |
| 6511510 | de Bruijn et al. | Jan 2003 | B1 |
| 6511767 | Calver et al. | Jan 2003 | B1 |
| 6511958 | Atkinson et al. | Jan 2003 | B1 |
| 6514514 | Atkinson et al. | Feb 2003 | B1 |
| 6524452 | Clark et al. | Feb 2003 | B1 |
| 6528052 | Smith et al. | Mar 2003 | B1 |
| 6528245 | Sanchez-Ramos et al. | Mar 2003 | B2 |
| 6530956 | Mansmann | Mar 2003 | B1 |
| 6531445 | Cohen et al. | Mar 2003 | B1 |
| 6534084 | Vyakarnam et al. | Mar 2003 | B1 |
| 6537807 | Smith et al. | Mar 2003 | B1 |
| 6541024 | Kadiyala et al. | Apr 2003 | B1 |
| 6541249 | Wager et al. | Apr 2003 | B2 |
| 6544506 | Reisner | Apr 2003 | B2 |
| 6548734 | Glimcher et al. | Apr 2003 | B1 |
| 6555324 | Olweus et al. | Apr 2003 | B1 |
| 6555374 | Gimble et al. | Apr 2003 | B1 |
| 6559119 | Burgess et al. | May 2003 | B1 |
| 6562616 | Toner et al. | May 2003 | B1 |
| 6565843 | Cohen et al. | May 2003 | B1 |
| 6566126 | Cadwell | May 2003 | B2 |
| 6569421 | Hodges | May 2003 | B2 |
| 6569427 | Boyse et al. | May 2003 | B1 |
| 6569428 | Isner et al. | May 2003 | B1 |
| 6569654 | Shastri et al. | May 2003 | B2 |
| 6576188 | Rose et al. | Jun 2003 | B1 |
| 6576428 | Assenmacher et al. | Jun 2003 | B1 |
| 6576464 | Gold et al. | Jun 2003 | B2 |
| 6576465 | Long | Jun 2003 | B1 |
| 6582471 | Bittmann et al. | Jun 2003 | B1 |
| 6582955 | Martinez et al. | Jun 2003 | B2 |
| 6586192 | Peschle et al. | Jul 2003 | B1 |
| 6589728 | Csete et al. | Jul 2003 | B2 |
| 6589786 | Mangano et al. | Jul 2003 | B1 |
| 6596274 | Abatangelo et al. | Jul 2003 | B1 |
| 6599300 | Vibe-Hansen et al. | Jul 2003 | B2 |
| 6599520 | Scarborough et al. | Jul 2003 | B2 |
| 6610535 | Lu et al. | Aug 2003 | B1 |
| 6613798 | Porter et al. | Sep 2003 | B1 |
| 6616912 | Eddleman et al. | Sep 2003 | B2 |
| 6617070 | Morrissey et al. | Sep 2003 | B1 |
| 6617152 | Bryhan et al. | Sep 2003 | B2 |
| 6617159 | Cancedda et al. | Sep 2003 | B1 |
| 6617161 | Luyten et al. | Sep 2003 | B2 |
| 6623749 | Williams et al. | Sep 2003 | B2 |
| 6623942 | Ruben et al. | Sep 2003 | B2 |
| 6624108 | Clark et al. | Sep 2003 | B1 |
| 6626950 | Brown et al. | Sep 2003 | B2 |
| 6627191 | Bartelmez et al. | Sep 2003 | B1 |
| 6632425 | Li et al. | Oct 2003 | B1 |
| 6632620 | Makarovskiy | Oct 2003 | B1 |
| 6632934 | Moreadith et al. | Oct 2003 | B1 |
| 6638765 | Rosenberg | Oct 2003 | B1 |
| 6642019 | Anderson et al. | Nov 2003 | B1 |
| 6642048 | Xu et al. | Nov 2003 | B2 |
| 6642049 | Chute et al. | Nov 2003 | B1 |
| 6642201 | Khavinson et al. | Nov 2003 | B1 |
| 6645489 | Pykett et al. | Nov 2003 | B2 |
| 6645727 | Thomas et al. | Nov 2003 | B2 |
| 6645763 | Kobayashi et al. | Nov 2003 | B2 |
| 6649189 | Talmadge et al. | Nov 2003 | B2 |
| 6649595 | Clackson et al. | Nov 2003 | B2 |
| 6649631 | Orme et al. | Nov 2003 | B1 |
| 6653105 | Triglia et al. | Nov 2003 | B2 |
| 6653134 | Prockop et al. | Nov 2003 | B2 |
| 6660523 | Blom et al. | Dec 2003 | B2 |
| 6662805 | Frondoza et al. | Dec 2003 | B2 |
| 6667034 | Palsson et al. | Dec 2003 | B2 |
| 6667176 | Funk et al. | Dec 2003 | B1 |
| 6670169 | Schob et al. | Dec 2003 | B1 |
| 6670175 | Wang et al. | Dec 2003 | B2 |
| 6673603 | Baetge et al. | Jan 2004 | B2 |
| 6673606 | Tennekoon et al. | Jan 2004 | B1 |
| 6677306 | Veis et al. | Jan 2004 | B1 |
| 6680166 | Mullon et al. | Jan 2004 | B1 |
| 6683192 | Baxter et al. | Jan 2004 | B2 |
| 6685936 | McIntosh et al. | Feb 2004 | B2 |
| 6685971 | Xu | Feb 2004 | B2 |
| 6686198 | Melton et al. | Feb 2004 | B1 |
| 6696575 | Schmidt et al. | Feb 2004 | B2 |
| 6699716 | Sullivan et al. | Mar 2004 | B2 |
| 6703017 | Peck et al. | Mar 2004 | B1 |
| 6703209 | Baetscher et al. | Mar 2004 | B1 |
| 6703279 | Lee | Mar 2004 | B2 |
| 6706293 | Quintanilla Almagro et al. | Mar 2004 | B1 |
| 6709864 | Pittenger et al. | Mar 2004 | B1 |
| 6712850 | Vyakarnam et al. | Mar 2004 | B2 |
| 6719969 | Hogaboam et al. | Apr 2004 | B1 |
| 6719970 | Costantino et al. | Apr 2004 | B1 |
| 6720340 | Cooke et al. | Apr 2004 | B1 |
| 6730314 | Jeschke et al. | May 2004 | B2 |
| 6730315 | Usala et al. | May 2004 | B2 |
| 6730510 | Roos et al. | May 2004 | B2 |
| 6733746 | Daley et al. | May 2004 | B2 |
| 6734000 | Chin et al. | May 2004 | B2 |
| 6737072 | Angele et al. | May 2004 | B1 |
| 6740493 | Long et al. | May 2004 | B1 |
| 6759039 | Tsang et al. | Jul 2004 | B2 |
| 6759245 | Toner et al. | Jul 2004 | B1 |
| 6761883 | Weissman et al. | Jul 2004 | B2 |
| 6761887 | Kavalkovich et al. | Jul 2004 | B1 |
| 6767699 | Polo et al. | Jul 2004 | B2 |
| 6767737 | Wilson et al. | Jul 2004 | B1 |
| 6767738 | Gage et al. | Jul 2004 | B1 |
| 6767740 | Sramek et al. | Jul 2004 | B2 |
| 6770478 | Crowe et al. | Aug 2004 | B2 |
| 6777227 | Ricci et al. | Aug 2004 | B2 |
| 6777231 | Katz et al. | Aug 2004 | B1 |
| 6780612 | Ford et al. | Aug 2004 | B1 |
| 6787355 | Miller et al. | Sep 2004 | B1 |
| 6790455 | Chu et al. | Sep 2004 | B2 |
| 6793939 | Badylak | Sep 2004 | B2 |
| 6797269 | Mosca et al. | Sep 2004 | B2 |
| 6797514 | Berenson et al. | Sep 2004 | B2 |
| 6800480 | Bodnar et al. | Oct 2004 | B1 |
| 6802971 | Gorsuch et al. | Oct 2004 | B2 |
| 6805860 | Alt | Oct 2004 | B1 |
| 6809117 | Enikolopov et al. | Oct 2004 | B2 |
| 6811773 | Gentz et al. | Nov 2004 | B1 |
| 6811776 | Kale et al. | Nov 2004 | B2 |
| 6814961 | Jensen et al. | Nov 2004 | B1 |
| 6821513 | Fleming | Nov 2004 | B1 |
| 6821790 | Mahant et al. | Nov 2004 | B2 |
| 6828145 | Avital et al. | Dec 2004 | B2 |
| 6833269 | Carpenter | Dec 2004 | B2 |
| 6835377 | Goldberg et al. | Dec 2004 | B2 |
| 6835566 | Smith et al. | Dec 2004 | B2 |
| 6838284 | de Bruijn et al. | Jan 2005 | B2 |
| 6841150 | Halvorsen et al. | Jan 2005 | B2 |
| 6841151 | Stringer | Jan 2005 | B2 |
| 6841294 | Morrissey et al. | Jan 2005 | B1 |
| 6841355 | Livant | Jan 2005 | B2 |
| 6841386 | Kraus et al. | Jan 2005 | B2 |
| 6841542 | Bartelmez et al. | Jan 2005 | B2 |
| 6844011 | Faustman | Jan 2005 | B1 |
| 6844187 | Weschler et al. | Jan 2005 | B1 |
| 6849051 | Sramek et al. | Feb 2005 | B2 |
| 6849255 | Gazit et al. | Feb 2005 | B2 |
| 6849454 | Kelly et al. | Feb 2005 | B2 |
| 6849662 | Enikolopov et al. | Feb 2005 | B2 |
| 6852308 | Kohn et al. | Feb 2005 | B2 |
| 6852321 | Colucci et al. | Feb 2005 | B2 |
| 6852533 | Rafii et al. | Feb 2005 | B1 |
| 6855242 | Comninellis et al. | Feb 2005 | B1 |
| 6855542 | DiMilla et al. | Feb 2005 | B2 |
| 6863900 | Kadiyala et al. | Mar 2005 | B2 |
| 6866843 | Habener et al. | Mar 2005 | B2 |
| 6872389 | Faris | Mar 2005 | B1 |
| 6875430 | McIntosh et al. | Apr 2005 | B2 |
| 6875607 | Reubinoff et al. | Apr 2005 | B1 |
| 6887600 | Morrissey et al. | May 2005 | B2 |
| 6887704 | Peled et al. | May 2005 | B2 |
| 6908763 | Akashi et al. | Jun 2005 | B1 |
| 6911201 | Merchav et al. | Jun 2005 | B1 |
| 6914279 | Lu et al. | Jul 2005 | B2 |
| 6933144 | Cadwell | Aug 2005 | B2 |
| 6939955 | Rameshwar | Sep 2005 | B2 |
| 6943008 | Ma | Sep 2005 | B1 |
| 6965018 | Mikesell et al. | Nov 2005 | B2 |
| 6969308 | Doi et al. | Nov 2005 | B2 |
| 6979308 | McDonald et al. | Dec 2005 | B1 |
| 6979321 | Geis et al. | Dec 2005 | B2 |
| 6988004 | Kanno et al. | Jan 2006 | B2 |
| 7008394 | Geise et al. | Mar 2006 | B2 |
| 7015037 | Furcht et al. | Mar 2006 | B1 |
| 7029666 | Bruder et al. | Apr 2006 | B2 |
| 7029913 | Thomson | Apr 2006 | B2 |
| 7033339 | Lynn | Apr 2006 | B1 |
| 7033823 | Chang | Apr 2006 | B2 |
| 7037721 | Wille, Jr. | May 2006 | B1 |
| 7041493 | Rao | May 2006 | B2 |
| 7045098 | Stephens | May 2006 | B2 |
| 7052517 | Murphy et al. | May 2006 | B2 |
| 7056493 | Kohn et al. | Jun 2006 | B2 |
| 7109032 | Cancedda et al. | Sep 2006 | B2 |
| 7112437 | Pera | Sep 2006 | B2 |
| 7112441 | Uemura et al. | Sep 2006 | B2 |
| 7118672 | Husain et al. | Oct 2006 | B2 |
| 7122178 | Simmons et al. | Oct 2006 | B1 |
| 7145057 | Van de Lavoir et al. | Dec 2006 | B2 |
| 7153684 | Hogan | Dec 2006 | B1 |
| 7160719 | Nyberg | Jan 2007 | B2 |
| 7169295 | Husain et al. | Jan 2007 | B2 |
| 7169610 | Brown | Jan 2007 | B2 |
| 7172696 | Martinez et al. | Feb 2007 | B1 |
| 7175763 | Husain et al. | Feb 2007 | B2 |
| 7192776 | Stephens | Mar 2007 | B2 |
| 7195711 | Gorsuch et al. | Mar 2007 | B2 |
| 7250154 | Kohn et al. | Jul 2007 | B2 |
| 7270996 | Cannon et al. | Sep 2007 | B2 |
| 7271234 | Kohn et al. | Sep 2007 | B2 |
| 7294259 | Cote et al. | Nov 2007 | B2 |
| 7294508 | Parikh et al. | Nov 2007 | B2 |
| 7300571 | Cote et al. | Nov 2007 | B2 |
| 7303676 | Husain et al. | Dec 2007 | B2 |
| 7303677 | Cote et al. | Dec 2007 | B2 |
| 7341062 | Chachques et al. | Mar 2008 | B2 |
| 7358001 | Morrissey et al. | Apr 2008 | B2 |
| 7361493 | Hammond et al. | Apr 2008 | B1 |
| 7368169 | Kohn et al. | May 2008 | B2 |
| 7378271 | Bader | May 2008 | B2 |
| 7399872 | Webster et al. | Jul 2008 | B2 |
| 7416884 | Gemmiti et al. | Aug 2008 | B2 |
| 7425440 | Malinge et al. | Sep 2008 | B2 |
| 7435586 | Bartlett et al. | Oct 2008 | B2 |
| 7438902 | Habener et al. | Oct 2008 | B2 |
| 7439057 | Frangos et al. | Oct 2008 | B2 |
| 7452529 | Brown, Jr. et al. | Nov 2008 | B2 |
| 7491388 | McIntosh et al. | Feb 2009 | B1 |
| 7494811 | Wolfinbarger, Jr. et al. | Feb 2009 | B2 |
| 7514074 | Pittenger et al. | Apr 2009 | B2 |
| 7514075 | Hedrick et al. | Apr 2009 | B2 |
| 7524676 | Reiter et al. | Apr 2009 | B2 |
| 7531351 | Marx et al. | May 2009 | B2 |
| 7534609 | Merchav et al. | May 2009 | B2 |
| 7572374 | Gorsuch et al. | Aug 2009 | B2 |
| 7579179 | Bryhan et al. | Aug 2009 | B2 |
| 7585412 | Gorsuch et al. | Sep 2009 | B2 |
| 7588938 | Ma | Sep 2009 | B2 |
| 7598075 | Smith et al. | Oct 2009 | B2 |
| 7608447 | Cohen et al. | Oct 2009 | B2 |
| 7659118 | Furcht et al. | Feb 2010 | B2 |
| 7678573 | Merchav et al. | Mar 2010 | B2 |
| 7682822 | Noll et al. | Mar 2010 | B2 |
| 7682823 | Runyon | Mar 2010 | B1 |
| 7718430 | Antwiler | May 2010 | B2 |
| 7722896 | Kohn et al. | May 2010 | B2 |
| D620732 | Andrews | Aug 2010 | S |
| 7838122 | Kohn et al. | Nov 2010 | B2 |
| 7838289 | Furcht et al. | Nov 2010 | B2 |
| 7892829 | Pittenger et al. | Feb 2011 | B2 |
| 7919307 | Klaus et al. | Apr 2011 | B2 |
| 7927587 | Blazer et al. | Apr 2011 | B2 |
| 7989851 | Lu et al. | Aug 2011 | B2 |
| 8008528 | Kohn et al. | Aug 2011 | B2 |
| 8034365 | Baluca | Oct 2011 | B2 |
| 8075881 | Verfaillie et al. | Dec 2011 | B2 |
| 8147824 | Maziarz et al. | Apr 2012 | B2 |
| 8147863 | Kohn et al. | Apr 2012 | B2 |
| 8158120 | Pittenger et al. | Apr 2012 | B2 |
| 8158121 | Pittenger et al. | Apr 2012 | B2 |
| 8252280 | Verfaillie et al. | Aug 2012 | B1 |
| 8252887 | Bolikal et al. | Aug 2012 | B2 |
| 8288159 | Warren et al. | Oct 2012 | B2 |
| 8288590 | Kohn et al. | Oct 2012 | B2 |
| 8298823 | Warren et al. | Oct 2012 | B2 |
| 8309347 | Antwiler | Nov 2012 | B2 |
| 8361453 | Uhrich et al. | Jan 2013 | B2 |
| 8377683 | Lu et al. | Feb 2013 | B2 |
| 8383397 | Wojciechowski et al. | Feb 2013 | B2 |
| 8383806 | Rameshwar | Feb 2013 | B2 |
| 8399245 | Leuthaeuser et al. | Mar 2013 | B2 |
| 8415449 | Kohn et al. | Apr 2013 | B2 |
| 8435781 | Kodama | May 2013 | B2 |
| 8461289 | Kohn et al. | Jun 2013 | B2 |
| 8476399 | Bolikal et al. | Jul 2013 | B2 |
| 8486621 | Luo et al. | Jul 2013 | B2 |
| 8486695 | Danilkovitch et al. | Jul 2013 | B2 |
| 8492140 | Smith et al. | Jul 2013 | B2 |
| 8492150 | Parker et al. | Jul 2013 | B2 |
| 8524496 | Meiron et al. | Sep 2013 | B2 |
| 8529888 | Meiron et al. | Sep 2013 | B2 |
| 8540499 | Page et al. | Sep 2013 | B2 |
| 8551511 | Brandom et al. | Oct 2013 | B2 |
| 8580249 | Blazar et al. | Nov 2013 | B2 |
| 8678638 | Wong | Mar 2014 | B2 |
| 8785181 | Antwiler | Jul 2014 | B2 |
| 8852570 | Pittenger et al. | Oct 2014 | B2 |
| 8852571 | Pittenger et al. | Oct 2014 | B2 |
| 8852572 | Pittenger et al. | Oct 2014 | B2 |
| 8852573 | Pittenger et al. | Oct 2014 | B2 |
| 8852574 | Pittenger et al. | Oct 2014 | B2 |
| 8852575 | Pittenger et al. | Oct 2014 | B2 |
| 9109193 | Galliher et al. | Aug 2015 | B2 |
| 9220810 | Ma et al. | Dec 2015 | B2 |
| 9441195 | Wojciechowski et al. | Sep 2016 | B2 |
| 9534198 | Page et al. | Jan 2017 | B2 |
| 9617506 | Jones et al. | Apr 2017 | B2 |
| 9732313 | Hirschel et al. | Aug 2017 | B2 |
| 9902928 | Hirschel et al. | Feb 2018 | B2 |
| 10093956 | Hirschel et al. | Oct 2018 | B2 |
| 10494421 | Castillo | Dec 2019 | B2 |
| 10557112 | Frank | Feb 2020 | B2 |
| 20010017188 | Cooley et al. | Aug 2001 | A1 |
| 20010020086 | Hubbell et al. | Sep 2001 | A1 |
| 20010021516 | Wei et al. | Sep 2001 | A1 |
| 20010029046 | Beaulieu | Oct 2001 | A1 |
| 20010033834 | Wilkison et al. | Oct 2001 | A1 |
| 20010036663 | Kraus et al. | Nov 2001 | A1 |
| 20010041687 | Mruk | Nov 2001 | A1 |
| 20010044413 | Pierce et al. | Nov 2001 | A1 |
| 20010049139 | Lagasse et al. | Dec 2001 | A1 |
| 20020015724 | Yang et al. | Feb 2002 | A1 |
| 20020018804 | Austin et al. | Feb 2002 | A1 |
| 20020028510 | Sanberg et al. | Mar 2002 | A1 |
| 20020031757 | Ohgushi et al. | Mar 2002 | A1 |
| 20020037278 | Ueno et al. | Mar 2002 | A1 |
| 20020045260 | Hung et al. | Apr 2002 | A1 |
| 20020064869 | Ebner et al. | May 2002 | A1 |
| 20020076400 | Katz et al. | Jun 2002 | A1 |
| 20020077687 | Ahn | Jun 2002 | A1 |
| 20020082698 | Parenteau et al. | Jun 2002 | A1 |
| 20020116054 | Lundell et al. | Aug 2002 | A1 |
| 20020128581 | Vishnoi et al. | Sep 2002 | A1 |
| 20020128582 | Farrell et al. | Sep 2002 | A1 |
| 20020128583 | Min et al. | Sep 2002 | A1 |
| 20020128584 | Brown et al. | Sep 2002 | A1 |
| 20020130100 | Smith | Sep 2002 | A1 |
| 20020132343 | Lum | Sep 2002 | A1 |
| 20020139743 | Critz et al. | Oct 2002 | A1 |
| 20020142457 | Umezawa et al. | Oct 2002 | A1 |
| 20020146678 | Benvenisty | Oct 2002 | A1 |
| 20020146817 | Cannon et al. | Oct 2002 | A1 |
| 20020150989 | Greene et al. | Oct 2002 | A1 |
| 20020151056 | Sasai et al. | Oct 2002 | A1 |
| 20020159981 | Peled et al. | Oct 2002 | A1 |
| 20020160032 | Long et al. | Oct 2002 | A1 |
| 20020160510 | Hariri | Oct 2002 | A1 |
| 20020164794 | Wernet | Nov 2002 | A1 |
| 20020168765 | Prockop et al. | Nov 2002 | A1 |
| 20020169408 | Beretta et al. | Nov 2002 | A1 |
| 20020182241 | Borenstein et al. | Dec 2002 | A1 |
| 20020182664 | Dolecek et al. | Dec 2002 | A1 |
| 20020188962 | Denhardt et al. | Dec 2002 | A1 |
| 20020197240 | Chiu | Dec 2002 | A1 |
| 20030021850 | Xu | Jan 2003 | A1 |
| 20030022390 | Stephens | Jan 2003 | A1 |
| 20030027330 | Lanza et al. | Feb 2003 | A1 |
| 20030027331 | Yan et al. | Feb 2003 | A1 |
| 20030032143 | Neff et al. | Feb 2003 | A1 |
| 20030036168 | Ni et al. | Feb 2003 | A1 |
| 20030040113 | Mizuno et al. | Feb 2003 | A1 |
| 20030049236 | Kassem et al. | Mar 2003 | A1 |
| 20030054331 | Fraser et al. | Mar 2003 | A1 |
| 20030059414 | Ho et al. | Mar 2003 | A1 |
| 20030059851 | Smith | Mar 2003 | A1 |
| 20030059939 | Page et al. | Mar 2003 | A1 |
| 20030078345 | Morrisey | Apr 2003 | A1 |
| 20030082795 | Shuler et al. | May 2003 | A1 |
| 20030086915 | Rader et al. | May 2003 | A1 |
| 20030089471 | Gehr et al. | May 2003 | A1 |
| 20030092101 | Ni et al. | May 2003 | A1 |
| 20030101465 | Lawman et al. | May 2003 | A1 |
| 20030103957 | McKerracher | Jun 2003 | A1 |
| 20030104568 | Lee | Jun 2003 | A1 |
| 20030113813 | Heidaran et al. | Jun 2003 | A1 |
| 20030113910 | Levanduski | Jun 2003 | A1 |
| 20030124091 | Tuse et al. | Jul 2003 | A1 |
| 20030124721 | Cheatham et al. | Jul 2003 | A1 |
| 20030130593 | Gonzalez | Jul 2003 | A1 |
| 20030133918 | Sherley | Jul 2003 | A1 |
| 20030138950 | McAllister et al. | Jul 2003 | A1 |
| 20030143727 | Chang | Jul 2003 | A1 |
| 20030148152 | Morrisey | Aug 2003 | A1 |
| 20030149011 | Ackerman et al. | Aug 2003 | A1 |
| 20030152558 | Luft et al. | Aug 2003 | A1 |
| 20030157078 | Hall et al. | Aug 2003 | A1 |
| 20030157709 | DiMilla et al. | Aug 2003 | A1 |
| 20030161817 | Young et al. | Aug 2003 | A1 |
| 20030166272 | Abuljadayel | Sep 2003 | A1 |
| 20030170214 | Bader | Sep 2003 | A1 |
| 20030180296 | Salcedo et al. | Sep 2003 | A1 |
| 20030181269 | Griffin | Sep 2003 | A1 |
| 20030185817 | Thomas et al. | Oct 2003 | A1 |
| 20030202938 | Rameshwar | Oct 2003 | A1 |
| 20030203483 | Seshi | Oct 2003 | A1 |
| 20030204323 | Morrisey | Oct 2003 | A1 |
| 20030211602 | Atala | Nov 2003 | A1 |
| 20030211603 | Earp et al. | Nov 2003 | A1 |
| 20030216718 | Hamblin et al. | Nov 2003 | A1 |
| 20030219898 | Sugaya et al. | Nov 2003 | A1 |
| 20030223968 | Yang | Dec 2003 | A1 |
| 20030224420 | Hellerstein et al. | Dec 2003 | A1 |
| 20030224510 | Yamaguchi et al. | Dec 2003 | A1 |
| 20030225010 | Rameshwar | Dec 2003 | A1 |
| 20030232432 | Bhat | Dec 2003 | A1 |
| 20030232752 | Freeman et al. | Dec 2003 | A1 |
| 20030235909 | Hariri et al. | Dec 2003 | A1 |
| 20040009158 | Sands et al. | Jan 2004 | A1 |
| 20040009589 | Levenberg et al. | Jan 2004 | A1 |
| 20040010231 | Leonhardt et al. | Jan 2004 | A1 |
| 20040014209 | Lassar et al. | Jan 2004 | A1 |
| 20040018174 | Palasis | Jan 2004 | A1 |
| 20040018617 | Hwang | Jan 2004 | A1 |
| 20040023324 | Sakano et al. | Feb 2004 | A1 |
| 20040023370 | Yu et al. | Feb 2004 | A1 |
| 20040027914 | Vrane | Feb 2004 | A1 |
| 20040033214 | Young et al. | Feb 2004 | A1 |
| 20040033599 | Rosenberg | Feb 2004 | A1 |
| 20040037811 | Penn et al. | Feb 2004 | A1 |
| 20040037815 | Clarke et al. | Feb 2004 | A1 |
| 20040038316 | Kaiser et al. | Feb 2004 | A1 |
| 20040053869 | Andrews et al. | Mar 2004 | A1 |
| 20040062753 | Rezania et al. | Apr 2004 | A1 |
| 20040063205 | Xu | Apr 2004 | A1 |
| 20040067585 | Wang et al. | Apr 2004 | A1 |
| 20040071668 | Bays et al. | Apr 2004 | A1 |
| 20040072259 | Scadden et al. | Apr 2004 | A1 |
| 20040077079 | Storgaard et al. | Apr 2004 | A1 |
| 20040079248 | Mayer et al. | Apr 2004 | A1 |
| 20040087016 | Keating et al. | May 2004 | A1 |
| 20040091936 | West | May 2004 | A1 |
| 20040096476 | Uhrich et al. | May 2004 | A1 |
| 20040097408 | Leder et al. | May 2004 | A1 |
| 20040101959 | Marko et al. | May 2004 | A1 |
| 20040107453 | Furcht et al. | Jun 2004 | A1 |
| 20040110286 | Bhatia | Jun 2004 | A1 |
| 20040115804 | Fu et al. | Jun 2004 | A1 |
| 20040115806 | Fu | Jun 2004 | A1 |
| 20040120932 | Zahner | Jun 2004 | A1 |
| 20040121461 | Honmou et al. | Jun 2004 | A1 |
| 20040121464 | Rathjen et al. | Jun 2004 | A1 |
| 20040126405 | Sahatjian et al. | Jul 2004 | A1 |
| 20040128077 | Koebler et al. | Jul 2004 | A1 |
| 20040131601 | Epstein et al. | Jul 2004 | A1 |
| 20040132184 | Dennis et al. | Jul 2004 | A1 |
| 20040136967 | Weiss et al. | Jul 2004 | A1 |
| 20040137612 | Baksh | Jul 2004 | A1 |
| 20040137613 | Vacanti et al. | Jul 2004 | A1 |
| 20040143174 | Brubaker | Jul 2004 | A1 |
| 20040143863 | Li et al. | Jul 2004 | A1 |
| 20040151700 | Harlan et al. | Aug 2004 | A1 |
| 20040151701 | Kim et al. | Aug 2004 | A1 |
| 20040151706 | Shakhov et al. | Aug 2004 | A1 |
| 20040151729 | Michalopoulos et al. | Aug 2004 | A1 |
| 20040152190 | Sumita | Aug 2004 | A1 |
| 20040161419 | Strom et al. | Aug 2004 | A1 |
| 20040171533 | Zehentner et al. | Sep 2004 | A1 |
| 20040180347 | Stanton et al. | Sep 2004 | A1 |
| 20040191902 | Hambor et al. | Sep 2004 | A1 |
| 20040197310 | Sanberg et al. | Oct 2004 | A1 |
| 20040197375 | Rezania et al. | Oct 2004 | A1 |
| 20040208786 | Kevy et al. | Oct 2004 | A1 |
| 20040214275 | Soejima et al. | Oct 2004 | A1 |
| 20040219134 | Naughton et al. | Nov 2004 | A1 |
| 20040219136 | Hariri | Nov 2004 | A1 |
| 20040219563 | West et al. | Nov 2004 | A1 |
| 20040224403 | Bhatia | Nov 2004 | A1 |
| 20040229351 | Rodriguez et al. | Nov 2004 | A1 |
| 20040234972 | Owens et al. | Nov 2004 | A1 |
| 20040235158 | Bartlett et al. | Nov 2004 | A1 |
| 20040235160 | Nishikawa et al. | Nov 2004 | A1 |
| 20040235166 | Prockop et al. | Nov 2004 | A1 |
| 20040242469 | Lee et al. | Dec 2004 | A1 |
| 20040258669 | Dzau et al. | Dec 2004 | A1 |
| 20040259242 | Malinge et al. | Dec 2004 | A1 |
| 20040259254 | Honmou et al. | Dec 2004 | A1 |
| 20040260058 | Scheek et al. | Dec 2004 | A1 |
| 20040260318 | Hunter et al. | Dec 2004 | A1 |
| 20040265996 | Schwarz et al. | Dec 2004 | A1 |
| 20050002914 | Rosen et al. | Jan 2005 | A1 |
| 20050003460 | Nilsson et al. | Jan 2005 | A1 |
| 20050003527 | Lang et al. | Jan 2005 | A1 |
| 20050003530 | Gerlach | Jan 2005 | A1 |
| 20050003534 | Huberman et al. | Jan 2005 | A1 |
| 20050008624 | Peled et al. | Jan 2005 | A1 |
| 20050008626 | Fraser et al. | Jan 2005 | A1 |
| 20050009178 | Yost et al. | Jan 2005 | A1 |
| 20050009179 | Gemmiti et al. | Jan 2005 | A1 |
| 20050009181 | Black et al. | Jan 2005 | A1 |
| 20050013804 | Kato et al. | Jan 2005 | A1 |
| 20050014252 | Chu et al. | Jan 2005 | A1 |
| 20050014253 | Ehmann et al. | Jan 2005 | A1 |
| 20050014254 | Kruse | Jan 2005 | A1 |
| 20050014255 | Tang et al. | Jan 2005 | A1 |
| 20050019801 | Rubin et al. | Jan 2005 | A1 |
| 20050019908 | Hariri | Jan 2005 | A1 |
| 20050019910 | Takagi et al. | Jan 2005 | A1 |
| 20050019911 | Gronthos et al. | Jan 2005 | A1 |
| 20050026836 | Dack et al. | Feb 2005 | A1 |
| 20050031587 | Tsutsui et al. | Feb 2005 | A1 |
| 20050031595 | Peled et al. | Feb 2005 | A1 |
| 20050031598 | Levenberg et al. | Feb 2005 | A1 |
| 20050032122 | Hwang et al. | Feb 2005 | A1 |
| 20050032207 | Wobus et al. | Feb 2005 | A1 |
| 20050032209 | Messina et al. | Feb 2005 | A1 |
| 20050032218 | Gerlach | Feb 2005 | A1 |
| 20050036980 | Chaney et al. | Feb 2005 | A1 |
| 20050037488 | Mitalipova et al. | Feb 2005 | A1 |
| 20050037490 | Rosenberg et al. | Feb 2005 | A1 |
| 20050037492 | Xu et al. | Feb 2005 | A1 |
| 20050037493 | Mandalam et al. | Feb 2005 | A1 |
| 20050037949 | O'Brien et al. | Feb 2005 | A1 |
| 20050106119 | Brandom et al. | May 2005 | A1 |
| 20050106127 | Kraus et al. | May 2005 | A1 |
| 20050112447 | Fletcher et al. | May 2005 | A1 |
| 20050112762 | Hart et al. | May 2005 | A1 |
| 20050118712 | Tsai et al. | Jun 2005 | A1 |
| 20050130297 | Sarem et al. | Jun 2005 | A1 |
| 20050136093 | Denk | Jun 2005 | A1 |
| 20050137517 | Blickhan et al. | Jun 2005 | A1 |
| 20050142162 | Hunter et al. | Jun 2005 | A1 |
| 20050149157 | Hunter et al. | Jul 2005 | A1 |
| 20050152946 | Hunter et al. | Jul 2005 | A1 |
| 20050153442 | Katz et al. | Jul 2005 | A1 |
| 20050158289 | Simmons et al. | Jul 2005 | A1 |
| 20050172340 | Logvinov et al. | Aug 2005 | A1 |
| 20050175665 | Hunter et al. | Aug 2005 | A1 |
| 20050175703 | Hunter et al. | Aug 2005 | A1 |
| 20050178395 | Hunter et al. | Aug 2005 | A1 |
| 20050178396 | Hunter et al. | Aug 2005 | A1 |
| 20050180957 | Scharp et al. | Aug 2005 | A1 |
| 20050181502 | Furcht et al. | Aug 2005 | A1 |
| 20050182463 | Hunter et al. | Aug 2005 | A1 |
| 20050183731 | Hunter et al. | Aug 2005 | A1 |
| 20050186244 | Hunter et al. | Aug 2005 | A1 |
| 20050186671 | Cannon et al. | Aug 2005 | A1 |
| 20050187140 | Hunter et al. | Aug 2005 | A1 |
| 20050196421 | Hunter et al. | Sep 2005 | A1 |
| 20050208095 | Hunter et al. | Sep 2005 | A1 |
| 20050244963 | Teplyashin | Nov 2005 | A1 |
| 20050249731 | Aslan et al. | Nov 2005 | A1 |
| 20050255118 | Wehner | Nov 2005 | A1 |
| 20050261674 | Nobis et al. | Nov 2005 | A1 |
| 20050277577 | Hunter et al. | Dec 2005 | A1 |
| 20050281790 | Simmons et al. | Dec 2005 | A1 |
| 20050282733 | Prins et al. | Dec 2005 | A1 |
| 20050283844 | Furcht et al. | Dec 2005 | A1 |
| 20060002900 | Binder et al. | Jan 2006 | A1 |
| 20060008452 | Simmons et al. | Jan 2006 | A1 |
| 20060019388 | Hutmacher et al. | Jan 2006 | A1 |
| 20060019389 | Yayon et al. | Jan 2006 | A1 |
| 20060054941 | Lu et al. | Mar 2006 | A1 |
| 20060083720 | Fraser et al. | Apr 2006 | A1 |
| 20060099198 | Thomson et al. | May 2006 | A1 |
| 20060147246 | Richards | Jul 2006 | A1 |
| 20060166364 | Senesac | Jul 2006 | A1 |
| 20060172008 | Yayon et al. | Aug 2006 | A1 |
| 20060193840 | Gronthos et al. | Aug 2006 | A1 |
| 20060205071 | Hasson et al. | Sep 2006 | A1 |
| 20060228798 | Verfaillie et al. | Oct 2006 | A1 |
| 20060233834 | Guehenneux et al. | Oct 2006 | A1 |
| 20060239909 | Anderson et al. | Oct 2006 | A1 |
| 20060258586 | Sheppard et al. | Nov 2006 | A1 |
| 20060258933 | Ellis et al. | Nov 2006 | A1 |
| 20060259998 | Brumbley et al. | Nov 2006 | A1 |
| 20060280748 | Buckheit | Dec 2006 | A1 |
| 20060286077 | Gronthos et al. | Dec 2006 | A1 |
| 20070005148 | Barofsky et al. | Jan 2007 | A1 |
| 20070011752 | Paleyanda | Jan 2007 | A1 |
| 20070042462 | Hildinger | Feb 2007 | A1 |
| 20070065938 | Gronthos et al. | Mar 2007 | A1 |
| 20070105222 | Wolfinbarger et al. | May 2007 | A1 |
| 20070116612 | Williamson | May 2007 | A1 |
| 20070117180 | Morikawa et al. | May 2007 | A1 |
| 20070122904 | Nordon | May 2007 | A1 |
| 20070123996 | Sugaya et al. | May 2007 | A1 |
| 20070160583 | Lange et al. | Jul 2007 | A1 |
| 20070166834 | Williamson et al. | Jul 2007 | A1 |
| 20070178071 | Westenfelder | Aug 2007 | A1 |
| 20070196421 | Hunter et al. | Aug 2007 | A1 |
| 20070197957 | Hunter et al. | Aug 2007 | A1 |
| 20070198063 | Hunter et al. | Aug 2007 | A1 |
| 20070202485 | Nees et al. | Aug 2007 | A1 |
| 20070203330 | Kretschmar et al. | Aug 2007 | A1 |
| 20070208134 | Hunter et al. | Sep 2007 | A1 |
| 20070231305 | Noll et al. | Oct 2007 | A1 |
| 20070258943 | Penn et al. | Nov 2007 | A1 |
| 20070269486 | Parker et al. | Nov 2007 | A1 |
| 20070274970 | Gordon et al. | Nov 2007 | A1 |
| 20070275457 | Granchelli et al. | Nov 2007 | A1 |
| 20070295651 | Martinez et al. | Dec 2007 | A1 |
| 20070298015 | Beer et al. | Dec 2007 | A1 |
| 20070298497 | Antwiler | Dec 2007 | A1 |
| 20080003663 | Bryhan et al. | Jan 2008 | A1 |
| 20080009458 | Dornan et al. | Jan 2008 | A1 |
| 20080032398 | Cannon et al. | Feb 2008 | A1 |
| 20080050770 | Zhang et al. | Feb 2008 | A1 |
| 20080063600 | Aguzzi et al. | Mar 2008 | A1 |
| 20080064649 | Rameshwar | Mar 2008 | A1 |
| 20080069807 | Jy et al. | Mar 2008 | A1 |
| 20080095676 | Andretta | Apr 2008 | A1 |
| 20080095690 | Liu | Apr 2008 | A1 |
| 20080103412 | Chin | May 2008 | A1 |
| 20080110827 | Cote et al. | May 2008 | A1 |
| 20080113426 | Smith et al. | May 2008 | A1 |
| 20080113440 | Gurney et al. | May 2008 | A1 |
| 20080153077 | Henry | Jun 2008 | A1 |
| 20080160597 | van der Heiden et al. | Jul 2008 | A1 |
| 20080166808 | Nyberg | Jul 2008 | A1 |
| 20080181879 | Catelas et al. | Jul 2008 | A1 |
| 20080190857 | Beretta et al. | Aug 2008 | A1 |
| 20080194017 | Esser et al. | Aug 2008 | A1 |
| 20080206733 | Tanaka et al. | Aug 2008 | A1 |
| 20080206831 | Coffey et al. | Aug 2008 | A1 |
| 20080213894 | Antwiler | Sep 2008 | A1 |
| 20080220522 | Antwiler | Sep 2008 | A1 |
| 20080220523 | Antwiler | Sep 2008 | A1 |
| 20080220524 | Noll et al. | Sep 2008 | A1 |
| 20080220526 | Ellison et al. | Sep 2008 | A1 |
| 20080221443 | Ritchie et al. | Sep 2008 | A1 |
| 20080227189 | Bader | Sep 2008 | A1 |
| 20080227190 | Antwiler | Sep 2008 | A1 |
| 20080248572 | Antwiler | Oct 2008 | A1 |
| 20080254533 | Antwiler | Oct 2008 | A1 |
| 20080268165 | Fekety et al. | Oct 2008 | A1 |
| 20080306095 | Crawford | Dec 2008 | A1 |
| 20090004738 | Merchav et al. | Jan 2009 | A1 |
| 20090011399 | Fischer | Jan 2009 | A1 |
| 20090047289 | Denhardt et al. | Feb 2009 | A1 |
| 20090074728 | Gronthos et al. | Mar 2009 | A1 |
| 20090075881 | Catelas et al. | Mar 2009 | A1 |
| 20090076481 | Stegmann et al. | Mar 2009 | A1 |
| 20090081770 | Srienc et al. | Mar 2009 | A1 |
| 20090081797 | Fadeev et al. | Mar 2009 | A1 |
| 20090092608 | Ni et al. | Apr 2009 | A1 |
| 20090098103 | Madison et al. | Apr 2009 | A1 |
| 20090098645 | Fang et al. | Apr 2009 | A1 |
| 20090100944 | Newby | Apr 2009 | A1 |
| 20090104163 | Deans et al. | Apr 2009 | A1 |
| 20090104692 | Bartfeld et al. | Apr 2009 | A1 |
| 20090104699 | Newby et al. | Apr 2009 | A1 |
| 20090118161 | Cruz | May 2009 | A1 |
| 20090181087 | Kraus et al. | Jul 2009 | A1 |
| 20090183581 | Wilkinson et al. | Jul 2009 | A1 |
| 20090191627 | Fadeev et al. | Jul 2009 | A1 |
| 20090191631 | Bomemann | Jul 2009 | A1 |
| 20090191632 | Fadeev et al. | Jul 2009 | A1 |
| 20090191634 | Martin et al. | Jul 2009 | A1 |
| 20090196901 | Guilak et al. | Aug 2009 | A1 |
| 20090203065 | Gehman et al. | Aug 2009 | A1 |
| 20090203129 | Furcht et al. | Aug 2009 | A1 |
| 20090203130 | Furcht et al. | Aug 2009 | A1 |
| 20090214382 | Burgess et al. | Aug 2009 | A1 |
| 20090214481 | Muhs et al. | Aug 2009 | A1 |
| 20090214652 | Hunter et al. | Aug 2009 | A1 |
| 20090215022 | Page et al. | Aug 2009 | A1 |
| 20090227024 | Baker et al. | Sep 2009 | A1 |
| 20090227027 | Baker et al. | Sep 2009 | A1 |
| 20090233334 | Hildinger et al. | Sep 2009 | A1 |
| 20090233353 | Furcht et al. | Sep 2009 | A1 |
| 20090233354 | Furcht et al. | Sep 2009 | A1 |
| 20090258379 | Klein et al. | Oct 2009 | A1 |
| 20090270725 | Leimbach et al. | Oct 2009 | A1 |
| 20090280153 | Hunter et al. | Nov 2009 | A1 |
| 20090280565 | Jolicoeur et al. | Nov 2009 | A1 |
| 20090291890 | Madison et al. | Nov 2009 | A1 |
| 20100009409 | Hubbell et al. | Jan 2010 | A1 |
| 20100021954 | Deshayes et al. | Jan 2010 | A1 |
| 20100021990 | Edwards et al. | Jan 2010 | A1 |
| 20100028311 | Motlagh et al. | Feb 2010 | A1 |
| 20100042260 | Antwiler | Feb 2010 | A1 |
| 20100075410 | Desai et al. | Mar 2010 | A1 |
| 20100086481 | Baird et al. | Apr 2010 | A1 |
| 20100092536 | Hunter et al. | Apr 2010 | A1 |
| 20100093607 | Dickneite | Apr 2010 | A1 |
| 20100105138 | Dodd et al. | Apr 2010 | A1 |
| 20100111910 | Rakoczy | May 2010 | A1 |
| 20100129376 | Denhardt et al. | May 2010 | A1 |
| 20100129912 | Su et al. | May 2010 | A1 |
| 20100136091 | Moghe et al. | Jun 2010 | A1 |
| 20100144037 | Antwiler | Jun 2010 | A1 |
| 20100144634 | Zheng et al. | Jun 2010 | A1 |
| 20100183561 | Sakthivel et al. | Jul 2010 | A1 |
| 20100183585 | Van Zant et al. | Jul 2010 | A1 |
| 20100203020 | Ghosh | Aug 2010 | A1 |
| 20100209403 | Meiron et al. | Aug 2010 | A1 |
| 20100230203 | Karayianni | Sep 2010 | A1 |
| 20100233130 | Meretzki | Sep 2010 | A1 |
| 20100248366 | Fadeev et al. | Sep 2010 | A1 |
| 20100267134 | Pera et al. | Oct 2010 | A1 |
| 20100278933 | Sayeski et al. | Nov 2010 | A1 |
| 20100285453 | Goodrich | Nov 2010 | A1 |
| 20100285590 | Verfaillie et al. | Nov 2010 | A1 |
| 20100291180 | Uhrich | Nov 2010 | A1 |
| 20100291181 | Uhrich et al. | Nov 2010 | A1 |
| 20100297234 | Sugino et al. | Nov 2010 | A1 |
| 20100304427 | Faris et al. | Dec 2010 | A1 |
| 20100304482 | Deshayes et al. | Dec 2010 | A1 |
| 20100310524 | Bechor et al. | Dec 2010 | A1 |
| 20100316446 | Runyon | Dec 2010 | A1 |
| 20110085746 | Wong et al. | Apr 2011 | A1 |
| 20110111498 | Oh et al. | May 2011 | A1 |
| 20110129447 | Meretzki et al. | Jun 2011 | A1 |
| 20110129486 | Meiron | Jun 2011 | A1 |
| 20110143433 | Oh et al. | Jun 2011 | A1 |
| 20110159584 | Gibbons | Jun 2011 | A1 |
| 20110171182 | Abelman | Jul 2011 | A1 |
| 20110171659 | Furcht et al. | Jul 2011 | A1 |
| 20110177595 | Furcht et al. | Jul 2011 | A1 |
| 20110212493 | Hirschel et al. | Sep 2011 | A1 |
| 20110256108 | Meiron et al. | Oct 2011 | A1 |
| 20110256160 | Meiron et al. | Oct 2011 | A1 |
| 20110293583 | Aberman | Dec 2011 | A1 |
| 20120028352 | Oh et al. | Feb 2012 | A1 |
| 20120051976 | Lu et al. | Mar 2012 | A1 |
| 20120058554 | Deshayes et al. | Mar 2012 | A1 |
| 20120064047 | Verfaillie et al. | Mar 2012 | A1 |
| 20120064583 | Edwards et al. | Mar 2012 | A1 |
| 20120088224 | DiLorenzo et al. | Apr 2012 | A1 |
| 20120118919 | Cianciolo | May 2012 | A1 |
| 20120122220 | Merchav et al. | May 2012 | A1 |
| 20120135043 | Maziarz et al. | May 2012 | A1 |
| 20120145580 | Paruit et al. | Jun 2012 | A1 |
| 20120156779 | Anneren et al. | Jun 2012 | A1 |
| 20120178885 | Kohn et al. | Jul 2012 | A1 |
| 20120189713 | Kohn et al. | Jul 2012 | A1 |
| 20120208039 | Barbaroux et al. | Aug 2012 | A1 |
| 20120219531 | Oh et al. | Aug 2012 | A1 |
| 20120219737 | Sugino et al. | Aug 2012 | A1 |
| 20120226013 | Kohn et al. | Sep 2012 | A1 |
| 20120231519 | Bushman et al. | Sep 2012 | A1 |
| 20120237557 | Lewitus et al. | Sep 2012 | A1 |
| 20120295352 | Antwiler | Nov 2012 | A1 |
| 20120308531 | Pinxteren et al. | Dec 2012 | A1 |
| 20120315696 | Luitjens et al. | Dec 2012 | A1 |
| 20130004465 | Aberman | Jan 2013 | A1 |
| 20130039892 | Aberman | Feb 2013 | A1 |
| 20130058907 | Wojciechowski et al. | Mar 2013 | A1 |
| 20130059383 | Dijkhuizen Borgart et al. | Mar 2013 | A1 |
| 20130101561 | Sabaawy | Apr 2013 | A1 |
| 20130143313 | Niazi | Jun 2013 | A1 |
| 20130157353 | Dijkhuizen Borgart et al. | Jun 2013 | A1 |
| 20130259843 | Duda et al. | Oct 2013 | A1 |
| 20130319575 | Mendyk | Dec 2013 | A1 |
| 20130323213 | Meiron et al. | Dec 2013 | A1 |
| 20130337558 | Meiron et al. | Dec 2013 | A1 |
| 20140004553 | Parker et al. | Jan 2014 | A1 |
| 20140017209 | Aberman et al. | Jan 2014 | A1 |
| 20140030805 | Kasuto et al. | Jan 2014 | A1 |
| 20140051162 | Nankervis | Feb 2014 | A1 |
| 20140051167 | Nankervis et al. | Feb 2014 | A1 |
| 20140112893 | Tom et al. | Apr 2014 | A1 |
| 20140186937 | Smith et al. | Jul 2014 | A1 |
| 20140193895 | Smith et al. | Jul 2014 | A1 |
| 20140193911 | Newby et al. | Jul 2014 | A1 |
| 20140242039 | Meiron et al. | Aug 2014 | A1 |
| 20140248244 | Danilkovitch et al. | Sep 2014 | A1 |
| 20140315300 | Oh et al. | Oct 2014 | A1 |
| 20140342448 | Nagels | Nov 2014 | A1 |
| 20150004693 | Danilkovitch et al. | Jan 2015 | A1 |
| 20150104431 | Pittenger et al. | Apr 2015 | A1 |
| 20150111252 | Hirschel et al. | Apr 2015 | A1 |
| 20150125138 | Karnieli et al. | May 2015 | A1 |
| 20150175950 | Hirschel et al. | Jun 2015 | A1 |
| 20150225685 | Hirschel et al. | Aug 2015 | A1 |
| 20150247122 | Tom et al. | Sep 2015 | A1 |
| 20150259749 | Santos et al. | Sep 2015 | A1 |
| 20160362650 | Wojciechowski et al. | Dec 2016 | A1 |
| 20160362652 | Page et al. | Dec 2016 | A1 |
| 20170107488 | Petcavich | Apr 2017 | A1 |
| 20180010082 | Jaques et al. | Jan 2018 | A1 |
| 20180030398 | Castillo | Feb 2018 | A1 |
| 20180155668 | Hirschel et al. | Jun 2018 | A1 |
| 20190194628 | Rao et al. | Jun 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 1016332 | Aug 1977 | CA |
| 4007703 | Sep 1991 | DE |
| 10244859 | Apr 2004 | DE |
| 10327988 | Jul 2004 | DE |
| 102012200939 | Jul 2013 | DE |
| 0220650 | May 1987 | EP |
| 750938 | Jan 1997 | EP |
| 906415 | Apr 1999 | EP |
| 959980 | Dec 1999 | EP |
| 1007631 | Jun 2000 | EP |
| 1028737 | Aug 2000 | EP |
| 1028991 | Aug 2000 | EP |
| 1066052 | Jan 2001 | EP |
| 1066060 | Jan 2001 | EP |
| 1084230 | Mar 2001 | EP |
| 1147176 | Oct 2001 | EP |
| 1220611 | Jul 2002 | EP |
| 1223956 | Jul 2002 | EP |
| 1325953 | Jul 2003 | EP |
| 1367119 | Dec 2003 | EP |
| 1437404 | Jul 2004 | EP |
| 1437406 | Jul 2004 | EP |
| 1447443 | Aug 2004 | EP |
| 1452594 | Sep 2004 | EP |
| 1062321 | Dec 2004 | EP |
| 1484080 | Dec 2004 | EP |
| 1498478 | Jan 2005 | EP |
| 1036057 | Oct 2005 | EP |
| 1605044 | Dec 2005 | EP |
| 1756262 | Feb 2007 | EP |
| 1771737 | Apr 2007 | EP |
| 1882030 | Jan 2008 | EP |
| 1908490 | Apr 2008 | EP |
| 1971679 | Sep 2008 | EP |
| 1991668 | Nov 2008 | EP |
| 2027247 | Feb 2009 | EP |
| 1147176 | Dec 2009 | EP |
| 2200622 | Jun 2010 | EP |
| 2208782 | Jul 2010 | EP |
| 2208782 | Jul 2010 | EP |
| 2264145 | Dec 2010 | EP |
| 2027247 | Jan 2011 | EP |
| 2303293 | Apr 2011 | EP |
| 2311938 | Apr 2011 | EP |
| 2311938 | Apr 2011 | EP |
| 2331957 | Jun 2011 | EP |
| 2334310 | Jun 2011 | EP |
| 2334783 | Jun 2011 | EP |
| 2361968 | Aug 2011 | EP |
| 2366775 | Sep 2011 | EP |
| 2366775 | Sep 2011 | EP |
| 2465922 | Jun 2012 | EP |
| 2200622 | Aug 2012 | EP |
| 2548951 | Jan 2013 | EP |
| 2548951 | Jan 2013 | EP |
| 2561066 | Feb 2013 | EP |
| 2575831 | Apr 2013 | EP |
| 2591789 | May 2013 | EP |
| 2591789 | May 2013 | EP |
| 2624845 | Aug 2013 | EP |
| 2626417 | Aug 2013 | EP |
| 2626417 | Aug 2013 | EP |
| 2641606 | Sep 2013 | EP |
| 2641606 | Sep 2013 | EP |
| 2689008 | Jan 2014 | EP |
| 2694639 | Feb 2014 | EP |
| 2697362 | Feb 2014 | EP |
| 2739720 | Jun 2014 | EP |
| 2807246 | Dec 2014 | EP |
| 1414671 | Nov 1975 | GB |
| 2297980 | Aug 1996 | GB |
| 2360789 | Oct 2001 | GB |
| 3285 | May 2007 | HU |
| H02245177 | Sep 1990 | JP |
| 2003052360 | Feb 2003 | JP |
| 2003510068 | Mar 2003 | JP |
| 2005278564 | Oct 2005 | JP |
| 2005333945 | Dec 2005 | JP |
| 2007000038 | Jan 2007 | JP |
| 5548207 | Jul 2014 | JP |
| 115206 | Apr 2003 | MY |
| 8602379 | Apr 1986 | WO |
| 8801643 | Mar 1988 | WO |
| 9002171 | Mar 1990 | WO |
| WO-9013306 | Nov 1990 | WO |
| WO-9105238 | Apr 1991 | WO |
| 9107485 | May 1991 | WO |
| WO-9106641 | May 1991 | WO |
| WO-9109194 | Jun 1991 | WO |
| 9118972 | Dec 1991 | WO |
| 9210564 | Jun 1992 | WO |
| WO-9425571 | Nov 1994 | WO |
| 9504813 | Feb 1995 | WO |
| 9513088 | May 1995 | WO |
| 9521911 | Aug 1995 | WO |
| WO-9629395 | Sep 1996 | WO |
| 9639487 | Dec 1996 | WO |
| WO-9639035 | Dec 1996 | WO |
| WO-9705826 | Feb 1997 | WO |
| 9716527 | May 1997 | WO |
| WO-9729792 | Aug 1997 | WO |
| WO-9739104 | Oct 1997 | WO |
| WO-1997-040137 | Oct 1997 | WO |
| WO-9831403 | Jul 1998 | WO |
| 9850526 | Nov 1998 | WO |
| 9853046 | Nov 1998 | WO |
| WO-9851317 | Nov 1998 | WO |
| WO-9851785 | Nov 1998 | WO |
| 9901159 | Jan 1999 | WO |
| WO-9905180 | Feb 1999 | WO |
| WO-9924391 | May 1999 | WO |
| WO-9924490 | May 1999 | WO |
| WO-9927167 | Jun 1999 | WO |
| WO-9949015 | Sep 1999 | WO |
| WO-0006704 | Feb 2000 | WO |
| WO-0009018 | Feb 2000 | WO |
| WO-0016420 | Mar 2000 | WO |
| WO-0017326 | Mar 2000 | WO |
| WO-0029002 | May 2000 | WO |
| WO-0032225 | Jun 2000 | WO |
| WO-0044058 | Jul 2000 | WO |
| WO-0054651 | Sep 2000 | WO |
| WO-0056405 | Sep 2000 | WO |
| WO-0059933 | Oct 2000 | WO |
| WO-0069449 | Nov 2000 | WO |
| 0075275 | Dec 2000 | WO |
| WO-0075196 | Dec 2000 | WO |
| WO-0077236 | Dec 2000 | WO |
| WO-2001000783 | Jan 2001 | WO |
| WO-2001011011 | Feb 2001 | WO |
| WO-2001018174 | Mar 2001 | WO |
| WO-2001021766 | Mar 2001 | WO |
| 0123520 | Apr 2001 | WO |
| WO-2001025402 | Apr 2001 | WO |
| WO-2001029189 | Apr 2001 | WO |
| WO-0122810 | Apr 2001 | WO |
| WO-2001034167 | May 2001 | WO |
| WO-2001049851 | Jul 2001 | WO |
| WO-2001054706 | Aug 2001 | WO |
| WO-2001-094541 | Dec 2001 | WO |
| 0228996 | Apr 2002 | WO |
| WO-2002042422 | May 2002 | WO |
| WO-2002057430 | Jul 2002 | WO |
| WO-2002092794 | Nov 2002 | WO |
| WO-2002101385 | Dec 2002 | WO |
| WO-2003010303 | Feb 2003 | WO |
| WO-2003014313 | Feb 2003 | WO |
| WO-2003016916 | Feb 2003 | WO |
| WO-2003023018 | Mar 2003 | WO |
| WO-2003023019 | Mar 2003 | WO |
| WO-2003025167 | Mar 2003 | WO |
| WO-2003029402 | Apr 2003 | WO |
| WO-2003040336 | May 2003 | WO |
| WO-2003042405 | May 2003 | WO |
| WO-2003046161 | Jun 2003 | WO |
| WO-2003055989 | Jul 2003 | WO |
| WO-2003061685 | Jul 2003 | WO |
| WO-2003061686 | Jul 2003 | WO |
| 03070922 | Aug 2003 | WO |
| WO-2003068961 | Aug 2003 | WO |
| WO-2003072064 | Sep 2003 | WO |
| WO-2003078609 | Sep 2003 | WO |
| WO-2003078967 | Sep 2003 | WO |
| 03087292 | Oct 2003 | WO |
| WO-2003080816 | Oct 2003 | WO |
| WO-2003082145 | Oct 2003 | WO |
| WO-2003085099 | Oct 2003 | WO |
| WO-2003089631 | Oct 2003 | WO |
| WO-2003091398 | Nov 2003 | WO |
| WO-2003095631 | Nov 2003 | WO |
| 03105663 | Dec 2003 | WO |
| WO-2004001697 | Dec 2003 | WO |
| WO-2004012226 | Feb 2004 | WO |
| WO-2004016779 | Feb 2004 | WO |
| WO-2004018526 | Mar 2004 | WO |
| WO-2004018655 | Mar 2004 | WO |
| WO-2004026115 | Apr 2004 | WO |
| WO-2004029231 | Apr 2004 | WO |
| WO-2004042023 | May 2004 | WO |
| WO-2004042033 | May 2004 | WO |
| WO-2004042040 | May 2004 | WO |
| WO-2004044127 | May 2004 | WO |
| WO-2004044158 | May 2004 | WO |
| WO-2004046304 | Jun 2004 | WO |
| WO-2004050826 | Jun 2004 | WO |
| WO-2004053096 | Jun 2004 | WO |
| WO-2004055155 | Jul 2004 | WO |
| WO-2004056186 | Jul 2004 | WO |
| WO-2004065616 | Aug 2004 | WO |
| WO-2004069172 | Aug 2004 | WO |
| WO-2004070013 | Aug 2004 | WO |
| WO-2004072264 | Aug 2004 | WO |
| WO-2004073633 | Sep 2004 | WO |
| WO-2004074464 | Sep 2004 | WO |
| WO-2004076642 | Sep 2004 | WO |
| WO-2004076653 | Sep 2004 | WO |
| 2004090112 | Oct 2004 | WO |
| WO-2004087870 | Oct 2004 | WO |
| WO-2004094588 | Nov 2004 | WO |
| WO-2004096975 | Nov 2004 | WO |
| WO-2004104166 | Dec 2004 | WO |
| WO-2004106499 | Dec 2004 | WO |
| WO-2004113513 | Dec 2004 | WO |
| 2005007799 | Jan 2005 | WO |
| WO-2005001033 | Jan 2005 | WO |
| WO-2005001081 | Jan 2005 | WO |
| WO-2005003320 | Jan 2005 | WO |
| WO-2005007799 | Jan 2005 | WO |
| WO-2005010172 | Feb 2005 | WO |
| WO-2005011524 | Feb 2005 | WO |
| WO-2005012480 | Feb 2005 | WO |
| WO-2005012510 | Feb 2005 | WO |
| WO-2005012512 | Feb 2005 | WO |
| WO-05014775 | Feb 2005 | WO |
| WO-2005028433 | Mar 2005 | WO |
| WO-05044972 | May 2005 | WO |
| WO-2005056747 | Jun 2005 | WO |
| WO-05051316 | Jun 2005 | WO |
| WO-2005063303 | Jul 2005 | WO |
| WO-2005075636 | Aug 2005 | WO |
| 2005087915 | Sep 2005 | WO |
| WO-2005107760 | Nov 2005 | WO |
| WO-2005121311 | Dec 2005 | WO |
| WO-2006009291 | Jan 2006 | WO |
| 2006019357 | Feb 2006 | WO |
| WO-2006032075 | Mar 2006 | WO |
| WO-2006032092 | Mar 2006 | WO |
| WO-2006108229 | Oct 2006 | WO |
| WO-2006113881 | Oct 2006 | WO |
| WO-2006121445 | Nov 2006 | WO |
| WO-06124021 | Nov 2006 | WO |
| WO-06129312 | Dec 2006 | WO |
| 97012144 | Feb 2007 | WO |
| WO-2007115367 | Oct 2007 | WO |
| WO-2007115368 | Oct 2007 | WO |
| 2007136821 | Nov 2007 | WO |
| 2007139742 | Dec 2007 | WO |
| 2007139746 | Dec 2007 | WO |
| 2007139747 | Dec 2007 | WO |
| 2007139748 | Dec 2007 | WO |
| WO-2008006168 | Jan 2008 | WO |
| WO-2008011664 | Jan 2008 | WO |
| WO-2008017128 | Feb 2008 | WO |
| WO-2008028241 | Mar 2008 | WO |
| WO-08040812 | Apr 2008 | WO |
| 2008109674 | Sep 2008 | WO |
| WO-2008116261 | Oct 2008 | WO |
| WO-2008149129 | Dec 2008 | WO |
| 2009034186 | Mar 2009 | WO |
| WO-2009026635 | Mar 2009 | WO |
| WO-09058146 | May 2009 | WO |
| WO-09080054 | Jul 2009 | WO |
| WO-09081408 | Jul 2009 | WO |
| 2009116872 | Sep 2009 | WO |
| WO-2009140452 | Nov 2009 | WO |
| WO-09132457 | Nov 2009 | WO |
| 2009144720 | Dec 2009 | WO |
| WO-2009144720 | Dec 2009 | WO |
| WO-10005527 | Jan 2010 | WO |
| WO-2010019886 | Feb 2010 | WO |
| WO-10014253 | Feb 2010 | WO |
| WO-10019997 | Feb 2010 | WO |
| 2010026573 | Mar 2010 | WO |
| 2010026574 | Mar 2010 | WO |
| 2010026575 | Mar 2010 | WO |
| WO-2010026573 | Mar 2010 | WO |
| WO-2010026574 | Mar 2010 | WO |
| WO-2010026575 | Mar 2010 | WO |
| 10034468 | Apr 2010 | WO |
| WO-2010036760 | Apr 2010 | WO |
| WO-2010059487 | May 2010 | WO |
| WO-10061377 | Jun 2010 | WO |
| WO-10068710 | Jun 2010 | WO |
| WO-10071826 | Jun 2010 | WO |
| WO-10083385 | Jul 2010 | WO |
| WO-10111255 | Sep 2010 | WO |
| WO-10119036 | Oct 2010 | WO |
| WO-10123594 | Oct 2010 | WO |
| 10149597 | Dec 2010 | WO |
| WO-2011025445 | Mar 2011 | WO |
| 2011132087 | Oct 2011 | WO |
| WO-2011132087 | Oct 2011 | WO |
| 2011147967 | Dec 2011 | WO |
| WO-2011147967 | Dec 2011 | WO |
| WO-2012072924 | Jun 2012 | WO |
| 2012127320 | Sep 2012 | WO |
| WO-2012127320 | Sep 2012 | WO |
| 2012140519 | Oct 2012 | WO |
| WO-2012138968 | Oct 2012 | WO |
| WO-2012140519 | Oct 2012 | WO |
| 2012171026 | Dec 2012 | WO |
| 2012171030 | Dec 2012 | WO |
| WO-2013110651 | Aug 2013 | WO |
| 2014037862 | Mar 2014 | WO |
| 2014037863 | Mar 2014 | WO |
| WO-2014037862 | Mar 2014 | WO |
| WO-2014037863 | Mar 2014 | WO |
| 2014068508 | May 2014 | WO |
| WO-2014068508 | May 2014 | WO |
| 2014128634 | Aug 2014 | WO |
| WO-2014128306 | Aug 2014 | WO |
| WO-2014128634 | Aug 2014 | WO |
| 2014141111 | Sep 2014 | WO |
| WO-2014131846 | Sep 2014 | WO |
| WO-2014141111 | Sep 2014 | WO |
| 2015004609 | Jan 2015 | WO |
| WO-2015004609 | Jan 2015 | WO |
| WO-2015118148 | Aug 2015 | WO |
| WO-2015118149 | Aug 2015 | WO |
| WO-2015131143 | Sep 2015 | WO |
| 2017066663 | Apr 2017 | WO |
| WO-2017072201 | May 2017 | WO |
| Entry |
|---|
| MCFETRIDGE et al. “Endothelial and Smooth Muscle Cell Seeding onto Processed Ex Vivo Arterial Scaffolds Using 3D Vascular Bioreactors.” ASAIO Journal (2004), pp. 591-599. (Year: 2004). |
| 00 et al. “The performance of primary human renal cells in hollow fiber bioreactors for bioartificial kidneys.” Biomaterials 32 (2011) 8806-8815. (Year: 2011). |
| Notice of Allowance, U.S. Appl. No. 15/482,168, filed Mar. 18, 2019. |
| Notice of Allowance, U.S. Appl. No. 15/482,168, filed Jun. 26, 2019. |
| Notice of Allowance, U.S. Appl. No. 15/482,168, filed Oct. 25, 2019. |
| Chang et al., “Membrane Bioreactors: Present and Prospects”, Advances in Biochemical Engineering, 1991, pp. 27-64, vol. 44. |
| Chang, Ho Nam, “Membrane Bioreactors: Engineering Aspects”, Biotech. Adv., 1987, pp. 129-145, vol. 5. |
| Edgington, Stephen M., “New Horizons for Stem-Cell Bioreactors”, Biotechnology, Oct. 1992, pp. 1099-1106, vol. 10. |
| Gastens et al., “Good Manufacturing Practice-Compliant Expansion of Marrow-Derived Stem and Progenitor Cells for Cell Therapy”, Cell Transplantation, 2007, pp. 685-696, vol. 16. |
| Cramer et al., “Screening Tool for Hollow-Fiber Bioreactor Process Development”, Biotechnol. Prog., 1998, pp. 203-209, vol. 14. |
| Hirschel et al., “An Automated Hollow Fiber System for the Large Scale Manufacture of Mammalian Cell Secreted Product”, Large Scale Cell Culture Technology, ed. Bjorn K. Lydersen, 1987, pp. 113-144, Hanser Publishers. |
| Infanger et al., “Simulated weightlessness changes the cytoskeleton and extracellular matrix proteins in papillary thyroid carcinoma cells”, Cell and Tissue Research, 2006, 324(2): 267-277. |
| International Search Report and Written Opinion, PCT/US2014/065829, dated Jan. 21, 2015. |
| Jones et al., “Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System”, Cytotherapy, 2013; 15: 1323-1339. |
| Nankervis et al., “Shear Stress Conditions in the Quantum Cell Expansion System”, Poster Session—TERMIS AM Annual Conference 2013, Nov. 12, 2013. |
| Nielsen, Lars Keld, “Bioreactors for Hematopoietic Cell Culture”, Annu. Rev. Biomed. Eng., 1999, vol. 1, pp. 129-152. |
| Office Action, U.S. Appl. No. 14/542,276, filed Jun. 17, 2016. |
| Pörtner et al., “An Overview on Bioreactor Design, Prototyping and Process Control for Reproducible Three-Dimensional Tissue Culture”, Drug Testing in Vitro: Breakthroughs and Trends in Cell Culture Technology, ed. Uwe Marx and Volker Sandig, 2007, Wiley-VCH, pp. 53-78. |
| Zhao et al., “Perfusion Bioreactor System for Human Mesenchymal Stem Cell Tissue Engineering: Dynamic Cell Seeding and Construct Development”, Biotechnology and Bioengineering, Aug. 20, 2005, vol. 91, No. 4, pp. 182-493. |
| Antwiler, et al., “Bioreactor Design and Implementation,” Methods in Bioengineering: Stem Cell Bioengineering, Parekkadan and Yarmush, eds., Artech House, Chapter 4, pp. 49-62 (2009). |
| Brambrink, et al., “Sequential Expression of Pluripotency Markers during Direct Reprogramming of Mouse Somatic Cells,” Cell Stem Cell, 2:151-159 (2008). |
| Chua, et al., “Stable immobilization of rat hepatocyte spheroids on galactosylated nanofiber scaffold,” Biomaterials, 26:2537-2547 (2004). |
| Drobinskaya, et al., “Scalable Selection of Hepatocyte- and Hepatocyte Precursor-Like Cells from Culture of Differentiating Transgenically Modified Murine Embryonic Stem Cells,” Stem Cells, 26:2245-2256 (2008). |
| Dvir-Ginzberg, et al., “Induced differentiation and maturation of newborn liver cells into functional hepatic tissue in macroporous alginate scaffolds,” FASEB J., 22:1440 1449 (2008). |
| Guan, et al., “Pluripotency of spermatogonial stem cells from adult mouse testis,” Nature, 440:1199-1203 (2006). |
| Hanna, et al., “Direct Reprogramming of Terminally Differentiated Mature B Lymphocytes to Pluripotency,” Cell, 133:250-264 (2008). |
| Hoenich, et al., “A Microdomain-Structured Synthetic High-Flux Hollow-Fiber Membrane for Renal Replacement Therapy,” ASAIO J., 46:70-75 (2000). |
| Jaenisch, et al., “Stem Cells, the Molecular Circuitry of Pluripotency and Nuclear Reprogramming,” Cell, 132:567-582 (2008). |
| Jahagirdar, B. N., et al., “Novel therapies for chronic myelogenous leukemia,” Experimental Hematology, 29:543-556 (2001). |
| Jiang, Y., et al., “Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain,” Experimental Hematology, 30:896-904 (2002). |
| Jiang, Y., et al., “Pluripotency of mesenchymal stem cells derived from adult marrow,” Nature, 418:41-49. (2002). |
| Kirouac, et al., “The Systematic Production of Cells for Cell Therapies,” Cell Stem Cell, 3:369-381 (2008). |
| Matsumoto, et al., “Hepatic Differentiation of Mouse Embryonic Stem Cells in a Three-Dimensional Culture System Using Polyurethane Foam,” Journal of Bioscience and Bioengineering, 105:350-354 (2008). |
| McNiece, et al., “Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer,” Hematol Cell Ther, 41:82-86 (1999). |
| McNiece, et al., “Increased expansion and differentiation of cord blood products using a two-step expansion culture,” Experimental Hematology, 28:1181-1186 (2000). |
| Miyazawa, et al., “Hepatocyte dynamics in a three-dimensional rotating Bioreactor,” Journal of Gastroenterology and Hepatology, 22:1959-1964 (2007). |
| Ohashi, et al., “Engineering functional two- and three-dimensional liver systems in vivo using hepatic tissue sheets,” Nature Medicine, 13:880-885 (2007). |
| Okita, et al., “Generation of germline-competent induced pluripotent stem cells,” Nature, 448:313-318 (2007). |
| Reyes, M. and C. M. Verfaillie, “Characterization of Multipotent Adult Progenitor Cells, a Subpopulation of Mesenchymal Stem Cells,” Ann NY Acad Sci, 938:231-235 (2001). |
| Takahashi, et al., “Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors,” Cell, 126:663-676 (2006). |
| Takahashi, et al., “Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors,” Cell, 131:861-872 (2007). |
| Turner, at al., “Human Hepatoblast Phenotype Maintained by Hyaluronan Hydrogels,” Journal of Biomedical Materials Research Part B: Applied Biomaterials, Wiley InterScience (www.interscience.wiley.com), 826:156-168 (2006). |
| Verfaillie, C. M., “Adult stem cells: assessing the case for pluripotency,” Trends Cell Biol 12:502-508 (2002). |
| Moss, Harald, “Bioreactors,” Ullmann's Encyclopedia Of Industrial Chemistry: Fifth ed., B. Elvers, S. Hawkins and G. Schulz Eds, VCH Publishers, 1992, vol. B4, pp. 381-433. |
| Wernig, et al., “Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease,” PNAS, 105:5856-5861 (2008). |
| Wilmut, et al., “Viable offspring derived from fetal and adult mammalian cells,” Nature, 385:810-813 (1997). |
| Yamanaka, S. “Strategies and New Developments in the Generation of Patient-Specific Pluripotent Stem Cells,” Cell Stem Cell, 1:39-49 (2007). |
| King, et al., “Changing potency by spontaneous fusion,” Nature, 416:545-548 (2002). |
| Zandstra, et al., “Expansion of Hematopoietic Progenitor Cell Populations in Stirred Suspension Bioreactors of Normal Human Bone Marrow Cells,” Biotechnol, 12:909-914 (1994). |
| Campagnoli Cesare, et al.: “Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow,” Blood, American Society of Hematology, US, vol. 98, No. 8, Oct. 15, 2001 (Oct. 15, 2001), pp. 2396-2402. |
| Colter, David C., et al., “Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow,” PNAS, Mar. 28, 2000, vol. 97, No. 7, pp. 3213-3218. |
| Deans, Robert J., et al., “Mesenchymal stem cells: Biology and potential clinical uses,” Experimental Hematology, 28 (2000), pp. 875-884. |
| De Kreuk, Arne M., et al., “A Single-Step Colony-Forming Unit Assay for Unseparated Mobilized Peripheral Blood, Cord Blood, and Bone Marrow,” Journal of Hematotherapy & Stem Cell Research, Mary Ann Liebert, Inc., 2001, vol. 10, pp. 795-806. |
| Deppisch, Reinhold, et al., “Microdomain structure of polymeric surfaces—Potential for improving blood treatment procedures,” Nephrol Dial Transplant, 1998, vol. 13, pp. 1354-1359. |
| Humes, HD, et al., “The future of hemodialysis membranes,” Kidney International, 2006, vol. 69, pp. 1115-1119. |
| Javazon, Elisabeth H., et al., “Rat Marrow Stromal Cells are More Sensitive to Plating Density and Expand More Rapidly from Single-Cell-Derived Colonies than Human Marrow Stromal Cells,” Stem Cells, 2001, vol. 19, pp. 219-225. |
| Lin, Wen-Ching, et al., “Blood compatibility of thermoplastic polyurethane membrane immobilized with water soluble chitosan/dextran sulfale,” Colloids and Surfaces B: Biointerfaces, 2005, vol. 44, pp. 82 92. |
| Martin, Ivan, et al., “Selective differentiation of mammalian bone marrow stromal cells cultured on three-dimensional polymer foams,” Engineering Skeletal Tissues from Bone Marrow, John Wiley & Sons, Inc., 2001, pp. 229-235. |
| Mesquita, Fernanda C. Paccola, et al., “Laminin as a Potent Substrate for Large-Scale Expansion of Human Induced Pluripotent Stem Cells in a Closed Cell Expansion System,” Hindawi, Stem Cells International, vol. 2019, Article ID 9704945, Jan. 22, 2019, pp. 1-9. |
| Sekiya, Ichiro, et al., “Expansion of Human Adult Stem Cells from Bone Marrow Stroma: Conditions that Maximize the Yields of Early Progenitors and Evaluate Their Quality,” Stem Cells, 2002, vol. 20, pp. 530-541. |
| Sheu, Jonathan, et al., “Large-scale production of lentiviral vector in a closed system hollow fiber bioreactor,” Nature, Molecular Therapy—Methods & Clinical Development, 2, Article No. 15020 (2015), doi:10.1038/mtm.2015.20, Jun. 17, 2015, <http://www.nature.com/articles/mtm201520>, pp. 1-18. |
| Sotiropoulou, Panagiota A., et al., “Characterization of the Optimal Culture Conditions for Clinical Scale Production of Human Mesenchymal Stem Cells,” Stem Cells, 2006, vol. 24, pp. 462-471. |
| Tsai, Ming-Song, et al., “Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol,” Human Reproduction, 2004, vol. 19, No. 6, pp. 1450-1456. |
| Abumiya, et al at National Cardiovascular Center Research Institute in Japan, suggest that subjecting human umbilical vein endothelial cells (HUVECs) to laminar shear stress for a period of 8 hours increased the relative expression of VEGFR-2 mRNA (Ateriosclerosis, Thrombosis, and Vascular Biology, 2002). |
| Afzali B, Edozie FC, Fazekasova H, Scotta C, Mitchell PJ, Canavan JB, Kordasti SY, Chana PS, Ellis R, Lord GM, John S, Hilton R, Lechler RI, Lombardi G. Comparison of regulatory T cells in hemodialysis patients and healthy controls: implications for cell therapy in transplantation. Clin J Am Soc Nephrol. 2013;8(8):1396-405. |
| Akram, Khondoker M., et al. “Mesenchymal stem cells promote alveolar epithelial cell wound repair in vitro through distinct migratory and paracrine mechanisms.” Respiratory research 14.1 (2013): 1-16. |
| Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. Fibroblasts and Their Transformations: The Connective-Tissue Cell Family. Available from: https://www.ncbi.nlm.nih.gov/books/NBK26889. |
| Alenazi, Noof A., et al. “Modified polyether-sulfone membrane: A mini review.” Designed monomers and polymers 20.1 (2017): 532-546. |
| Almeida L, Lochner M, Berod L, Sparwasser T. Metabolic pathways in T cell activation and lineage differentiation. Semin Immunol. 2016;28(5):514-524. |
| Amy Putnam, Todd M. Brusko, Michael R. Lee, Weihong Liu, Gregory L. Szot, Taumoha Ghosh, Mark A. Atkinson, and Jeffrey A. Bluestone. Expansion of human regulatory T-Cells from patients with Type 1 Diabetes. Diabetes, 58: 652-662, 2009. |
| Anamelechi, Charles C., et al. “Streptavidin binding and endothelial cell adhesion to biotinylated fibronectin.” Langmuir 23.25 (2007): 12583-12588. |
| Anurathapan et al., “Engineered T cells for cancer treatment,” Cytotherapy, vol. 16, pp. 713-733, 2014. |
| Aronowski J, Samways E, Strong R, Rhoades HM, Grotta JC. An alternative method for the quantitation of neuronal damage after experimental middle cerebral artery occlusion in rats: Analysis of behavioral deficit. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 1996;16:705-713. |
| Arrigoni, Chiara, et al. “Rotating versus perfusion bioreactor for the culture of engineered vascular constructs based on hyaluronic acid.” Biotechnology and bioengineering 100.5 (2008): 988-997. |
| Azar, Toni, Jody Sharp, and David Lawson. “Heart rates of male and female Sprague-Dawley and spontaneously hypertensive rats housed singly or in groups.” Journal of the American Association for Laboratory Animal Science 50.2 (2011): 175-184. |
| Baecher-Allan, Clare, et al. “CD4+ CD25high regulatory cells in human peripheral blood.” The Journal of Immunology 167.3 (2001): 1245-1253. |
| Bai, Tao, et al. “Expansion of primitive human hematopoietic stem cells by culture in a zwitterionic hydrogel.” Nature medicine 25.10 (2019): 1566-1575. |
| Bai/Delaney (Nohla Therapeutics) showed that expanding Cord Blood-derived CD34+CD38-CD45RA-HSPCs in a biodegradable zwitterionic hydrogel with a rNotch ligand cocktail for 24 days mitigated HSPC differentiation and promoted self-renewal of lymphoid and myeloid cell phenotypes in an NSG mouse model (Nature Medicine, 2019). |
| Ballas CB, Zielske SP, Gerson SL (2002) Adult bone marrow stem cells for cell and gene therapies: implications for greater use. J Cell Biochem Suppl 38: 20-28. |
| Ballke C, Gran E, Baekkevold ES, Jahnsen FL. Characterization of Regulatory T-Cell Markers in CD4+T Cells of the Upper Airway Mucosa. PLoS One. 2016;11(2):e0148826. |
| Baraniak PR, McDevitt TC (2010) Stem cell paracrine actions and tissue regeneration. Regen Med 5(1): 121-143. |
| Barckhausen C, Rice B, Baila S, et al. (2016) GMP-Compliant Expansion of Clinical-Grade Human Mesenchymal Stromal/Stem Cells Using a Closed Hollow Fiber Bioreactor. Methods Mol Biol 1416: 389-412. |
| Barker et al. “CD34+ Cell Content of 126 341 Cord Blood Units in the US Inventory: Implications for Transplantation and Banking,” blood Advances, vol. 3, No. 8, pp. 1267-1271, Apr. 23, 2019. |
| Barker, Juliet N., et al. “CD34+ cell content of 126 341 cord blood units in the US inventory: implications for transplantation and banking.” Blood advances 3.8 (2019): 1267-1271. |
| Bazarian JJ, Cernak I, Noble-Haeusslein L, Potolicchio S, Temkin N. Long-term neurologic outcomes after traumatic brain injury. The Journal of head trauma rehabilitation. 2009;24:439-451. |
| Bending D, Pesenacker AM, Ursu S, Wu Q, Lom H, Thirugnanabalan B, Wedderburn LR. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis. J Immunol. 2014;193(6):2699-708. |
| Berendse M, Grounds MD, Lloyd CM (2003) Myoblast structure affects subsequent skeletal myotube morphology and sarcomere assembly. Exp Cell Res 291(2): 435-450. |
| Bernard, A., Payton, Mar. 1995. “Fermentation and Growth of Escherichia coli for Optimal Protein Production”, John Wiley & Sons. Current Protocols in Protein Science (1995) 5.3.1-5.3.18. |
| Berney SM, Schaan T, Wolf RE, van der Heyde H, Atkinson TP. CD2 (OKT11) augments CD3-mediated intracellular signaling events in human T lymphocytes. J Investig Med. 2000;48(2):102-9. |
| Bioheart Clinical Trial Clinica 1302 Apr. 18, 2008. |
| Biomolecular and Cellular Interactions with the Hollow Fiber Membrane Currently Used in the Quantum® Cell Expansion System. 12th NJ Symposium on Biomaterials Science, Oct. 6-7, 2014, New Brunswick, NJ. |
| Blache C, Chauvin JM, Marie-Cardine A, Contentin N, Pommier P, Dedreux I, Francois S, Jacquot S, Bastit D, Boyer O. Reduced frequency of regulatory T cells in peripheral blood stem cell compared to bone marrow transplantations. Biol Blood Marrow Transplant. 2010;16(3):430-4. |
| Bluestone et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Science Iranslational Medicine 7(315):1-34, 2015. |
| Bluestone JA, Tang Q. Treg cells—the next frontier of cell therapy. Science. 2018;362(6411):154-155. |
| Bluestone, Jeffrey A., et al. “Type 1 diabetes immunotherapy using polyclonal regulatory T cells.” Science translational medicine 7.315 (2015): 315ra189-315ra189. |
| Blum S, Moore AN, Adams F, Dash PK. A mitogen-activated protein kinase cascade in the ca1/ca2 subfield ofthe dorsal hippocampus is essential for long-term spatial memory. The Journal of neuroscience : the official journal ofthe Society for Neuroscience. 1999;19:3535-3544. |
| Boitano, Anthony E., et al. “Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells.” Science 329.5997 (2010): 1345-1348. |
| Bojun Li et al. Heparin-induced conformation changes of fibronectin within the extracellular matrix promote hMSC osteogenic differentiation. Biomaterials Science 3: 73-84, 2015. |
| Boquest AC, Shahdadfar A, Brinchmann JE, Collas P. Isolation of Stromal Stem Cells from Human Adipose Tissue. Methods Mol Biol. 2006;325:35-46. doi: 10.1385/1-59745-005-7:35. PMID: 16761717. |
| Borden, M. and Longo, M., “Dissolution Behavior of Lipid Monolayer-Coated, Air-Filled Microbubbles: Effect of Lipid Hydrophobic Chain Length,” Langmuir, vol. 18, pp. 9225-9233, 2002. |
| Bourke, Sharon L., and Joachim Kohn. “Polymers derived from the amino acid L-tyrosine: polycarbonates, polyarylates and copolymers with poly (ethylene glycol).” Advanced drug delivery reviews 55.4 (2003): 447-466. |
| Brand, K. and Hermfisse, U., “Aerobic Glycolysis by Proliferating Cells: a Protective Strategy against Reactive Oxygen Species,” The FASEB Journal, vol. 11, pp. 388-395, Apr. 1997. |
| Brentjens et al., “CD19-Targeted T Cells Rapidly Induce Molecular Remission in Adults with Chemotherapy-Refractory Acute Lympohblastic Leukemia,” Science Translational Medicine, vol. 5, Issue 177, pp. 1-9, Mar. 20, 2013. |
| Brentjens et al., “Safety and Persistance of Adoptively Transferred Autologous CD19-Target T Cells in Patients with Relapsed or Chemotherapy Refractory B-Cell Leukemias,” Blood, vol. 118, No. 18, pp. 4817-4828, Nov. 3, 2011. |
| Brunstein C, Miller J, Cao Q, McKenna D, Hippen K, Curtsinger J, DeFor T, Levine B, June C, Rubinstein P, McGlave P, Blazar B, Wagner J. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117(3):1061-1070. |
| C. H. Weaver, et al. An Analysis of Engraftment Kinetics as a function of the CD34 Content of the Peripheral Blood Progenitor Cell Collections in 692 Patients After the Administration of Myeloblative Chemotherapy. Blood 86(10): 3691-3969, 1995. |
| Cano, Àngels, Cristina Minguillon, and Cristina Palet. “Immobilization of endo-1, 4-ß-xylanase on polysulfone acrylate membranes: Synthesis and characterization.” Journal of membrane science 280.1-2 (2006): 383-388. |
| Carswell, K. and Papoutsakis, E. “Culture of Human T Cells in Stirred Bioreactors for Cellular Immunotherapy Applications: Shear, Proliferation, and the IL-2 Receptor,” Biotechnology and Bioengineering, vol. 68, No. 3, pp. 329-338, May 5, 2000. |
| Celeste Nelson et al., Emergent patterns of growth controlled by multicellular form and mechanics, (in Christopher Chen's Lab demonstrated, in separate experiments, that curved surfaces with a radius of curvature (200 ?m) that is greater than the cell diameter and surfaces that have undulating special patterning (depressions) increase the patterned growth of ECs [PNAS 102(33): 11594-11599, 2005]. |
| Chapman NM, Chi H. mTOR signaling, Tregs and immune modulation. Immunotherapy. 2014;6(12):1295-311. |
| Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT, Bruning JC, Muller W, Rudensky AY. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. 2011;34(4):566-78. |
| Chen, C. and Broden, M., “The Role of Poly(theylene glycol) Brush Architecture in Complement Activation on Targeted Microbubble Surfaces,” Biomaterials, vol. 32, No. 27, pp. 6579-6587, Jun. 17, 2011. |
| Choi W, Kwon SJ, Jin HJ, et al. (2017) Optimization of culture conditions for rapid clinical-scale expansion of human umbilical cord blood-derived mesenchymal stem cells. Clin Transl Med 6(1): 38. |
| Chullikana A, Majumdar AS, Gottipamula S, et al. (2015) Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. Cytotherapy 17(3): 250-261. |
| Claudio G. Brunstein, Jeffrey S. Miller, Qing Cao, Daivd H. McKenna, Keii L. Hippen, Julie Curtsinger, Todd Defor, Bruce L. Levine, Carl H. June, Pablo Rubinstein, Philip B. McGlave, Bruce R. Blazar, and John E. Wagner. Infusion of ex vivo expanded T regulatory cells in Adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood, 117(3): 1061-1070, 2010. |
| Coeshott C, Vang B, Jones M, Nankervis B. Large-scale expansion and characterization of CD3(+) T-cells in the Quantum((R)) Cell Expansion System. J Transl Med. 2019;17(1):258. |
| Coombes JL, Robinson NJ, Maloy KJ, Uhlig HH, Powrie F. Regulatory T cells and intestinal homeostasis. Immunol Rev. 2005;204:184-94. |
| Coquillard C. mTOR Signaling in Regulatory T cell Differentiation and Expansion. SOJ Immunology. 2015;3(1):1-10. |
| Creed JA, DiLeonardi AM, Fox DP, Tessier AR, Raghupathi R. Concussive brain trauma in the mouse results in acute cognitive deficits and sustained impairment of axonal function. Journal of neurotrauma. 2011;28:547-563. |
| Cuchiara, Maude L., et al. “Covalent immobilization of stem cell factor and stromal derived factor 1α for in vitro culture of hematopoietic progenitor cells.” Acta biomaterialia 9.12 (2013): 9258-9269. |
| Da Silva, Ricardo MP, Joao F. Mano, and Rui L. Reis. “Smart thermoresponsive coatings and surfaces fortissue engineering: switching cell-material boundaries.” Trends in Biotechnology 25.12 (2007): 577-583. |
| Dash PK, Hochner B, Kandel ER. Injection ofthe camp-responsive element into the nucleus of aplysia sensory neurons blocks long-term facilitation. Nature. 1990;345:718-721. |
| Dash PK, Johnson D, Clark J, Orsi SA, Zhang M, Zhao J, Grill RJ, Moore AN, Pati S. Involvement ofthe glycogen synthase kinase-3 signaling pathway in tbi pathology and neurocognitive outcome. PloS one. 2011;6:e24648. |
| Dash PK, Mach SA, Blum S, Moore AN. Intrahippocampal wortmannin infusion enhances long-term spatial and contextual memories. Learn Mem. 2002;9:167-177. |
| Dash PK, Orsi SA, Zhang M, Grill RJ, Pati S, Zhao J, Moore AN. Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PloS one. 2010;5:e11383. |
| Dash PK, Zhao J, Orsi SA, Zhang M, Moore AN. Sulforaphane improves cognitive function administered following traumatic brain injury. Neuroscience letters. 2009;460:103-107. |
| Davila et al., “Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B cell Acute Lymphoblastic Leukemia,” Science Translational Medicine, vol. 6, No. 224, pp. 1-10, Feb. 19, 2014. |
| Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and ve-cadherin in the control of vascular permeability. Journal of cell science. 2008;121:2115-2122. |
| Dejana E, Spagnuolo R, Bazzoni G. Interendothelial junctions and their role in the control of angiogenesis, vascular permeability and leukocyte transmigration. Thrombosis and haemostasis. 2001;86:308-315. |
| Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular integrity by endothelial cell junctions: Molecular basis and pathological implications. Developmental cell. 2009;16:209-221. |
| Del Pino A, Ligero G, Lopez MB, et al. (2015) Morphology, cell viability, karyotype, expression of surface markers and plasticity of three primary cell line cultures before and after the cryostorage in LN2 and GN2. Cryobiology 70(1): 1-8. |
| Delaney, Colleen, et al. “Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution.” Nature medicine 16.2 (2010): 232-236. |
| Ding, Zhongli, Guohua Chen, and Allan S. Hoffman. “Synthesis and purification of thermally sensitive oligomer? enzyme conjugates of poly (N-isopropylacrylamide)? trypsin.” Bioconjugate chemistry 7.1 (1996): 121-125. |
| Dixon CE, Clifton GL, Lighthall JW, Yaghmai AA, Hayes RL. A controlled cortical impact model of traumatic brain injury in the rat. Journal of neuroscience methods. 1991;39:253-262. |
| Dominici M, Le Blanc K, Mueller I, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4): 315-317. |
| Durrani S, Konoplyannikov M, Ashraf M, Haider KH (2010) Skeletal myoblasts for cardiac repair. Regen Med 5(6): 919-932. |
| Esensten JH, Muller YD, Bluestone JA, Tang Q. Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier. J Allergy Clin Immunol. 2018;142(6):1710-1718. |
| Fakin R, Hamacher J, Gugger M, Gazdhar A, Moser H, Schmid RA. Prolonged amelioration of acute lung allograft rejection by sequential overexpression of human interleukin-10 and hepatocyte growth factor in rats. Exp Lung Res. 2011;37(9):555-62. |
| Fedorov et al., “PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses,” Science Translational Medicine, vol. 5, No. 215, pp. 1-12, Dec. 11, 2013. |
| Ferreira LMR, Muller YD, Bluestone JA, Tang Q. Next-generation regulatory T cell therapy. Nat Rev Drug Discov. 2019;18(10):749-769. |
| Fischbach, Michael A., Jeffrey A. Bluestone, and Wendell A. Lim. “Cell-based therapeutics: the next pillar of medicine.” Science translational medicine 5.179 (2013): 179ps7-179ps7. |
| Fisk, Nicholas M., et al. “Can routine commercial cord blood banking be scientifically and ethically justified?.” PLoS medicine 2.2 (2005): e44. |
| Forbes Jun. 23, 2014 article “Will this man cure cancer?”. |
| Fowler DH. Rapamycin-resistant effector T-cell therapy. Immunol Rev. 2014;257(1):210-25. |
| Fraser H, Safinia N, Grageda N, Thirkell S, Lowe K, Fry LJ, Scotta C, Hope A, Fisher C, Hilton R, Game D, Harden P, Bushell A, Wood K, Lechler RI, Lombardi G. A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials. Mol Ther Methods Clin Dev. 2018;8:198-209. |
| Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, Elstrom RL, June CH, Thompson CB. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002;16(6):769-77. |
| Fuchs A, Gliwinski M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhauser M, Ten Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Golab K, Hafler DA, van Ham SM, Hester J et al. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Front Immunol. 2017;8:1844. |
| G0211: Study for Gamma Irradiation of Bioreactor Membranes, undated, author unknown, 3 pages. |
| Galgani M, De Rosa V, La Cava A, Matarese G. Role of Metabolism in the Immunobiology of Regulatory T Cells. J Immunol. 2016;197(7):2567-75. |
| Garlie, Nina K., et al. “T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer.” Journal of immunotherapy (Hagerstown, Md.: 1997) 22.4 (1999): 336-345. |
| Gedaly R, De Stefano F, Turcios L, Hill M, Hidalgo G, Mitov MI, Alstott MC, Butterfield DA, Mitchell HC, Hart J, Al-Attar A, Jennings CD, Marti F. mTOR Inhibitor Everolimus in Regulatory T Cell Expansion for Clinical Application in Transplantation. Transplantation. 2019;103(4):705-715. |
| Gimble, Jeffrey M., Adam J. Katz, and Bruce A. Bunnell. “Adipose-derived stem cells for regenerative medicine.” Circulation research 100.9 (2007): 1249-1260. |
| Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15(7):807-26. |
| Godin, Michel, et al. “Measuring the mass, density, and size of particles and cells using a suspended microchannel resonator.” Applied physics letters 91.12 (2007): 123121. |
| Goh, Celeste, Sowmya Narayanan, and Young S. Hahn. “Myeloid-derived suppressor cells: the dark knight or the joker in viral infections?.” Immunological reviews 255.1 (2013): 210-221. |
| Golab K, Leveson-Gower D, Wang XJ, Grzanka J, Marek-Trzonkowska N, Krzystyniak A, Millis JM, Trzonkowski P, Witkowski P. Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. Int Immunopharmacol. 2013;16(3):371-5. |
| Goldring CE, Duffy PA, Benvenisty N, Andrews PW, Ben-David U, Eakins R, French N, Hanley NA, Kelly L, Kitteringham NR, Kurth J, Ladenheim D, Laverty H, McBlane J, Narayanan G, Patel S, Reinhardt J, Rossi A, Sharpe M, Park BK. Assessing the safety of stem cell therapeutics. Cell stem cell. 2011;8:618-628. |
| Griesche, Nadine, et al. “A simple modification of the separation method reduces heterogeneity of adipose-derived stem cells.” cells tissues organs 192.2 (2010): 106-115. |
| Gutcher I, Donkor MK, Ma Q, Rudensky AY, Flavell RA, Li MO. Autocrine transforming growth factor-beta1 promotes in vivo Th17 cell differentiation. Immunity. 2011;34(3):396-408. |
| Haack-Sorensen M, Follin B, Juhl M, et al. (2016) Culture expansion of adipose derived stromal cells. A closed automated Quantum Cell Expansion System compared with manual flask-based culture. J Transl Med 14(1): 319. |
| Hall ED, Sullivan PG, Gibson TR, Pavel KM, Thompson BM, Scheff SW. Spatial and temporal characteristics of neurodegeneration after controlled cortical impact in mice: More than a focal brain injury. Journal of neurotrauma. 2005;22:252-265. |
| Hami et al., “GMP Production and Testing of Xcellerated T Cells for the Treatment of Patients with CLL,” Cytotherapy, pp. 554-562, 2004. |
| Hamm RJ, Dixon CE, Gbadebo DM, Singha AK, Jenkins LW, Lyeth BG, Hayes RL. Cognitive deficits following traumatic brain injury produced by controlled cortical impact. Journal of neurotrauma. 1992;9:11-20. |
| Hanley PJ, Mei Z, Durett AG, et al. (2014) Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. Cytotherapy 16(8): 1048-1058. |
| Harimoto, Masami, et al. “Novel approach for achieving double-layered cell sheets co-culture: overlaying endothelial cell sheets onto monolayer hepatocytes utilizing temperature-responsive culture dishes.” Journal of Biomedical Materials Research: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials 62.3 (2002): 464-470. |
| He N, Fan W, Henriquez B, Yu RT, Atkins AR, Liddle C, Zheng Y, Downes M, Evans RM. Metabolic control of regulatory T cell (Treg) survival and function by Lkb1. Proc Natl Acad Sci USA. 2017;114(47):12542-12547. |
| He X, Landman S, Bauland SC, van den Dolder J, Koenen HJ, Joosten I. A TNFR2-Agonist Facilitates High Purity Expansion of Human Low Purity Treg Cells. PLoS One. 2016;11(5):e0156311. |
| Heskins, Michael, and James E. Guillet. “Solution properties of poly (N-isopropylacrylamide).” Journal of Macromolecular Science—Chemistry 2.8 (1968): 1441-1455. |
| Hill JA, Feuerer M, Tash K, Haxhinasto S, Perez J, Melamed R, Mathis D, Benoist C. Foxp3 transcription-factor-dependent and -independent regulation ofthe regulatory T cell transcriptional signature. Immunity. 2007;27(5):786-800. |
| Högstedt, Benkt, Anita Karlsson, and Anders Holmén. “Frequency and size distribution of micronuclei in lymphocytes stimulated with phytohemagglutinin and pokeweed mitogen in workers exposed to piperazine.” Hereditas 109.(1988): 139-142. |
| Hollyman et al., “Manufacturing Validation of Biologicall Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy,” J Immunother, vol. 32, No. 2, pp. 169-180, Feb.-Mar. 2009. |
| Horwitz, Mitchell E., et al. “Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide.” Journal of Clinical Oncology 37.5 (2019): 367-373. |
| http://www.ucdenver.edu/academics/colleges/medicalschool/centers/cancercenter/Research/sharedresources/AnimalImaging/smallanimalimaging/Pages/MRI.aspx. |
| ISCT Webinar “Volume Reduction technology for Large Scale Harvest or Post-thaw Manipulation of Cellular Therapeutics”. |
| Itkin, Tomer, and Tsvee Lapidot. “SDF-1 keeps HSC quiescent at home.” Blood, The Journal ofthe American Society of Hematology 117.2 (2011): 373-374. |
| Iwashima, Shigejiro, et al. “Novel culture system of mesenchymal stromal cells from human subcutaneous adipose tissue.” Stem cells and development 18.4 (2009): 533-544. |
| Jang, Eugene, et al. “Syndecan-4 proteoliposomes enhance fibroblast growth factor-2 (FGF-2)-induced proliferation, migration, and neovascularization of ischemic muscle.” Proceedings of the National Academy of Sciences 109.5 (2012): 1679-1684. |
| Jarocha D, Stangel-Wojcikiewicz K, Basta A, Majka M (2014) Efficient myoblast expansion for regenerative medicine use. Int J Mol Med 34(1): 83-91. |
| Jin, H., and J. Bae. “Neuropeptide Y regulates the hematopoietic stem cell microenvironment and prevents nerve injury in the bone marrow.” 22nd Annual ISCT Meeting (2016): S29. |
| Jo CH, Lee YG, Shin WH, et al. (2014) Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells 32(5): 1254-1266. |
| Johansson, Ulrika, et al. “Pancreatic islet survival and engraftment is promoted by culture on functionalized spider silk matrices.” PloS one 10.6 (2015): e0130169. |
| John Carvell, et al. Monitoring Live Biomass in Disposable Bioreactors, BioProcess International 14(3)s, Mar. 2016. |
| John Nicolette, et al (Abbott Laboratories). In Vitro Micronucleus Screening of Pharmaceutical Candidates by Flow Cyto9metry in Chinese Hamster V79 Cells, Environmental and Molecular Mutagenesis 00:000-000, 2010. |
| John P. Carvell and Jason E. Dowd. On-line measurements and control of viable cell density in cell culture manufacturing processes using radio frequency impedance. Cytotechnology 50:35-48, 2006. |
| Johnson, Patrick A., et al. “Interplay of anionic charge, poly (ethylene glycol), and iodinated tyrosine incorporation within tyrosine?derived polycarbonates: Effects on vascular smooth muscle cell adhesion, proliferation, and motility.” Journal of Biomedical Materials Research Part A: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials 93.2 (2010): 505-514. |
| Johnston LC, Su X, Maguire-Zeiss K, Horovitz K, Ankoudinova I, Guschin D, Hadaczek P, Federoff HJ, Bankiewicz K, Forsayeth J. Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease. Mol Ther. 2008;16(8):1392-9. |
| Jones M, Varella-Garcia M, Skokan M, et al. (2013) Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System. Cytotherapy 15(11): 1323-1339. |
| Jones2016ISCT 2016 Poster 69. |
| Joy, Abraham, et al. “Control of surface chemistry, substrate stiffness, and cell function in a novel terpolymer methacrylate library.” Langmuir 27.5 (2011): 1891-1899. |
| Kalamasz et al., “Optimization of Human T-Cell Expansion Ex Vivo Using Magnetic Beads Conjugated with Anti-CD3 and Anti-CD28 Antibodies,” J Immunother, vol. 27, No. 5, pp. 405-418, Sep.-Oct. 2004. |
| Kim, Do-Hyung, et al. “mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.” Cell 110.2 (2002): 163-175. |
| Kishore M, Cheung KCP, Fu H, Bonacina F, Wang G, Coe D, Ward EJ, Colamatteo A, Jangani M, Baragetti A, Matarese G, Smith DM, Haas R, Mauro C, Wraith DC, Okkenhaug K, Catapano AL, De Rosa V, Norata GD, Marelli-Berg FM. Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis. Immunity. 2017;47(5):875-889 e10. |
| Klapper et al., “Single-Pass, Closed-System Rapid Expansion of Lymphocyte Cultures for Adoptive Cell Therapy,” Journal of Immunological Methods, 345, pp. 90-99, Apr. 21, 2009. |
| Klein, Elias, Eva Eichholz, and Don H. Yeager. “Affinity membranes prepared from hydrophilic coatings on microporous polysulfone hollow fibers.” Journal of membrane science 90.1-2 (1994): 69-80. |
| Klysz D, Tai X, Robert PA, Craveiro M, Cretenet G, Oburoglu L, Mongellaz C, Floess S, Fritz V, Matias MI, Yong C, Surh N, Marie JC, Huehn J, Zimmermann V, Kinet S, Dardalhon V, Taylor N. Glutamine-dependent alpha-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. Sci Signal. 2015;8(396):ra97. |
| Korpanty et al., “Tageting Vascular Enothelium with Avidin Microbubbles,” Ultrasound in Medicine and Biology, vol. 31, No. 9, pp. 1279-1283, May 24, 2005. |
| Krauss et al., “Signaling Takes a Breath—New Quantitative Perspectives on Bioenergetics and Signal Transduction,” Immunity, vol. 15, pp. 497-502, Oct. 2001. |
| Kulikov, A. V., et al. “Application of multipotent mesenchymal stromal cells from human adipose tissue for compensation of neurological deficiency induced by 3-nitropropionic acid in rats.” Bulletin of experimental biology and medicine 145.4 (2008): 514-519. |
| Kumar P, Marinelarena A, Raghunathan D, Ragothaman VK, Saini S, Bhattacharya P, Fan J, Epstein AL, Maker AV, Prabhakar BS. Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation. Cell Mol Immunol. 2019;16(2):138-153. |
| Kwan, J. and Borden, M., “Lipid Monolayer Collapse and Microbubble Stability,” Advances in Colloid and Interface Science, vols. 183-184, pp. 82-99, Aug. 21, 2012. |
| Lampugnani MG, Caveda L, Breviario F, Del Maschio A, Dejana E. Endothelial cell-to-cell junctions. Structural characteristics and functional role in the regulation of vascular permeability and leukocyte extravasation. Bailliere's clinical haematology. 1993;6:539-558. |
| Lang, Julie, et al. “Generation of hematopoietic humanized mice in the newborn BALB/c-Rag2nullII2rYnull mouse model: a multivariable optimization approach.” Clinical Immunology 140.1 (2011): 102-116. |
| Lataillade, Jean-Jacques, et al. “Chemokine SDF-1 enhances circulating CD34+ cell proliferation in synergy with cytokines: possible role in progenitor survival.” Blood, The Journal of the American Society of Hematology 95.3 (2000): 756-768. |
| Lee et al., “Continued Antigen Stimulation Is Not Required During CD4+ T Cell Clonal Expansion,” The Journal of Immunology, 168, pp. 1682-1689, 2002. |
| Lee III, Daniel W., et al. “Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation.” Blood 128.22 (2016): 218. |
| Lee, Jae W., et al. “Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung.” Proceedings of the national academy of Sciences 106.38 (2009): 16357-16362. |
| Levine, B., “T Lymphocyte Engineering ex vivo for Cancer and Infectious Disease,” Expert Opinion on Biological Therapy, vol. 4, No. 4, pp. 475-489, 2008. |
| Lindstein, Tullia, et al. “Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway.” Science 244.4902 (1989): 339-343. |
| Liotta, Francesco, et al. “Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma.” BJU International 107.9 (2011): 1500-1506. |
| Liu W, Putnam AL, Xu—Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203(7):1701-1711. |
| Lum et al., “Ultrasound Radiation Force Enables Targeted Deposition of Model Drug Carriers Loaded on Microbubbles,” Journal of Controlled Release, 111, pp. 128-134, 2006. |
| M. R. Koller, et al. Clinical-scale human umbilical cord blood cell expansion in a novel automated perfusion culture system. Bone Marrow Transplantion 21:653-663, 1998. |
| Malin, Stephen F., et al. “Noninvasive prediction of glucose by near-infrared diffuse reflectance spectroscopy.” (1999): 1651-1658. |
| Malone et al., “Characterization of Human Tumor-Infiltrating Lymphocytes Expanded in Hollow-Fiber Bioreactors for Immunotherapy of Cancer,” Cancer Biotherapy & Radiopharmaceuticals, vol. 16, No. 5, pp. 381-390, 2001. |
| Mao AS, Mooney DJ (2015) Regenerative medicine: current therapies and future directions. Proc Natl Acad Sci USA 112(47): 14452-14459. |
| Marek-Trzonkowska, Natalia, et al. “Administration of CD4+ CD25highCD127-regulatory T cells preserves ß-cell function in type 1 diabetes in children.” Diabetes care 35.9 (2012): 1817-1820. |
| Markgraf CG, Clifton GL, Aguirre M, Chaney SF, Knox-Du Bois C, Kennon K, Verma N. Injury severity and sensitivity to treatment after controlled cortical impact in rats. Journal of neurotrauma. 2001;18:175-186. |
| Mathew et al. A Phase I Clinical Trials I with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants. Nature, Scientific Reports 8:7428 (1-12), 2018. |
| Mathew, James M., et al. “A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants.” Scientific reports 8.1 (2018): 1-12. |
| Matthay, Michael A., et al. “Therapeutic potential of mesenchymal stem cells for severe acute lung injury.” Chest 138.4 (2010): 965-972. |
| Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, Rudensky AY, Weaver CT. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3− precursor cells in the absence of interleukin 10. Nat Immunol. 2007;8(9):931-41. |
| McKenna DH, Jr., Sumstad D, Kadidlo DM, et al. Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. Cytotherapy 2017;19:250-62. |
| McLimans W, Kinetics of Gas Diffusion in Mammalian Cell Culture Systems. Biotechnology and Bioengineering 1968; 10:725-740. |
| McMurtrey, Richard J. “Analytic models of oxygen and nutrient diffusion, metabolism dynamics, and architecture optimization in three-dimensional tissue constructs with applications and insights in cerebral organoids.” Tissue Engineering Part C: Methods 22.3 (2016): 221-249. |
| Menge, Tyler, et al. “Mesenchymal stem cells regulate blood-brain barrier integrity through TIMP3 release after traumatic brain injury.” Science translational medicine 4.161 (2012): 161ra150-161ra150. |
| Miska J, Lee-Chang C, Rashidi A, Muroski ME, Chang AL, Lopez-Rosas A, Zhang P, Panek WK, Cordero A, Han Y, Ahmed AU, Chandel NS, Lesniak MS. HIF-1alpha Is a Metabolic Switch between Glycolytic-Driven Migration and Oxidative Phosphorylation-Driven Immunosuppression of Tregs in Glioblastoma. Cell Rep. 2019;27(1):226-237 e4. |
| Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, Mathian A, Nakahata T, Yamaguchi T, Nomura T, Ono M, Amoura Z, Gorochov G, Sakaguchi S. Functional delineation and differentiation dynamics of human CD4+ T cells Expressing the FoxP3 transcription factor. Immunity. 2009;30(6):899-911. |
| Murugappan, G., et al. “Human hematopoietic progenitor cells grow faster under rotational laminar flows.” Biotechnology progress 26.5 (2010): 1465-1473. |
| Nankervis B, Jones M, Vang B et al. (2018) Optimizing T Cell Expansion in a Hollow-Fiber Bioreactor. Curr Stem Cell Rep. Advanced online publication, https://doi.org/10.1007/s40778-018-0116-x. |
| Nankervis, Brian, et al. “Optimizing T cell expansion in a hollow-fiber bioreactor.” Current Stem Cell Reports 4.1 (2018): 46-51. |
| Nedoszytko B, Lange M, Sokolowska-Wojdylo M, Renke J, Trzonkowski P, Sobjanek M, Szczerkowska-Dobosz A, Niedoszytko M, Gorska A, Romantowski J, Czarny J, Skokowski J, Kalinowski L, Nowicki R. The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part II: The Treg role in skin diseases pathogenesis. Postepy Dermatol Alergol. 2017;34(5):405-417. |
| Nehlin JO, Just M, Rustan AC (2011) Human myotubes from myoblast cultures undergoing senescence exhibit defects in glucose and lipid metabolism. Biogerontology 12: 349-365. |
| New victories for adult Stem Cell Research New York Feb. 6, 2007. |
| Newton R, Priyadharshini B, Turka LA. Immunometabolism of regulatory T cells. Nat Immunol. 2016;17(6):618-25. |
| Ng TH, Britton GJ, Hill EV, Verhagen J, Burton BR, Wraith DC. Regulation of adaptive immunity; the role of interleukin-10. Front Immunol. 2013;4:129. |
| Nikolaychik, V. V., M. M. Samet, and P. L Lelkes. “A New, Cryoprecipitate Based Coating For Improved Endothelial Cell Attachment And Growth On Medical Grade Artificial Surfaces.” ASAIO Journal (American Society for Artificial Internal Organs: 1992) 40.3 (1994): M846-52. |
| Nish SA, Schenten D, Wunderlich FT, Pope SD, Gao Y, Hoshi N, Yu S, Yan X, Lee HK, Pasman L, Brodsky I, Yordy B, Zhao H, Bruning J, Medzhitov R. T cell-intrinsic role of IL-6 signaling in primary and memory responses. Elife. 2014;3:e01949. |
| Niwayama, Jun, et al. “Analysis of hemodynamics during blood purification therapy using a newly developed noninvasive continuous monitoring method.” Therapeutic Apheresis and Dialysis 10.4 (2006): 380-386. |
| Nugent, Helen M., et al. “Adventitial endothelial implants reduce matrix metalloproteinase-2 expression and increase luminal diameter in porcine arteriovenous grafts.” Journal of vascular surgery 46.3 (2007): 548-556. |
| Okano et al. (Tokyo Women's Medical College, Japan) demonstrated the recovery of endothelial cells and hepatocytes from plasma-treated polystyrene dishes grafted with PNIAAm (Journal of Biomedical Materials Research, 1993). |
| Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA. 2008;105(29):10113-8. |
| Onyszchuk G, LeVine SM, Brooks WM, Berman NE. Post-acute pathological changes in the thalamus and internal capsule in aged mice following controlled cortical impact injury: A magnetic resonance imaging, iron histochemical, and glial immunohistochemical study. Neuroscience letters. 2009;452:204-208. |
| Pacella I, Procaccini C, Focaccetti C, Miacci S, Timperi E, Faicchia D, Severa M, Rizzo F, Coccia EM, Bonacina F, Mitro N, Norata GD, Rossetti G, Ranzani V, Pagani M, Giorda E, Wei Y, Matarese G, Barnaba V, Piconese S. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Proc Natl Acad Sci U S A. 2018;115(28):E6546-E6555. |
| Parhi, Purnendu, Avantika Goias, and Erwin A. Vogler. “Role Of Proteins And Water In The Initial Attachment Of Mammalian Cells To Biomedical Surfaces: A Review.” Journal of Adhesion Science and Technology 24.5 (2010): 853-888. |
| Pati S, Gerber MH, Menge TD, Wataha KA, Zhao Y, Baumgartner JA, Zhao J, Letourneau PA, Huby MP, Baer LA, Salsbury JR, Kozar RA, Wade CE, Walker PA, Dash PK, Cox CS, Jr., Doursout MF, Holcomb JB. Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock. PloS one. 2011;6:e25171. |
| Pati S, Khakoo AY, Zhao J, Jimenez F, Gerber MH, Harting M, Redell JB, Grill R, Matsuo Y, Guha S, Cox CS, Reitz MS, Holcomb JB, Dash PK. Human mesenchymal stem cells inhibit vascular permeability by modulating vascular endothelial cadherin/beta-catenin signaling. Stem cells and development. 2011;20:89-101. |
| Pati, Shibani, and Todd E. Rasmussen. “Cellular therapies in trauma and critical care medicine: Looking towards the future.” PLoS Medicine 14.7 (2017): e1002343. |
| Pati, Shibani, et al. “Lyophilized plasma attenuates vascular permeability, inflammation and lung injury in hemorrhagic shock.” PloS one 13.2 (2018): eQ192363. |
| Peters JH, Preijers FW, Woestenenk R, Hilbrands LB, Koenen HJ, Joosten I. Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion, and Treg cryopreservation. PLoS One. 2008;3(9):e3161. |
| Peters, R.; Jones, M.; Brecheisen, M.; Startz, T.; Vang, B.; Nankervis, B.; Frank, N.; Nguyen, K. (2012) TerumoBCT. https://www.terumobct.com/location/north-america/products-and-services/Pages/Quantum-Materials.aspx. |
| Porter CM, Horvath-Arcidiacono JA, Singh AK, Horvath KA, Bloom ET, Mohiuddin MM. Characterization and expansion of baboon CD4+CD25+ Treg cells for potential use in a non-human primate xenotransplantation model. Xenotransplantation. 2007;14(4):298-308. |
| Povsic TJ, O'Connor CM, Henry T, et al. (2011) A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. Am Heart J 162(4): 654-662. |
| Prockop, Darwin J., Carl A. Gregory, and Jeffery L. Spees. “One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues.” Proceedings ofthe National Academy of Sciences 100.suppl_1 (2003): 11917-11923. |
| Q. L. Hao, et al. A functional comparison of CD34+ CD38= cells in cord blood and bone marrow. Blood 86:3745-3753, 1995. |
| Rahmahwati, Nurlaela, Deana Wahyuningrum, and Anita Alni. “The Synthesis Of Polyethersulfone (PES) Derivatives For The Immobilization Of Lipase Enzyme.” Key Engineering Materials. vol. 811. Trans Tech Publications Ltd, 2019. |
| Rey-Jurado, Emma, et al. “Assessing the importance of domestic vaccine manufacturing centers: an overview of immunization programs, vaccine manufacture, and distribution.” Frontiers in immunology 9 (2018): 26. |
| Roballo KC, Dhungana S, Z. J, Oakey J, Bushman J. Localized delivery of immunosuppressive regulatory! cells to peripheral nerve allografts promotes regeneration of branched segmental defects. Biomaterials. 2019;209:1-9. |
| Rodrigues, C., Fernandes, T., Diogo, M., Lobato da Silva, C., Cabral, J. Stem Cell Cultivation in Bioreactors. 2011. Biotechnology Advances v. 29, pp. 815-829. |
| Ronco C1, Levin N, Brendolan A, Nalesso F, Cruz D, Ocampo C, Kuang D, Bonello M, De Cal M, Corradi V, Ricci Z. Flow distribution analysis by helical scanning in polysulfone hemodialyzers: effects of fiber structure and design on flow patterns and solute clearances. Hemodial Int. Oct. 2006; 10(4):380-8. |
| Ronco, C., Brendolan, A., Crepaldi, C., lodighiero, M., Scabardi, M. Blood and Dialysate Flow Distributions in Hollow-Fiber Hemodialyzers Analyzed by Computerized Helical Scanning Technique. 2002. Journal of the American Society of Nephrology. V. 13, pp. S53-S61. |
| Rosenblum MD, Way SS, Abbas AK. Regulatory T cell memory. Nat Rev Immunol. 2016;16(2):90-101. |
| Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, Treuting P, Siewe L, Roers A, Henderson WR, Jr., Muller W, Rudensky AY. Regulatory! cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008;28(4):546-58. |
| Rudensky, Alexander Y. “Regulatory T cells and Foxp3.” Immunological reviews 241.1 (2011): 260-268. |
| Ryu, Min-Hyung, and Mark Gomelsky. “Near-infrared light responsive synthetic c-di-GMP module for optogenetic applications.” ACS synthetic biology 3.11 (2014): 802-810. |
| S. Koestenbauer, et al. Protocols for Hematopoietic Stem Cell Expansion from Umbilical Cord Blood. Cell Iransplantation 18: 1059-1068, 2009. |
| S. L. Smith, et al. Expansion of neutrophil precursors and progenitors in suspension cultures of CD34+ cells enriched from human bone marrow. Experimental Hematology 21:870-877, 1993. |
| Safinia N, Grageda N, Scotta C, Thirkell S, Fry LJ, Vaikunthanathan T, Lechler RI, Lombardi G. Cell Therapy in Organ Iransplantation: Our Experience on the Clinical Iranslation of Regulatory T Cells. Front Immunol. 2018;9:354. |
| Sahay A, Scobie KN, Hill AS, O'Carroll CM, Kheirbek MA, Burghardt NS, Fenton AA, Dranovsky A, Hen R. Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation. Nature. 2011;472:466-470. |
| Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated I cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151-64. |
| Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18-32. |
| Schild, Howard G. “Poly (N-isopropylacrylamide): experiment, theory and application.” Progress in polymer science 17.2 (1992): 163-249. |
| Schmitz R, Alessio A, Kina P. The Physics of PET/CT scanners. Imaging Research Laboratory, Department of Radiology, University of Washington http://depts.washington.edu/imreslab/education/Physics%20of%20PET.pdf. |
| Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21:305-34. |
| Shevkoplyas et al., “Ihe Force Acting on a Superparamagnetic Bead due to an Applied Magnetic Field,” Lab on a Chip , 7, pp. 1294-1302, 2007. |
| Shimazu Y, Shimazu Y, Hishizawa M, Hamaguchi M, Nagai Y, Sugino N, Fujii S, Kawahara M, Kadowaki N, Nishikawa H, Sakaguchi S, Takaori-Kondo A. Hypomethylation of the Treg-Specific Demethylated Region in FOXP3 Is a Hallmark of the Regulatory T-cell Subtype in Adult T-cell Leukemia. Cancer Immunol Res. 2016;4(2):136-45. |
| Shimizu et al.l., “Fabrication of Pulsatile Cardiac Tissue Grafts Using a Novel 3-Dimensional Cell Sheet Manipulation Technique and Temperature-Responsive Cell Culture Surfaces,” Circulation Research, vol. 90, Feb. 22, 2022, e40-e48, pp. 1-9. |
| Sigma-Aldrich Cheimcals Mitomycin C (M4287) MSDS, v4.4, Jul. 7, 2011. |
| Sirsi, S. and Borden, M., “Microbubble Composition, Properties, and Biomedical Applications,” Bubble Science, Engineering & Technolology, vol. 1, No. 1-2, pp. 3-17, 2009. |
| Smith C, Okern G, Rehan S, et al. Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement. Clinical & Translational Immunology 2015;4:e31. |
| Somerville et al., “Clinical Scale Rapid Expansion of Lymphocytes for Adoptive Cell Transfer Therapy in the WAVE® Bioreactor,” Journal of Translational Medicine, vol. 10, No. 69, pp. 1-11, 2012. |
| Somerville, R. and Dudley, M., “Bioreactors Get Personal,” OncoImmunology, vol. 1, No. 8, pp. 1435-1437, Nov. 2012. |
| Spectrum Labs KrosFlo Research IIi TFF System, undated, Spectrum Laboratories, Inc., 4 pages. |
| Stafano Tiziani, et al. Metabolomic Profiling of Drug Response in Acute Myeloid Leukaemia Cell lines. PLOSone 4(1): e4251 (Jan. 22, 2009). |
| StAR_Abstract, undated, author unknown, 1 page. |
| Startz et al May 2016 TBCT T-cell White Paper. |
| Startz, T., et al. “Maturation of dendritic cells from CD14+ monocytes in an automated functionally closed hollow fiber bioreactor system.” Cytotherapy 16.4 (2014): S29. |
| Steven M. Bryce, et al. (Litron Laboratories). In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity. Mutation Research 630(1-2): 78-91, 2007. |
| Steven M. Bryce, et al (Novartis Pharma AG, Johnson & Johnson Pharmaceutical Research, GlaxoSmithKline). Interlaboratory evaluation of a flow cytometric, high content in vitro micronucleus assay. Genetic Toxicology and Environmental Mutagenesis 650: 181-195, 2008. |
| Streltsova et al., “Recurrent Stimulation of Natural Killer Cell Clones with K562 Expressing Membrane-Bound interleukin-21 Affects Their Phenotype, Interferon-y Production, and Lifespan,” International Journal of Molecular Sciences, vol. 20, No. 443, 2019, pp. 1-18. |
| Stuart, Martien A. Cohen, et al. “Emerging applications of stimuli-responsive polymer materials.” Nature materials 9.2 (2010): 101-113. |
| Su LF, Del Alcazar D, Stelekati E, Wherry EJ, Davis MM. Antigen exposure shapes the ratio between antigen-specific Tregs and conventional T cells in human peripheral blood. Proc Natl Acad Sci U S A. 2016;113(41):E6192-E6198. |
| Takezawa, Toshiaki, Yuichi Mori, and Katsutoshi Yoshizato. “Cell culture on a thermo-responsive polymer surface.” Bio/technology 8.9 (1990): 854-856. |
| The effect of rocking rate and angle on T cell cultures grown in Xuri™ Cell Expansion Systems, Aug. 2014, GE Healthcare UK Limited, 4 pages. |
| Trzonkowski et al., “Ex Vivo Expansion of CD4+ CD25+ T Regulatory Cells for Immunosuppressive Therapy,” Cytometry Part A, 75A, pp. 175-188, 2009. |
| Trzonkowski, Piotr, et al. “First-in-man clinical results ofthe treatment of patients with graft versus host disease with human ex vivo expanded CD4+ CD25+ CD127? T regulatory cells.” Clinical immunology 133.1 (2009): 22-26. |
| Tsvetkov, Ts, et al. “Isolation and cryopreservation of human peripheral blood monocytes.” Cryobiology 23.6 (1986): 531-536. |
| Ueda, Ryosuke, et al. “Interaction of natural killer cells with neutrophils exerts a significant antitumor immunity in hematopoietic stem cell transplantation recipients.” Cancer medicine 5.1 (2015): 49-60. |
| Underwood, P. Anne, et al. “Effects of base material, plasma proteins and FGF2 on endothelial cell adhesion and growth.” Journal of Biomaterials Science, Polymer Edition 13.8 (2002): 845-862. |
| Urbich, et al from the Goethe-Universitat, demonstrated that human endothelial cells increased VEGFR-2 mRNA expression when exposed to 5-15 dynes/cm2 of constant shear force for a period of 6-24 hours (FEBS, 2002). |
| Van der Net JB, Bushell A, Wood KJ, Harden PN. Regulatory T cells: first steps of clinical application in solid organ transplantation. Transpl Int. 2016;29(1):3-11. |
| Van der Windt GJ, Pearce EL. Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol Rev. 2012;249(1):27-42. |
| Vera et al., “Accelerated Production of Antigen-Specific T-Cells for Pre-Clinical and Clinical Applications Using Gas-Permeable Rapid Expansion Cultureware (G-Rex),” J Immunother, vol. 33, No. 3, pp. 305-315, Apr. 2010. |
| Villa, Alma Y. Camacho, et al. “CD133+ CD34+ and CD133+ CD38+ blood progenitor cells as predictors of platelet engraftment in patients undergoing autologous peripheral blood stem cell transplantation.” Transfusion and Apheresis Science 46.3 (2012): 239-244. |
| Visser EP1, Disselhorst JA, Brom M, Laverman P, Gotthardt M, Oyen WJ, Boerman OC. Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med. Jan. 2009;50(1):139-47. |
| Von Laer, D., et al. “Loss of CD38 antigen on CD34+ CD38+ cells during short-term culture.” Leukemia 14.5 (2000): 947-948. |
| Wagner Jr, John E., et al. “Phase I/II trial of StemRegenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft.” Cell stem cell 18.1 (2016): 144-155. |
| Walker, Peter A., et al. “Direct intrathecal implantation of mesenchymal stromal cells leads to enhanced neuroprotection via an NF?B-mediated increase in interleukin-6 production.” Stem cells and development 19.6 (2010): 867-876. |
| Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, McCormick LL, Fitzgerald P, Chi H, Munger J, Green DR. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011;35(6):871-82. |
| Wang, Jiamian, John A. Jansen, and Fang Yang. “Electrospraying: possibilities and challenges of engineering carriers for biomedical applications—a mini review.” Frontiers in Chemistry 7 (2019): 258. |
| Ward H, Vigues S, Poole S, Bristow AF. The rat interleukin 10 receptor: cloning and sequencing of cDNA coding for the alpha-chain protein sequence, and demonstration by western blotting of expression in the rat brain. Cytokine. 2001;15(5):237-40. |
| Wawman, Rebecca Ellen, Helen Bartlett, and Ye Htun Oo. “Regulatory T cell metabolism in the hepatic microenvironment.” Frontiers in immunology 8 (2018): 1889. |
| Weber et al., “White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report ofthe CTEP Subcommittee on Adoptive Cell Therapy,” Clinical Cancer Research, vol. 17, No. 7, pp. 1664-1673, Apr. 1, 2011. |
| Weiss RA, Weiss MA, Beasley KL, Munavalli G (2007) Autologous cultured fibroblast injection for facial contour deformities: a prospective, placebo-controlled, Phase III clinical trial. Dermatol Surg 33(3): 263-268. |
| Widdel, F. 2010. “Theory and measurement of bacterial growth” http://www.mpi-bremen.de/Binaries/Binary13037/Wachstumsversuch.pdf. |
| Yamada, Noriko, et al. “Thermo?responsive polymeric surfaces; control of attachment and detachment of cultured cells.” Die Makromolekulare Chemie, Rapid Communications 11.11 (1990): 571-576. |
| Yang, Hee Seok, et al. “Suspension culture of mammalian cells using thermosensitive microcarrier that allows cell detachment without proteolytic enzyme treatment.” Cell transplantation 19.9 (2010): 1123-1132. |
| Yi, Zhuan, et al. “A readily modified polyethersulfone with amino-substituted groups: its amphiphilic copolymer synthesis and membrane application.” Polymer 53.2 (2012): 350-358. |
| Yoshinari, Masao, et al. “Effect of cold plasma-surface modification on surface wettability and initial cell attachment.” International Journal of Biomedical and Biological Engineering 3.10 (2009): 507-511. |
| Zappasodi et al., “The Effect Of Artificial Antigen-Presenting Cells with Preclustered Anit-CD28/-CD3/LFA-1 Monoclonal Antibodies on the Induction of ex vivo Expansion of Functional Human Antitumor T Cells,” Haematologica, vol. 93, No. 10, pp. 1523-1534, 2008. |
| Zemmour D, Zilionis R, Kiner E, Klein AM, Mathis D, Benoist C. Publisher Correction: Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR. Nat Immunol. 2018;19(6):645. |
| Zeng B, Kwak-Kim J, Liu Y, Liao AH. Treg cells are negatively correlated with increased memory B cells in pre-eclampsia while maintaining suppressive function on autologous B-cell proliferation. Am J Reprod Immunol. 2013;70(6):454-63. |
| Zheng, et al. at the University of Iowa have shown that the differential effects of pulsatile blood flow and cyclic stretch are an important growth stimulus (American Journal of Physiology—Heart and Circulatory Physiology, 2008). |
| Number | Date | Country | |
|---|---|---|---|
| 20200248126 A1 | Aug 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61905182 | Nov 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14542304 | Nov 2014 | US |
| Child | 16858058 | US |
